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Approximately 27% of global mortality is caused by cardiovascular disease (CVD).1 
Furthermore, ischemic heart disease is the leading cause of years of life lost, both 
globally and in the Netherlands.1 As a result of more effective treatment options and an 
increase in preventive measures and surveillance, the worldwide age-standardized death 
rate has decreased with a median percentage of 22 from 1990 onwards, and years of life 
lost due to CVD have decreased  about two- to four-fold.1, 2 Reduction of hypertension 
and hypercholesterolemia on a population-level can (cost-)effectively prevented new 
cases of CVD and death from CVD, resulting in a reduction of Disability Adjusted Life 
Years (DALYs).2, 3 Hence, the impact of preventive strategies on reducing CVD is evident.
Because of the importance of CVD prevention, many countries have guidelines with 
recommendations on prevention of CVD in adults with as well as without a history of 
CVD.4-10 Although these guidelines have the same goal, there is no consensus about 
the screening methods, which prediction models to apply, and what thresholds to use 
regarding initiation of drug treatment in patients in order to prevent CVD.11 The European 
Society of Cardiology, for example, recommends to initiate anithypertensive drugs based 
on a combination of total cardiovascular risk and blood pressure, whereas the guideline 
from the Centers of Disease Control and Prevention/American Heart Association 
recommends to start treatment based on a combination of blood pressure level and the 
presence of chronic kidney disease or diabetes mellitus.11
Medical science continuously investigates the optimal way to prevent CVD in individuals, 
which is the reason for regular revision and further refinement of guidelines in the area 
of prevention of CVD.5, 6, 12-19 
1. THIS THESIS
This thesis addresses a problem that was raised, predominantly in Dutch general 
practice, as a result of revisions of guidelines in the area of primary prevention of CVD 
and that expands into the area of further individualizing preventive interventions during 
lifetime. This thesis concerns the practical problem of general practitioners (GPs) on 
how to deal with patients using antihypertensive and/or lipid-lowering drugs (preventive 
cardiovascular medication) in whom guideline changes, changing insights in risk 
assessment or changing individual circumstances, result in losing the strict indication 
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To illustrate this problem, first the history of the Dutch guidelines in the area of primary 
prevention of CVD will be discussed. Next, two vignets of patients will be introduced 
(miss Bremer and mister Aalbers), to exemplify the issues that GPs encounter in general 
practice. Finally, the aims of the thesis are presented.
2. THE DUTCH SITUATION
In the Netherlands, the first guidelines in the area of primary prevention of CVD were 
the guidelines “Hypertensie” [Hypertension] and “Cholesterol”, launched by the Dutch 
College of General Practitioners (Nederlands Huisartsen Genootschap, NHG) in 
1993. These guidelines recommended opportunistic screening of blood pressure and 
cholesterol in patients at risk of hypertension, hypercholesterolemia, or patients at 
increased risk of developing CVD (e.g., in case of diabetes mellitus). Recommendations 
in these two former guidelines differ from the recommendations in the current 
Cardiovascular Risk Management (CVRM) guideline with respect to, for example, 
definition of hypertension, preferred prescribed medications, and thresholds for initiation 
of medication.
As of 2003, the Dutch hypertension guideline advocated for the assessment of total 
(or: global) cardiovascular risk, using a 10-year risk of cardiovascular morbidity 
essentially based on the Framingham Risk Score to evaluate whether drug treatment 
should be initiated. In 2006, the guidelines on hypertension and on hyperlipidaemia 
were integrated into one CVRM guideline advocating for the assessment of total (or: 
global) cardiovascular risk, based on all traditional risk factors. However, the 2006 
CVRM guideline refrained from using the Framingham Risk Score, and started using 
a 10-year risk of CVD morbidity and mortality (10-year CVD risk) score based on the 
SCORE equation to evaluate drug treatment initiation.20 In the CVRM guideline that was 
established in 2012, this 10-year CVD risk score was based on the SCORE equation 
for low-risk European countries and improved for the Dutch population with help of 
data of the Dutch MORGEN-cohort and a Dutch cohort from the ERGO study.4, 16, 21 Five 
determinants currently define a patient’s 10-year CVD risk: systolic blood pressure 
(range 120 to 180 mmHg), total cholesterol/high-density lipoprotein cholesterol (TC/HDL) 
ratio (range 4 to 8), age (range  40 to 70 years; 15 years are added to age in the presence 
of diabetes mellitus or rheumatoid arthritis), sex (male or female), and smoking status 
(yes or no). In case a patient has a low risk, i.e. 10-year CVD risk <10%, the guideline 
recommends physicians to discuss lifestyle when necessary. In case a patient has a 
medium risk, i.e. 10-year CVD risk 10% to 20%, the recommendation for initiation of 
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CHAPTER 1
drug treatment depends on the presence of additional determinants that could increase 
CVD risk, such as family history of CVD, physical activity level, body mass index, and 
kidney function. This means that, if there are no or few risk increasing factors, these 
medium-risk patients are considered low-risk patients and initiation of drug treatment 
is not recommended (and vice versa: with many risk increasing factors, drug treatment 
is recommended). In case a patient has a high risk, i.e. 10-year CVD risk ≥20%, initiation 
of drug treatment is recommended under all context circumstances.
2.1. Consequences of a guideline revision for clinical practice
Guideline revisions resulting in different thresholds for initiation of drug treatment 
compared to previous guidelines, as described above, can have implications for clinical 
practice. This is because guideline recommendations do not only refer to ‘new patients’, 
but also to patients who are already being treated for their specific disease or risk 
factor(s). However, these implications are often not considered by physicians, policy 
makers and guideline committees, and most guidelines lack recommendations for 
physicians on how to deal with the consequences of guideline revisions.22
In Part 1 of this thesis we describe the effects of the last revision of the Dutch CVRM 
guideline on a population- and an individual patient-level.
3. ILLUSTRATION OF THE PROBLEM WITH PATIENT CASES
To illustrate the problem that is addressed in this thesis we describe the cases of miss 
Bremer and mister Aalbers who both did not experience a cardiovascular event and have 
a low overall CVD risk. They both visit the same GP. The most recent CVRM guideline 
does not recommend initiation of drug treatment in low-CVD-risk patients such as miss 
Bremer and mister Aalbers, and drug treatment in low-CVD-risk could be considered as 
overtreatment. However, they are already using preventive cardiovascular medication, 
because in earlier days antihypertensive and/or lipid-lowering drugs were prescribed 
following guidelines that were in force at the time. Both patients present themselves 
to their GP because of the routine preventive check-up, which is recommended when 
patients use preventive cardiovascular medication. How should the GP deal with the 
possible overtreatment in these patients?
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Just after the revision of the CVRM guideline, miss Bremer visits her GP for her routine 
preventive check-up. She is 50 years old and uses an ACE-inhibitor (enalapril 5 mg once 
daily) for three years now. Her antihypertensive drugs were initiated during a period in 
which she had headache complaints and a relatively high systolic as well as diastolic 
blood pressure found repeatedly during consultations in the past (160/90 mmHg). She 
has never smoked, her TC/HDL ratio is 5, her current systolic blood pressure is 135 
mmHg, and she has no additional risk increasing factors (no elevated body mass index, 
normal kidney function, no family history of CVD, and a good physical activity level). 
She sees her GP during the yearly preventive check-up. Her headache has faded since, 
and the general practitioner questions herself whether miss Bremer could stop her 
antihypertensive drugs.
Just after the revision of the CVRM guideline, mister Aalbers visits his GP for his routine 
preventive check-up. He is 40 years old and uses antihypertensive and lipid-lowering 
drugs for two years now (hydrochlorothiazide 12.5 mg, enalapril 5 mg, and simvastatin 
40 mg, all once daily). At the time, the GP had advised him to start medication because 
of his risk factors for developing a cardiovascular disease. He is a smoker, has a TC/
HDL ratio of 5 (it was 6 at the time he started his medication), an LDL-cholesterol of 
2.4 mmol/L (it was 4.1 mmol/L at the time he started his medication), and his systolic 
blood pressure is 136 mmHg (it was 155 mmHg at the time he started his medication). 
Furthermore, he has a body mass index of 37 kg/m2, he has a sedentary lifestyle, and his 
kidney function is 55 ml/min/1.73m2. His brother was 48 when he had a heart attack and 
his mother suffered from a stroke at the age of 62. Mister Aalbers visits his GP and asks 
her if he could stop his medication because he does not see or feel any benefits of it and 
dislikes use of medication.
Figure 1 shows miss Bremers’ and mister Aalbers’ 10-year CVD risk score, based on 
their pre-treatment levels of blood pressure (miss Bremer), and LDL-cholesterol (mister 
Aalbers), as if they would currently not be using preventive cardiovascular medication. 
Because there is a lack of evidence to judge overtreatment and to guide the decision 
whether or not to deprescribe in these cases, assessing the 10-year CVD risk score as 
if patients do not use preventive cardiovascular medication is used here to inform the 
decision-making process.
The general discussion of this thesis will address recommendations for the GP on how 
to deal with the potential overtreatment in these two patients, based on the findings of 
the studies discussed in this thesis.
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3.1. Potentially inappropriate prescribing
As illustrated by the cases of miss Bremer and mister Aalbers, for patients who 
are already using preventive cardiovascular medication based on former guideline 
recommendations, a revision of the guideline may question the need to continue 
preventive cardiovascular medication. In these two low-CVD-risk patients the guideline 
revision may change the feeling of urgency for treatment in hindsight and potentially 
results in inappropriate prolonging of prescription, where potential risks of the 
medication (e.g., side effects) outweigh their potential benefits.23-25
The question whether or not to continue the preventive cardiovascular medication will 
probably lead to a physician-patient discussion about deprescribing. Deprescribing 
has been defined as the process of withdrawal (or dose reduction) of medication that 
became inappropriate following evaluation, supervised by a healthcare professional.26 
GPs seem to be reluctant to advise about deprescribing, since evidence to change 
a supposedly “winning team” is lacking and the impact of deprescribing preventive 
cardiovascular medication on a low-CVD-risk patient’s health actually is unknown. Is 
it safe to deprescribe? And, if it is safe, should GPs invite all low-CVD-risk patients 
in a structured way for a deprescribing consultation to discuss whether to withdraw 
preventive cardiovascular medication? Time and costly efforts should be balanced 
against the impact of the guideline revision on patients’ health to assess whether 
such a structured deprescribing strategy is an effort that should be made. In Part 2 
of this thesis we have investigated the safety, effectiveness, and cost-effectiveness 
of a structured deprescribing strategy, to evaluate whether active invitations for 
deprescribing consultations in possibly overtreated, low-CVD-risk patient populations in 
general practice are recommended.
3.2. The deprescribing consultation
The deprescribing consultation, in which patients like miss Bremer and mister Aalbers 
discuss with their GP whether or not to withdraw their preventive cardiovascular 
medication, may play a big role in the (cost-)effectiveness of the overall deprescribing 
strategy; if none of the patients, as outcome of a shared decision with their GP, would 
decide to stop the medication, the deprescribing strategy would definitely not be (cost-)
effective. Because the (cost-)effectiveness of a structured deprescribing strategy could 
be highly influenced by the course of the deprescribing consultation, it is worthwhile 
to find out more about the course of these conversations and what factors have a 
bearing on its outcome (deprescription or continuation). In addition, knowledge of the 
factors that play a role in the decision-making process can aid the physician-patient 
communication in future deprescribing consultations
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In Part 3 of this thesis we have discussed the factors influencing the outcome of the 
deprescribing consultation.
3.3. Predictors of successful deprescribing
Regardless of the risks and benefits of a deprescribing strategy for the total population 
of low-CVD-risk patients, there will always be individual low-CVD-risk patients that 
embrace the idea to stop their medication. The other way around, some GPs will 
always question the necessity of preventive cardiovascular medication in some low-
CVD-risk patients. In these cases, information about the patient’s individual probability 
to successfully stop the medication could be helpful in the decision-making process. 
In addition, this information can be used to screen the electronic medical records of 
general practices for patients who have a high probability of successful stopping.
In Part 3 we have investigated predictors of successful stopping preventive 
cardiovascular medication.
4. AIMS OF THIS THESIS: SUMMARY
The overall aim of this thesis is to improve cardiovascular preventive care in general 
practice for low-CVD-risk patients, aged 40 to 70 years, and with a changed indication or 
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ABSTRACT
Background
Guidelines and accompanying risk charts concerning cardiovascular risk management 
(CVRM) are regularly revised worldwide.
Objective
To evaluate whether revision of the Dutch CVRM guideline has led to the reclassification 
of patients and, accordingly, to changes in drug recommendations.
Methods
All medical records (year 2011) of patients aged 40 – 65 years with no history of 
cardiovascular disease (CVD) but using antihypertensive and/or lipid-lowering 
drugs, were selected from the Registration Network of General Practices associated 
with Leiden University Medical Center. Multiple imputation techniques for missing 
determinants were used. The individual cardiovascular risk was calculated and the 
resulting drug recommendation was assessed according to both the 2006 and 2012 
versions of the guideline.
Results
In total, 2075 patients were selected, of whom 1248 fulfilled the guideline criteria 
(systolic blood pressure 115 – 180 mmHg and total cholesterol/high-density-lipoprotein-
cholesterol ratio 3.5 – 8). According to the 2012 guideline, 58.2% of the patients had low 
risk and 249 patients (20.0%) shifted to a different risk category. For 150 of these patients 
(12.0%), this category shift implied a shift in drug recommendation. The probability of 
shifting in drug recommendation increased with increasing age, cholesterol level, and 
blood pressure, and by being male.
Conclusion
Guideline revision may have important implications: based on identical values for risk 
factors, according to the latest revision of the Dutch CVRM guideline 20% of patients 
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In primary preventive cardiovascular disease (CVD) care, risk classification — based 
on a patient’s absolute risk of developing CVD as calculated by combining several risk 
factors — is widely used.1-12 Increasing knowledge about the underlying assumptions and 
calculations of these risk classification systems, and about the effects of interventions, 
leads to regular revisions of guidelines.1-14
Like in many other countries, the first Dutch guidelines on the prevention of CVD 
introduced by the Dutch College of General Practitioners, had a ‘single risk factor 
approach’, i.e. they looked at either blood pressure, or cholesterol levels, or at diabetes 
as a risk factor, but the risk factors were not combined into an integrated approach of 
risk management.15-17 In 2006, the first comprehensive guideline on cardiovascular risk 
management (CVRM) was introduced.18 Five risk factors for CVD, i.e. age, sex, smoking 
status, systolic blood pressure (SBP) and total cholesterol/high-density-lipoprotein 
cholesterol (TC/HDL) ratio, were integrated into one risk chart depicting absolute 
cardiovascular risk. This risk chart was based on the SCORE risk function, as described 
in the European guideline developed by the Third Joint Task Force 2003.19 A patient’s 
10-year risk of cardiovascular mortality was calculated, and the need for preventive 
medication was assessed accordingly, using a 10%, 10-year risk on cardiovascular 
mortality as threshold for entering the high-risk category.
The latest European guideline on CVD prevention was published in 2012, presenting a 
risk chart for high CVD risk countries and low CVD risk countries.8 In the Netherlands, a 
new guideline on CVRM was launched in 2012 as well, presenting a risk chart based on 
the European risk chart for low CVD risk countries.20 This new guideline included some 
differences regarding the calculation of CVD risk; differences that are also seen in recent 
updates of other CVD prevention guidelines.1, 2, 7, 8, 11, 12 The first difference is that the 
age range now is set at 40 – 70 years instead of 40 – 65 years; second, cardiovascular 
risk assessment is now based on both cardiovascular mortality and morbidity; third, 
a 20% 10 – year risk of cardiovascular mortality and morbidity was now chosen as the 
threshold for entering the high-risk category; and finally, the additional risks by diabetes 
mellitus and rheumatoid arthritis were quantified into the risk chart.
At first glance, this 2012 guideline identifies more patients requiring preventive 
medication than the 2006 guideline. However, due to other differences between the 
two versions (especially the weight of additional risk-increasing factors) the exact 
implications of the 2012 revision on an individual level are not known.
Although the CVRM guidelines in other countries are also regularly revised and most of 
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at the population level have not yet been examined. Therefore, we used data from 19 
general practices in the western part of the Netherlands to assess whether patients 
using preventive cardiovascular medication would shift in risk category according to the 
most recent revision of the Dutch CVRM guideline, and whether these patients would 
shift in drug recommendation.
METHODS
Study population
A cross-sectional study was performed with data from the Registration Network of 
General Practices associated with Leiden University (RNUH — LEO); this is a longitudinal 
database of electronic medical records (EMRs) of all patients (approximately 30 000) 
enlisted with 19 regular general practitioners (GPs) (located in four healthcare centres) 
in the western part of the Netherlands.21
Medical records of patients aged 40 – 65 years who were using antihypertensive 
treatment (anatomical therapeutic chemical codes C02*, C03*, C07*, C08*, C09*) and/
or lipid-lowering drugs (C10*) during the whole year 2011 were selected.22 All medical 
records of patients with previous atherothrombotic CVD (international classification of 
primary care (ICPC) codes K75, K76*, K89, K90*, K91, K92*, K99*) and not using platelet 
aggregation inhibitors excluding heparin (anatomical therapeutic chemical code B01AC), 
providing an undisputed indication for medication, were excluded.23 Medical records of 
patients with diabetes mellitus (T90*) or rheumatoid arthritis (L88*) were also excluded, 
as inclusion of medical records of these patients would lead to an overestimation of 
reclassifications because only the 2012 guideline takes these two diseases into account 
as quantifiable risk-increasing factors. With these criteria, 2075 medical records of 
patients were selected.
Classification in risk charts
Based on data in the medical records, we calculated the patient’s 10-year cardiovascular 
risk before start of treatment according to the 2006 and 2012 risk charts respectively, 
using age, sex, smoking status, pre-treatment SBP and pre-treatment TC/HDL ratio, and 
assessed the risk category and drug recommendation for each patient according to both 
guidelines. Pre-treatment values were selected closest to the date the medication was 
started, up to one year before the start of medication. The same was done for smoking 
status, except that when the patient was registered as a non-smoker or a former smoker 
longer than one year ago, we considered the patient a current non-smoker.
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database of electronic medical records (EMRs) of all patients (approximately 30 000) 
enlisted with 19 regular general practitioners (GPs) (located in four healthcare centres) 
in the western part of the Netherlands.21
Medical records of patients aged 40 – 65 years who were using antihypertensive 
treatment (anatomical therapeutic chemical codes C02*, C03*, C07*, C08*, C09*) and/
or lipid-lowering drugs (C10*) during the whole year 2011 were selected.22 All medical 
records of patients with previous atherothrombotic CVD (international classification of 
primary care (ICPC) codes K75, K76*, K89, K90*, K91, K92*, K99*) and not using platelet 
aggregation inhibitors excluding heparin (anatomical therapeutic chemical code B01AC), 
providing an undisputed indication for medication, were excluded.23 Medical records of 
patients with diabetes mellitus (T90*) or rheumatoid arthritis (L88*) were also excluded, 
as inclusion of medical records of these patients would lead to an overestimation of 
reclassifications because only the 2012 guideline takes these two diseases into account 
as quantifiable risk-increasing factors. With these criteria, 2075 medical records of 
patients were selected.
Classification in risk charts
Based on data in the medical records, we calculated the patient’s 10-year cardiovascular 
risk before start of treatment according to the 2006 and 2012 risk charts respectively, 
using age, sex, smoking status, pre-treatment SBP and pre-treatment TC/HDL ratio, and 
assessed the risk category and drug recommendation for each patient according to both 
guidelines. Pre-treatment values were selected closest to the date the medication was 
started, up to one year before the start of medication. The same was done for smoking 
status, except that when the patient was registered as a non-smoker or a former smoker 
longer than one year ago, we considered the patient a current non-smoker.
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CHAPTER 2
To calculate the risk according to both the 2006 and 2012 guidelines, we used the same 
values of the determinants. Supplementary Appendix 1 to be found online at http://
informahealthcare.com/doi/abs/10.3109/13814788.2015.1064389 shows the 2006 risk 
chart and Supplementary Appendix 2 to be found online at http://informahealthcare.
com/doi/abs/10.3109/13814788.2015.1064389 the currently used 2012 risk chart. The 
Dutch College of General Practitioners provided us with the underlying algorithms of the 
risk charts of both guidelines. These algorithms were used to calculate cardiovascular
risk and are being used by the college itself for their online implementation support; 
subsequently, patients were divided into the three risk categories (low-, medium- and 
high-risk) for each of both guidelines.
In both guidelines, drug recommendations depend on a patient’s 10-year cardiovascular 
risk. In low-risk patients, lifestyle changes are advised and in high-risk patients with 
hypertension and/or hypercholesterolemia, preventive medication is advised. However, 
in the medium-risk group, drug recommendations also depend on weighing several 
additional risk factors, including family history, renal function, overweight and physical 
activity.
Patients in the medium-risk group are regarded either as low-risk patients or as 
high-risk patients taking into account these additional risk factors and are treated 
accordingly.
Because the additional risk-increasing factors listed in the 2006 guideline differ from 
those in the 2012 guideline, we made some assumptions to harmonize these two sets of 
additional risk factors (Table 1).
When patients were classified in a different risk category according to the 2012 guideline 
than according to the 2006 guideline, we reported this as a ‘shift in risk category’. When 
the 2012 guideline recommended a different drug treatment for a certain patient than 
the 2006 guideline, we reported this as a ‘shift in drug recommendation’. Thus, patients 
could shift in risk category but not in drug recommendation (e.g. from low-risk category 
in 2006 to medium-risk category without additional risk factors in 2012), but also vice 
versa (e.g. in both guidelines in medium-risk category, but in 2012 requiring a different 
drug recommendation than in 2006, based on a different weighing of the additional risk 
factors).
Statistical analysis
Patients’ shifts in the risk category and drug recommendation were described using 
frequency tables. Using an independent t -test, mean cardiovascular risk was compared 
between the group shifting in risk category and the non-shifting group, as well as 
for the group shifting in drug recommendation versus the group not shifting in drug 
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recommendation. The odds ratios of risk factors for shift in risk category or drug 
recommendation were calculated with logistic regression analysis to explore further 
the differences between these groups. We rounded to whole patient numbers in all our 
analyses.
Missing patient data
Data on SBP were missing in 48.3% of the patients, TC/HDL ratio in 50.2% and smoking 
status in 48.1%. To deal with missing data, we used multiple imputation techniques 
generating 10 imputed datasets, all presenting different values of imputed variables 
because of the between-imputation component of variability.24 The imputation model 
included the following variables: sex, age, smoking status, SBP, TC/HDL ratio, low 
density lipoprotein (LDL) cholesterol, antihypertensive medication use, lipid-lowering 
drug use, family history, exercise, kidney function, and body mass index. The range for 
imputed values of SBP was set at 50 – 250 mmHg, and for TC/HDL ratio at 1 – 15 to avoid 
clinically impossible values. After  multiple imputation probabilities of variables, shifts 
in risk category and drug recommendation were calculated based on the population 
fulfilling the guideline criteria; as the risk charts use a range for SBP (120 – 180 mm Hg) 
and for TC/HDL ratio (4 – 8), patients with a SBP 115 – 180 and a TC/HDL ratio 3.5 – 8 
fulfilled guideline criteria, making risk calculation possible. Age, SBP and TC/HDL ratio 
were quantified using the means and standard deviations; sex and smoking status were 
quantified as percentages and its ranges.
Sensitivity analysis
Shifts in risk category as described above were compared with the original dataset and 
with a set with imputed data without range restrictions. All analyses were performed 
with the IBM SPSS version 20.
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Mean age of the patients was 55.4 years (SD 3.9), 50.2% were men (range: 49.2 – 51.2), 
16% were smokers (range: 15 – 18%), mean SBP was 153 mmHg (SD 16.7), and the 
mean TC/HDL ratio was 5.0 (SD 1.0).
Due to the different values of SBP and TC/HDL ratio in the imputed datasets, the number 
of patients fulfilling guideline criteria differed per dataset. On average 827 (range: 792 – 
841) out of 2075 patients did not fit the guideline, leading to an eligible study population 
of on average 1248 patients (range: 1234 – 1283).
Shifts in risk category and drug recommendation
The percentage of patients remaining in the same risk category was 80% [(999/1248) * 
100]. Furthermore, 726 patients (58.2% of all patients) had a low risk according to the 
2012 guideline despite being treated with preventive medication (Table 2).
Table 2. Patients (n=205) distributed over the risk categories as well as drug 
recommendation (yes or no) according to the 2006 and 2012 version of the 
cardiovascular risk management guidelines (in %)
Risk Low Medium High
Risk Drug recommendation yes no yes no yes no
Low yes - - - - - -
2006 no - 50.2% 5.4% 8.8% - -
Medium yes - 0.5% 8.8% 2.4% 5.4% -
no - - - 8.3% 3.4% -
High yes - - - - 6.8% -
no - - - - - -
In total, 249 patients (20.0%) shifted in risk category due to the new guidelines. In 
these latter patients, the mean cardiovascular risk according to the 2006 and 2012 
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In total, 249 patients (20.0%) shifted in risk category due to the new guidelines. In 
these latter patients, the mean cardiovascular risk according to the 2006 and 2012 
guidelines was increased compared with the patients that did not shift in risk category 
2012
        
30
(both P < 0.0001). Of those 249 patients, 150 (12.0% of all patients) shifted in drug 
recommendation. These 150 patients showed a higher cardiovascular risk according 
to the 2006 and 2012 guideline compared with the group that did not shift in drug 
recommendation (both P < 0.0001). In 126 of these 150 patients (10.1% of all patients) 
drugs were not recommended according to the 2006 guideline but were recommended 
according to the 2012 guideline; in the other patients vice versa (Table 2).
Predictors of shift in drug recommendation
Table 3 shows the differences between the group shifting in drug recommendation and 
the group not shifting in drug recommendation. Differences were found for age, SBP 
and TC/HDL ratio: i.e. the higher the age, SBP or the TC/HDL ratio, the greater the 
probability that a patient would shift in drug recommendation. Moreover, being male 
also increased the probability of shifting in drug recommendation.
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CHAPTER 2
Table 3. Determinants of change in drug recommendation between the 2006 and 2012 
guideline.
Change in drug  
recommendation
Yes (n=24) No (n=181) Odds Ratioa (CI 95%) P value
Determinant 3.170 (1.203 to 8.354) 0.020
Male 18 (75.0) 88 (48.6)
total no. (%) 0.520 (0.147 to 1.835) 0.309
Smoker 3 (12.5) 39 (21.5)
total no. (%) 1.091 (1.009 to 1.180) 0.029
Age (per year) 58.7 55.5
Mean 52 to 65 40 to 65
Range 1.224 (0.929 to 1.612) 0.151
SBP (per 10 mmHg) 160.5 155.1
Mean 122 to 180 116 to 180
Range 1.712 (1.129 to 2.596) 0.011
TC/HDL ratio 5.3 4.7
Mean 3.8 to 7.4 3.5 to 7.6
Range
No., number; SBP, systolic blood pressure; TC, total cholesterol; HDL, HDL-cholesterol.




When we imputed data without range restrictions, there was no difference in the 
percentage of shifts in risk category compared to the shifts in risk category mentioned 
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When we imputed data without range restrictions, there was no difference in the 
percentage of shifts in risk category compared to the shifts in risk category mentioned 
above (data not shown). The same results emerged from the complete case analysis  
(n = 236).




In our primary care cohort, revision of the guideline on cardiovascular risk management 
led to a shift in risk category in one in five patients (20%) and to a concomitant shift in 
drug recommendation in 12% of the patients.
In addition, the finding that about 60% of the patients use preventive medication whilst 
having a low risk suggests considerable overtreatment of low-risk patients.
Strengths and limitations
Data for the present study were based on patients’ EMRs because, in the Netherlands, 
CVRM is predominantly primary care based, and all Dutch citizens are enlisted with 
a general practice. This ensures that our cohort is a representative sample from the 
general population that is eligible for primary preventive cardiovascular care. Sampling 
from a large cohort of patients strengthens the external validity of our results. Moreover, 
over 96% of the problems registered in the EMRs of the healthcare centres of RNUH — 
LEO are coded with an ICPC code (which is higher than in the average Dutch general 
practices), ensuring a reliable selection of our study participants.25
We imputed 48.1 – 50.2% of the SBP, TC/HDL ratio and smoking status-values in the 
dataset to be able to calculate 10-year cardiovascular risk. This may be a true reflection 
of the incompleteness of relevant data before deciding on the prescription of preventive 
medication, but can also be due to the incomplete registration of data in the EMRs. 
However, the imputed dataset showed the same percentage of shifts in the risk category 
as the complete case analysis.
Comparison with existing literature
In an earlier study, we found that 61.4% of the patients had a predicted low 
cardiovascular 10-year risk according to the 2006 Dutch CVRM guideline before start 
of medication, compared with 70.6% (based on the 2006 version) in the present study.26 
Besides this confirmation in a new patient population, the present study reports on 
the implications of a guideline revision at a population level with regard to shifts in risk 
categories and drug recommendations.
Scheltens et al., compared the Framingham risk score with the SCORE risk function 
with regard to the number of patients assigned to treatment; a difference with our 
study is that we examined an actually revised guideline, making the present study less 
hypothetical.27 Another additional aspect of this study is that we report the determinants 
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In this study, we observed that about 60% of the patients use preventive medication 
whilst having a low risk. This can be explained by former guidelines (before the guideline 
on integrated CVRM was issued) recommending preventive medication based on a single 
risk factor (‘hypertension’ or ‘hypercholesterolemia’, etc.) without taking other risk 
factors (e.g. age, sex and smoking status) into account and not integrating the risk. It is 
likely that also a considerable number of low-risk patients in other European countries 
are unnecessarily treated as well. For example in Germany, as in the Netherlands, 
the concept of starting treatment based on the total burden of risk was adopted only 
recently,9, 17 although the European guideline adopted this idea much earlier.28
Implications for research and practice
GPs should be aware that a revised guideline in the area of primary prevention of 
CVD could have consequences for their patients: it is advisable to re-evaluate drug 
recommendations in patients assessed according to the former guideline and not yet 
using preventive treatment.
Then again, a large proportion of patients seem to use medication without a clear 
indication, irrespective of the version of the guideline used. It remains unclear how 
to proceed when a revised guideline has a higher threshold for starting preventive 
medication, resulting in situations where patients may well be advised to stop taking 
preventive medication they have been using, sometimes for years on a row. Obviously, it 
is important to establish whether withdrawal of medication in patients with low risk is 
safe in the long run, and whether this is efficacious and cost effective.
CONCLUSION
Revision of a guideline in the area of primary prevention of CVD may have a considerable 
impact on patient care since it may lead to shifts in risk categories and, accordingly, to 
shifts in drug recommendation. Professional medical organizations in countries with 
guidelines for primary preventive CVD care, especially when using risk charts, should be 
aware of these consequences and develop protocols for healthcare professionals on how
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aware of these consequences and develop protocols for healthcare professionals on how
to cope with these reclassifications.
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KEY MESSAGE
-  Revising the Dutch guideline on cardiovascular risk management implied a shift in 
drug recommendation in 12% of the patients.
-  GPs should be aware of the possible consequences of guideline revisions for 
patients.
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Table 1. Differences in additional risk factors, used for determining recommendations 
for medication in medium-risk patients, between the two Dutch guidelines 
on cardiovascular risk management (200618 and 201220) and conversion of the 
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Additional risk factor Conversion of EMR registration to be 
able to assess drug recommendation
Additional 
risk factors





CVD in a first degree 
relative <60 years
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relative <65 years
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relatives <65 years
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30-35 kg/m2
CVD in a first-
degree relative 
<60 years
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min/1.73m2
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60 ml/min/1.73m2













<30 min/d, ≤5 d/wk
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≥30 min/d, ≥5 d/wk
CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; MDRD, modification of diet 
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ABSTRACT
Background
Use of cardiovascular medication for primary prevention of cardiovascular disease 
(CVD) is potentially inappropriate when potential risks outweigh the potential benefits. 
It is unknown whether deprescribing preventive cardiovascular medication in patients 
without a strict indication for such medication is safe and cost-effective in general 
practice.
Methods
In this pragmatic cluster randomised controlled non-inferiority trial we recruited 46 
general practices in the Netherlands. Patients, aged 40-70 years, using antihypertensive 
and/or lipid-lowering drugs without CVD and with low risk of future CVD, were followed 
for two years. The intervention was an attempt to deprescribe preventive cardiovascular 
medication. The primary outcome was the difference in the increase in predicted (10-
year) CVD risk in the per-protocol (PP) population with a non-inferiority margin of 2.5 
percentage points. An economic evaluation was performed in the intention-to-treat (ITT) 
population. We used multilevel (generalised) linear regression with multiple imputation 
of missing data.
Results
Of 1067 participants recruited between November 7, 2012 and February 18, 2014 72% 
were female; mean age was 55 years; mean predicted CVD risk at baseline was 5%. Of 
492 participants  (ITT intervention group), 319 (65%) quit the medication (PP intervention 
group); 135 (27%) of those participants were still not taking medication after two years.
The predicted CVD risk increased by 2.0 percentage points in the PP intervention group 
compared to 1.9 percentage points in the usual care group. The difference of 0.1 (95% CI 
-0.3 to 0.6) fell within the non-inferiority margin. Compared to the usual care group, the 
SBP was 6 mmHg higher after two years in the PP intervention group, DBP was 4 mmHg 
higher, and the total cholesterol and LDL-cholesterol levels were both 7 mg/dl higher 
(all P<0.05). Cost and quality-adjusted life-years did not differ between the groups.
Conclusions
The results of the ECSTATIC study show that an attempt to deprescribe preventive 
cardiovascular medication in low-CVD-risk patients is safe when blood pressure and 
cholesterol levels are monitored after stopping. An attempt to deprescribe medication 
can be considered, taking patient preferences into consideration.
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BACKGROUND
Cardiovascular disease (CVD) remains a leading cause of mortality and morbidity 
worldwide and is associated with a loss of quality of life and high costs.1, 2 Physicians 
use their clinical judgement as well as clinical practice guidelines to determine whether 
treatment with antihypertensive and lipid-lowering drugs is necessary in individual 
patients. Recommendations concerning initiation of drug treatment in patients with 
hypertension or hypercholesterolemia, but without established CVD, are subject to 
change and are still under debate. Currently, guideline recommendations concerning 
initiation of drug treatment are often based on composite risk scores.3-7 However, 
recommendations to start medication in previous guidelines used to be based on single 
risk factors, such as increased blood pressure or cholesterol levels, or diabetes, and 
thus lacked an integrated approach to risk management8-10 which resulted in drug 
prescription to patients that are now considered low-CVD-risk patients. Over time, 
these evolving recommendations have resulted in the potentially inappropriate use 
of antihypertensive and lipid-lowering drugs, namely, in situations where potential 
risks (e.g., side effects) outweigh the potential benefits.11-14 Although physicians are 
aware that medication use in low-CVD-risk patients is of little benefit, fear of negative 
consequences and lack of evidence for withdrawal keep them from stopping the 
medication.15 A study investigating the positive (e.g., quality of life) and negative effects 
(e.g., increase in CVD risk, experiencing inconvenient symptoms) of deprescribing 
preventive cardiovascular medication in low-CVD-risk patients may improve the 
knowledge of the physician on this point. Depending on the outcome, this may lead to 
a more positive or negative attitude towards deprescribing in this patient population 
amongst physicians. Therefore, the aim of the Evaluating Cessation STatins and 
Antihypertensive Treatment In primary Care (ECSTATIC) study was to evaluate whether 
an attempt to deprescribe preventive cardiovascular medication in low-CVD-risk patients 




The ECSTATIC study was designed and carried out as a cluster randomised non-blinded 
parallel-group active-control non-inferiority study, including patients from 46 general 
practices in the western part of the Netherlands from November 7, 2012, with a follow-
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up period lasting until November 20, 2015 (Dutch Trial Register, NTR3493). To reduce 
contamination of the participants in the control group, the unit of randomisation and 
analysis was the general practice. The primary outcome was the difference in the 
increase in the predicted 10-year CVD risk in the two years after the first visit. Our 
choice for a non-inferiority trial design was based on the expectation that the attempt 
to deprescribe preventive cardiovascular medication in low CVD risk patients would 
increase CVD risk to some extent, but, at the same time, would lead to fewer side 
effects, less cost and the disutility of daily medication use, together tipping the risk-
benefit ratio into its favour.
The study protocol was approved by the medical ethics committee of the Leiden 
University Medical Center. The study was conducted in accordance with the Declaration 
of Helsinki. The study received external funding from ZonMw, The Netherlands 
Organisation for Health Research and Development (reference number 200320017). The 
funder of the study had no role in the study design, data collection, data analysis, or 
interpretation to the data.
To avoid allocation bias and imbalance in the number of general practices allocated to 
the study groups, we used computer-generated block randomisation in a 1:1 ratio, with 
random block sizes consisting of 10 or 12 general practices.
General practices and participants
All general practices in our network were invited. Before randomisation, general 
practitioners (GPs) of the practices selected possibly eligible patients who were 40 to 
70 years old without established CVD, using potentially inappropriate antihypertensive 
or lipid-lowering drugs for at least one year based on their electronic medical record 
(EMR) (Figure 1). Patients aged below 40 years old or over 70 years old were excluded, 
because the SCORE risk function (recalibrated for the Dutch population), that we used 
to assess eligibility for inclusion, is only available for patients aged 40 to 70 years old.4 
Subsequently, the participating general practices were randomised. GPs sent a written 
invitation for trial participation to their patients who had already been declared eligible 
before randomisation. We used a complete-double consent design in which informed 
consent was sought in both the intervention group and usual care group, mentioning the 
use of the other comparison group. To avoid contamination of the usual care group, the 
invitation letter sent to the usual care group did not specify the exact intervention. The 
letter sent to the intervention group explained the intervention and mentioned the use of 
a control group that was given care as usual.16
After obtaining informed consent of the patients, the researchers re-assessed the 
patients for eligibility using the SCORE risk function recalibrated for the Dutch 
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population as used in the Dutch guideline for Cardiovascular Risk Management (Figure 
2).4 An overview of all patient inclusion and exclusion criteria is listed in Additional file 1.
Inclusion criteria
- Age 40 to 70 years
-  Using antihypertensive and/or lipid-lowering drugs for ≥ 12 months
-   No recommendation for drug treatment according to Dutch guideline cardiovascular 
risk management
Exclusion criteria
- History of cardiovascular disease
Figure 2. Inclusion and exclusion criteria ECSTATIC trial
We assessed the pre-treatment CVD risk based on current (i.e., at first visit) age, sex, 
and smoking behaviour (smoking yes/no), in combination with reported pre-treatment 
systolic blood pressure (SBP) and total cholesterol/HDL-cholesterol ratio levels in 
general practice EMRs. If these values were not available up to one year before the 
start of drug treatment, pre-treatment SBP was conservatively estimated at 180 mmHg, 
and low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol levels 
were estimated based on current levels of total cholesterol, HDL-cholesterol, and LDL- 
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CHAPTER 3
Center and led by a GP with special interest in cardiovascular risk management and the 
researcher of this project (CL).
 
At the first visit, the research nurse advised participants in the intervention practices to 
consult their GP to discuss deprescribing their preventive cardiovascular medication. 
For more details about the factors influencing this decision-making process we refer 
to an earlier study we performed.17 When deprescribing was attempted, GPs followed 
our predefined deprescribing guideline for gradual dose reduction and monitoring of 
blood pressure and cholesterol levels (Additional file 2). Furthermore, they were advised 
to follow the recommendations of the Dutch guideline for Cardiovascular Risk for (re-)
initiation of medication (Additional file 2).
 
There was no intervention planned for the GPs, practice nurses, and participants in the 
usual care group.
Outcome measures
For all participants, we aimed for a follow-up period of two years. The primary outcome 
assessed for non-inferiority was the increase in participants’ predicted 10 year CVD risk 
in the two years after the first visit. Non-inferiority would be declared if the upper limit 
of the 95% confidence interval of the difference between the mean increase in CVD risk 
in the intervention group and the mean increase in the CVD risk in the usual care group 
was below +2.50 percentage points (on an absolute scale). The non-inferiority margin 
was set at 2.50 percentage points, because we believed this difference in the increase in 
the 10-year CVD risk between the intervention group and usual care group was clinically 
acceptable.
 
Secondary outcomes assessed for superiority were SBP, diastolic blood pressure (DBP), 
total cholesterol, HDL-cholesterol and LDL-cholesterol levels, body mass index (BMI: 
body weight kg / height in meters squared), waist circumference, body weight, smoking 
behaviour, physical activity, fruit and vegetable intake, and alcohol consumption; all 
were assessed at three months and two years after the first visit. These variables 
were assessed as outcomes, because we hypothesized that the intervention could 
induce lifestyle changes that could affect these variables. Other secondary outcomes 
were negative effects of deprescribing (in the intervention group) and side effects of 
antihypertensive and lipid-lowering drugs (in the usual care group) reported by GPs 
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We performed three post-hoc analyses to investigate differences between the 
intervention group and the usual care group after two years of follow-up, using a 
generalised logistic mixed linear model to assess the relative risk (RR) of: 1) having a 
mean increase in CVD risk >2.50 percentage points; 2) having hypertension, defined by 
a SBP >140 mmHg; and 3) having hypercholesterolemia, defined by a LDL-cholesterol 
level >96.5 mg/dl (=2.5 mmol/L). We did not adjust for the baseline values in order to 
calculate RR based on the observed odds ratio (OR) 18.
Measurements
Participants were visited at baseline (first visit), after three months and after 24 months 
by trained research nurses at the general practice of their GP. During these visits, 
smoking behaviour was registered, and SBP and DBP were measured twice with a five-
minute interval on the arm where SBP at baseline was highest after at least five minutes 
of seated rest4 (Omron HEM-907); additionally, body weight in kilograms (seca 762), 
height in centimetres (seca 213), and waist circumference in centimetres (seca 201) were 
measured and registered. The research nurse registered the total cholesterol, HDL-
cholesterol, and LDL-cholesterol values that local laboratories reported to the general 
practices.
If research nurses measured a mean SBP >180 mmHg, or registered a total cholesterol 
level  >308.9 mg/dl (8 mmol/l) or a LDL-cholesterol level  >193.1 mg/dl (5 mmol/l ) the 
participant’s GP was notified.
Two weeks before each visit, participants were asked to prospectively keep a 7-day diary 
of their alcohol consumption19 and to complete questionnaires concerning: 1) ethnicity 
and education level (only at baseline); 2) physical activity (short questionnaire to assess 
health-enhancing physical activity (SQUASH)20-22); and 3) fruit and vegetable intake 
(standard nutrition questionnaire of Dutch common health services23). The research 
nurse collected and checked the completed questionnaires during the visit.
At 24 months of follow-up, participants in the intervention group were asked to describe 
their ‘deprescribing status’ of preventive cardiovascular medication by choosing one 
of five options: 1) currently not using medication, 2) currently using fewer or lower 
doses of medications, 3) restarted some medications, 4) restarted all medications, or 5) 
never stopped or tried to stop. In case participants did not complete the deprescribing 
status questionnaire, we used the reported negative effects of deprescribing by the 
GP to search for information about their deprescribing status, and registrations of the 
participants’ deprescribing status by the research nurse during follow-up.
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GPs in the intervention group were asked to report negative effects of deprescribing to 
the researchers during trial follow-up, and GPs in the usual care group were asked to 
report side effects of antihypertensive and lipid-lowering drugs. Although assessment of 
negative effects of deprescribing in the control group would improve comparison of the 
safety profile of the intervention this was not possible for practical reasons (e.g., to avoid 
contamination).
The incidence of CVD in participants was determined, using corresponding ICPC codes 
for angina pectoris (K74), acute myocardial infarction (K75), other/chronic ischaemic 
heart disease (K76), transient ischaemic attack (K89), cerebrovascular accident (K90.03), 
atherosclerosis (K91), vascular claudication (K92.01), and aortic aneurysm (K99.01), as 
registered by the GP in the EMR (standard care) during follow-up.
Economic evaluation
Costs were estimated in the intention-to-treat (ITT) population from a societal 
perspective at the price level from 2015.24 Costs are reported in pounds (based on 
purchasing power parities of 08-08-2016). Primary care specific costs included 
costs for periodically carried out patient selection (Additional file 3), general practice 
consultations, antihypertensive and lipid-lowering drug use, and cardiovascular 
management related laboratory measurements; all of these were based on the 
EMR from the general practices. Total healthcare costs also included specialist and 
physical therapist consultations, use of home care, and hospitalisations, all reported 
by the participants in a cost questionnaire with a three-month recall period that was 
administered at 3, 6, 12 and 24 months in the follow-up period (months in between were 
interpolated). Cost-effectiveness acceptability curves were used to relate the difference 
in costs to the difference in 2-year quality-adjusted life years (QALYs), as assessed with 
the Dutch tariff for the EQ-5D-3L questionnaire.25 Hypothetically, QALYs would be higher 
in the intervention group compared to the usual care group because of the reduction 
of the burden of daily medication use and side effects but would be lower because of 
an increase in the 10-year CVD risk.  Acceptability curves show the probability that 
the intervention has better net benefit (NB = WTP x QALY – Costs) than the usual care, 
depending on the willingness to pay (WTP) for one QALY.26 
The economic evaluation was limited to the 2-year trial period, because no reliable 
information is available to extrapolate the long-term impact on medication use and the 
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Statistical analysis
For sample size calculation, we set the expected difference in the increase in the 10-
year CVD risk at 1.50 percentage points and the standard deviation (SD) at 3.5, and we 
estimated the number of participating patients per general practice attempting to have 
their medication deprescribed at 10 (per-protocol population) based on data from a 
previous study concerning deprescribing preventive cardiovascular medication in low 
CVD risk patients.12 We assumed an intraclass correlation coefficient of 0.05, taking into 
account differences between the participating general practices that could influence 
study outcomes. The prespecified non-inferiority margin of 2.50 percentage points was 
based on both statistical reasoning (sample size) and clinical judgement and was set as 
the maximum allowed upper limit of the 95% confidence interval (one-sided alpha of 5%) 
of the difference in the increase in the 10-year CVD risk.27 Assuming that two-thirds of 
the participants would attempt to have their medication deprescribed, we estimated that 
464x1.5=696 participants from 46 general practices needed to undergo randomisation. 
Recruitment of general practices was stopped after the number of 46 included general 
practices was reached.
During the trial, the proportion of participants attempting to have their medication 
deprescribed was less than the expected 67% (approximately 55%), while the number of 
eligible patients per general practice was higher than expected. We therefore decided to 
increase the number of included patients per general practice, allowing us to decrease 
the planned one-sided alpha from 5% to 2.5%. At the end of the inclusion period we 
again had to randomly exclude patients from invitation, because the number of possibly 
eligible patients per general practice was even higher than anticipated early on in the 
trial (Figure 1).
The primary outcome was evaluated in the per-protocol (PP) population, defined as all 
patients who were included at the first visit and were allocated to the usual care group, 
and all patients who were included at the first visit in the intervention group who had 
(attempted to have) their preventive cardiovascular medication stopped based on their 
self-reported deprescribing status. In non-inferiority trials an ITT analysis tends to bias 
towards making the intervention and usual care look similar. Therefore, we chose to 
evaluate the primary outcome in a PP analysis, as this analysis is more likely to reflect 
differences between two treatments.28 Secondary outcomes were evaluated in the PP 
population as well. All analyses were repeated for the ITT population; the ITT population 
is defined as all usual care and intervention group patients who were included at the first 
visit. Furthermore, we evaluated the primary outcome, SBP, DBP and LDL-cholesterol 
levels in the ‘quitters’ population, defined as all usual care group patients and all 
intervention group patients who were able to permanently stop their medication based 
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CHAPTER 3
on their self-reported deprescribing status. The intervention group patients are defined 
as ITT intervention group; the intervention group patients who had (attempted to have) 
their preventive cardiovascular medication stopped are defined as PP intervention group; 
and the intervention group patients who persisted without cardiovascular medication two 
years after the first visit are defined as the quitters intervention group.
We used multiple imputations to deal with missing values of primary and secondary 
outcomes and predictors in 15 imputation sets.29 The following baseline predictors, 
without any missing values, were used to build the imputation model: allocation group, 
sex, age, SBP, total cholesterol, HDL-cholesterol, and the utility value of the EQ-5D-
3L questionnaire. The clusters were not included as predictors to avoid instability of 
the model. The imputation model for symmetrically distributed continuous variables 
was based on linear regression, for skewly distributed continuous variables (skewness 
statistic >1 or <-1) predictive mean matching was used. The imputation model for 
dichotomous variables was based on logistic regression. For missing values of height at 
baseline, we used the value reported at the end of follow-up and vice versa. For age, we 
calculated the patient’s age at median date of the assessments at 24 months of other 
patients coming from the same general practice. One intervention group patient, who 
never attempted to have her preventive cardiovascular medication deprescribed, died of 
an unknown cause, and was left out of our intention-to-treat analyses at 24 months.
To compare continuous and binary outcomes, linear mixed and generalised (logistic) 
mixed linear models were used, respectively, to adjust for cluster randomization and 
baseline values of the outcome that was evaluated. Given the low incidence of CVD 
estimation of a clustereffect would be unreliable, therefore CVD incidence was analysed 
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patients coming from the same general practice. One intervention group patient, who 
never attempted to have her preventive cardiovascular medication deprescribed, died of 
an unknown cause, and was left out of our intention-to-treat analyses at 24 months.
To compare continuous and binary outcomes, linear mixed and generalised (logistic) 
mixed linear models were used, respectively, to adjust for cluster randomization and 
baseline values of the outcome that was evaluated. Given the low incidence of CVD 
estimation of a clustereffect would be unreliable, therefore CVD incidence was analysed 
with Fisher’s Exact test. SPSS Statistics for Windows, version 23 was used for all 
analyses.
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RESULTS
A total of 1067 participants at 46 general practices (16% of invited general practices) 
were included between November 2012 and February 2014 (Figure 1 and Table 1). The 
median follow-up period was 23 months (range 17 to 32 months), and the intraclass 
correlation coefficient for the primary outcome was <0.01. The ITT intervention group 
consisted of 492 participants; the PP intervention group consisted of 319 (65% of the 
ITT intervention group), and had (temporarily) deprescribed medication; the quitters 
intervention group  consisted of 135 participants (27% of the ITT intervention group), and 
persisted without cardiovascular medication two years after the first visit (Figure 3). At 
baseline, there were some differences between the usual care group, and the PP and ITT 
intervention groups (Table 1).
Baseline CVD risk in the PP intervention group was 4.7% compared to 5.3% in the 173 
intervention group participants who continued their medication or had unknown de-
prescribing status. The total cholesterol/HDL-cholesterol ratio at baseline was lower 
in participants who had (temporarily) deprescribed medication. However, there was no 
difference in age, sex, smoking behaviour, SBP, or LDL-cholesterol levels.
In 15% of the participants levels of SBP, total cholesterol/HDL-cholesterol ratio, or 
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Primary outcome
The PP analysis showed a two-year increase in CVD risk in both the intervention group 
and usual care group, from 4.7% to 6.7% (+2.0 percentage points) and from 5.1% to 
7.0% (+1.9 percentage points), respectively. The mean increase in CVD risk was +0.1 
percentage points higher in the deprescribing group, with a 95% CI of -0.3 to 0.6 
percentage points, establishing non-inferiority (Figure 4). The ITT analysis showed 
similar results; CVD risk increased from 4.9 to 6.9% (+2.0 percentage points) in the 
intervention group, with a mean difference in the increase of 0.1 percentage points (95% 
CI -0.4 to 0.7).
Secondary outcomes
Figure 5 shows SBP, LDL-cholesterol levels, and predicted 10-year CVD risk at the first 
visit, and three and 24 months after the first visit. At the end of follow-up, SBP, DBP, 
total cholesterol, and LDL-cholesterol levels were higher in the PP intervention group 
compared to the usual care group (all P<0.01, Table 2). Smoking behaviour and BMI were 
similar in both groups. Physical activity level, fruit and vegetable intake, and alcohol 
consumption were also similar in both groups. The ITT analysis showed similar results 
on the secondary outcomes.
Cardiovascular events and other negative effects
In the usual care group eight participants developed CVD during follow-up, and zero 
developed CVD in the PP intervention group (P=0.03). In the ITT intervention group two 
participants developed CVD (P=0.12 compared to the usual care group). CVD incidence 
could not be identified in 61 participants because of withdrawn informed consent (29 
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In the PP intervention group, GPs reported 76 negative effects because of deprescribing 
in 42 of 319 participants (13.2%) (Table 3). Antihypertensive and/or lipid-lowering drugs 
were restarted in 34 of these 42 participants. GPs in the usual care group reported no 
side effects of antihypertensive or lipid-lowering drugs during follow-up. 
Table 3. Negative effects of deprescribing reported to the researchers by GPs in the 
intervention groupa
Negative effects Participants (n= 42) Only restarted 
participants (n= 34)




Headache or migraine 18 11
Nervous or stressed feeling 7 5
Palpitations 7 5
Ankle edema/fluid buildup 4 3
Hypercholesterolemia 4 4




Not feeling well 2 2
Tachycardia 1 1




Hot flushes 1 1
Total 76 61
Abbreviations: GP denotes general practitioner
a GPs in the usual care group did not report any side effect of antihypertensive or lipid-
lowering drugs to the researchers during follow-up.
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Analysis of 135 participants who were still not taking medication two years after the 
first visit (Figure 3), showed a two-year increase in CVD risk from 4.3% to 6.6% (+2.3 
percentage points). This increase was a +0.4 percentage points higher compared to 
the usual care group, with a 95% CI of -0.3 to 1.1 percentage points, establishing non-
inferiority. Two years after the first visit, the difference in SBP between the quitters 
intervention group and the usual care group was 10 mmHg (146 vs. 136 mmHg, 
respectively); the difference in DBP was 7 mmHg (87 vs. 80 mmHg, respectively); and the 
difference in LDL-cholesterol was 13 mg/dl (141 vs. 128 mg/dl, respectively); all were 
P<0.01.
The difference in SBP between the 115 participants who had their antihypertensive 
drugs deprescribed (Figure 3) compared to the 479 participants using antihypertensive 
drugs at baseline in the usual care group was 13 mmHg two years after the first visit 
(149 vs. 136 mmHg, respectively, P<0.01). The difference in LDL-cholesterol of the 26 
participants who had their lipid-lowering drugs deprescribed (Figure 3) compared to the 
163 participants using lipid-lowering drugs at baseline in the usual care group was 56 
mg/dl (178 vs. 122 mg/dl, respectively, P<0.01).
Individual follow-up
The RR of having a mean increase in CVD risk >2.5 percentage points after two years 
of follow-up for the PP intervention group versus the usual care group was 1.29 (95% 
CI 1.01 to 1.61, based on a baseline risk of 0.222 and a OR of 1.40). The RR of having a 
SBP >140 mmHg and the RR of having a LDL-cholesterol level >96.5 mg/dl for the PP 
intervention group versus the usual care group was 1.41 (95% CI 1.18 to 1.64, based 
on a baseline risk of 0.372 and a OR of 1.87) and 1.10 (95% CI 1.04 to 1.15, based on a 
baseline risk of 0.807 and a OR of 1.96), respectively. The ITT analysis showed similar 
results for having a SBP >140 mmHg and having a LDL-cholesterol level >96.5 mg/dl, as 
the RR and 95% CI in the ITT analysis were comparable to the RR and 95% CI resulting 
from the PP analysis. In the ITT analysis, the RR of having mean increase in CVD risk 
>2.5 percentage points for the PP intervention group versus the usual care group was 
1.21 (95% CI 0.97 to 1.49).
Economic evaluation
In the first year, intervention costs and GP consultation costs were higher in the ITT 
intervention group by £86 per participant (Additional file 3: Table S3, P<0.01). In both 
years, medication costs were lower in the ITT intervention group by £28 (P<0.01). Total 
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2-year healthcare costs and primary care costs did not differ between the two groups 
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(P=1.00 and P=0.19, respectively). In addition, no difference was found in QALYs (P=0.45) 
(Additional file 3: Table S3). Whether an attempt to deprescribe preventive cardiovascular 
medication is cost-effective depends on how much one is willing to pay for one QALY. 
Figure S2 in Additional file 3 shows the probability that an attempt to deprescribe 
preventive cardiovascular medication in general practice is cost-effective compared with 
usual care. An attempt to deprescribe preventive cardiovascular medication is 70% to 
80% likely to be cost-effective for a willingness to pay between £20,000 and £30,000. 
DISCUSSION
The ECSTATIC study revealed that an attempt to deprescribe preventive cardiovascular 
medication in patients in general practice with predicted low 10-year CVD risk was safe 
in the short term compared to usual care based on a minimal difference in the increase 
in predicted 10-year CVD risk. After two years of follow-up, the mean blood pressure 
was 6 mmHg higher, and the total cholesterol and LDL-cholesterol levels were both on 
average 7 mg/dl higher compared to usual care in the intervention group. The risk of 
having hypertension after two years of follow-up was approximately 20% to 60% higher 
in the intervention group and the risk of having hypercholesterolemia was approximately 
5% to 15% compared to the usual care group. Only 27% of participants persisted without 
medication two years after the first visit. In the intervention group, 1-year primary care 
costs were higher, but 2-year primary care costs and total healthcare costs were similar 
and there was no difference in QALYs.
Based on our findings, an attempt to deprescribe preventive cardiovascular medication 
in low CVD risk patients is safe when blood pressure and cholesterol levels are 
monitored after stopping, but does not improve the quality of life or reduce healthcare 
costs.
Strengths and weaknesses of study
Study strengths include the large sample of general practices and patients, and the 
pragmatic trial design; both of these reflect the results of implementing such an 
intervention in daily practice.
The ECSTATIC study was not designed to answer questions about efficacy, but 
was designed as a pragmatic trial, to answer the question whether a structured 
deprescribing strategy in low-CVD-risk patients is (cost-)effective when implemented 
in general practice.30 The pragmatic choice to leave the decision to deprescribe to the 
patient and their GP and the choice to use an active control group may have resulted 
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CHAPTER 3
in an underestimation of the effect of the intervention on CVD risk, blood pressure and 
cholesterol levels.31 A PP analysis gave information on the potential effects of an attempt 
to deprescribe preventive cardiovascular medication.
The differences at baseline between the intervention group and the usual care group 
may be the consequence of the different invitation letters that both groups received. We 
minimised the effect of these differences by correcting all analyses (except for the post-
hoc analyses) for baseline values.
Our choice to include participants in the trial based on their predicted 10-year CVD risk 
was practice-driven. Although current debate questions the use of population-based 
prediction models for drug treatment in individuals, these models seem to predict 
individual CVD risk better in low risk than in high risk populations.32, 33 The predicted 
10-year CVD risk score is designed to assess risk while off treatment, however, the 
predictions of this risk assessment tool are partly based on cohorts of patients using 
cardiovascular medication, justifying its use in our patient population.34 Additionally, our 
choice to include participants based on their 10-year CVD risk was based on the best 
available evidence as aggregated in the current Dutch guideline for cardiovascular risk 
management. The long-term incidence of CVD would have been the optimal primary 
outcome measure for our trial; however, time and budgetary restrictions kept us from 
using this endpoint. We would encourage future studies to compare a deprescribing 
strategy with usual care in low-CVD-risk patients based on long-term incidence of CVD.
In 15% of the participants we had to impute for missing data to be able to analyse 
the primary outcome. This number of missing data may lead to less reliable results. 
However, we used rigorous imputation methods to ensure the validity of our data and the 
precision of our results.29 It was hard to verify based on the EMR whether a medication 
was stopped after two years of follow-up, or whether it was just not yet prescribed again. 
Therefore, self-reported deprescribing status seemed more reliable. The self-reported 
deprescribing status may have led to incorrect allocation to ITT intervention group, 
PP intervention group, and the quitters intervention group. However, SBP and LDL-
cholesterol levels in the PP intervention group and the quitters intervention were higher 
than in the ITT intervention group, suggesting that the allocation was quite reliable. 
Because adequate registration of cardiovascular events in the EMR is usual practice and 
its extraction based on ICPC-codes was protocolised, we believe the lack of blinding in 
these cases was not prohibiting objective registration and collection of events.
 
Comparison with other studies and interpretation
The ECSTATIC study adds new information to the body of knowledge concerning 
preventive cardiovascular drug treatment in primary prevention of CVD because of its 
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pragmatic design, carried out in a primary care population with low average CVD risk.
It has been known that the preventive effects of antihypertensive and lipid-lowering 
drugs in low CVD risk populations are less than in intermediate and high risk 
populations.35-39 The HOPE-3 investigators found that treatment with 16 mg of 
candesartan and 12.5 mg of hydrochlorothiazide per day in intermediate risk patients 
did not result in a significant lower risk of major cardiovascular events compared to a 
placebo.37 Antihypertensive therapy reduced CVD risk only in intermediate risk patients 
with higher baseline SBP (>143.5 mmHg).37 Furthermore, the meta-analysis of the 
Cholesterol Treatment Trialists’ (CTT) Collaborators found that a statin induced LDL-
cholesterol reduction of 1 mmol/l (38.6 mg/dl) in patients without vascular disease with 
a 5-year major vascular event risk <5%, did lower the rate ratio of vascular events, 
though not the rate ratio of vascular death.35 The findings of these studies are consistent 
with the similar and low incidence of CVD (although underpowered) in the usual care 
group and intervention group and the non-inferiority of an attempt to deprescribe in the 
ECSTATIC population (which had a mean SBP of 140 mmHg at baseline, and a mean 10-
year CVD risk of 5%).
With a mean 10-year CVD risk of 5%, the ECSTATIC population has lower risk compared 
to populations in other trials. Based on their reports of baseline characteristics, study 
populations of recent trials, such as the JUPITER Study (approximately 15% 10-year 
CVD risk), the HOPE-3 trial (approximately 17% 10-year CVD risk), and the SPRINT trial 
(approximately 24% 10-year CVD risk), have higher risks at baseline, predominantly 
because of higher ages and fewer female participants.37, 40-43 The findings from these 
trials can therefore not directly be compared with the ECSTATIC population. With a 
mean 10-year CVD risk of approximately 6%, mean age of 58.3 years and inclusion 
of 68% women, the total Asian population in the MEGA Study is most comparable to 
the ECSTATIC population.44 The MEGA Study showed that statins reduce relative risk 
of coronary heart disease in a subgroup of patients with LDL-cholesterol levels >4.01 
mmol/l (155 mg/dl).44 This suggests that the 26 ECSTATIC participants who had their 
lipid-lowering drugs deprescribed two years after the first visit, with a mean LDL-
cholesterol level of 178 mg/dl, may have beneficial preventive effects of statin use. 
However, other evidence suggests that the increase in total life expectancy and CVD-free 
life expectancy may be too small to justify long-term statin use at all, especially in an 
ageing population.45
It is remarkable that 35% of the participants in the intervention group ofthe ECSTATIC 
study did not do an attempt to have their medication deprescribed. Based on the 
findings of two of our previous studies, possible reasons for not doing an attempt are, for 
example, fear of the consequences of deprescribing, fear of cardiovascular events, the 
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CHAPTER 3
lack of negative effects of the medication participants experienced, or the GPs’ doubts 
about deprescribing.17, 46 Furthermore, only 27% of the participants in the intervention 
group persisted in quitting, while 65% of the participants did an attempt to have their 
medication deprescribed. Reasons for restarting medication were scarcely reported 
by GP, as reasons were reported in only 34 restarted participants (18% of all restarted 
participants). However, hypertension, headache, nervousness/stress, and palpitations 
were most frequently mentioned by GPs as reasons for restarting medication.
CONCLUSIONS
The results of the ECSTATIC study show that an attempt to deprescribe preventive 
cardiovascular medication in patients with predicted low CVD risk is safe in the 
short term, but does not necessarily improve quality of life or reduce healthcare 
costs. Moreover, less than one third of participants persisted without cardiovascular 
medication after two years of follow-up. Therefore, we do not recommend 
implementation of a structured deprescribing strategy for all patients with low CVD risk 
in general practice as was implemented in the intervention group of the ECSTATIC study.
However, an attempt to deprescribe may be considered in low CVD risk patients, e.g., 
during their routine (yearly) cardiovascular check-up and as the result of a shared 
decision between a doctor and his/her patient. In an earlier study we found that 
low-CVD-risk patients and their GPs may doubt the appropriateness of medication 
use, fear side effects, dislike medication use, and consider alternative prevention 
options.17 Although an attempt to deprescribe medication increases the risk of 
developing hypertension with approximately 20% to 60% and the risk of developing 
hypercholesterolemia with approximately 5% to 15%, the balance of the risks of (future) 
side effects and benefits for individual patients (e.g., no burden of daily medication use), 
together with patients’ preferences, may drift in the direction of an individual attempt 
to deprescribe medication. When an attempt to deprescribe preventive cardiovascular 
medication in low-CVD-risk patients is made, it is important to monitor blood pressure 
and cholesterol levels, especially in the first three months after withdrawal, and to 
assess whether drug treatment should be re-initiated. Combining deprescribing with a 
lifestyle intervention could possibly restrict increases in blood pressure and cholesterol 
levels and lower CVD risk.47-49 
In conclusion, a structured deprescribing strategy for all patients with low CVD risk in 
general practice is not recommended because of its low adherence (27% persistent 
quitters) and low gains in quality of life, but an attempt to deprescribe for those willing 
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to, is safe in the short term when blood pressure and cholesterol levels are monitored 
after stopping and can therefore be considered in low CVD risk patients during routine 
visits.
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Table 1. Baseline characteristics of general practices and participantsa 
Abbreviations: PP denotes per-protocol; ITT denotes intention-to-treat; GP denotes general practitioner; 
CVD denotes cardiovascular disease; HDL-cholesterol denotes high density lipoprotein cholesterol; LDL-
cholesterol denotes low density lipoprotein cholesterol.
a   Plus-minus values are means ±SD; all continuous variables were adjusted for cluster randomisation 
with multilevel linear models.
b  University (of Professional Education) level
c  P<0.05 compared to the usual care group
d   10-year CVD risk score estimated for inclusion with baseline values of age, sex, and smoking status, 
and pre-treatment systolic blood pressure and pre-treatment total cholesterol/HDL-cholesterol ratio 
as if participants did not use preventive cardiovascular medication.
e  10-year CVD risk score estimated at baseline with baseline values of age, sex, smoking status, systolic 
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Medication use at baseline
Using antihypertensive drugs – no. (%) 
-  Agents acting on the renin-angiotensin system 
– no. (%)
- Diuretics – no. (%)
- Beta blocking agents – no. (%)
- Calcium channel blockers – no. (%)
- Other antihypertensive drugs – no. (%)
-  Using antihypertensive drugs from ≥2 classes– 
no. (%)
Using lipid-lowering drugs – no. (%)
-HMG CoA reductase inhibitors – no. (%)
-Other lipid-lowering drugs – no. (%)
Using both antihypertensive and lipid-lowering 
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Table 2. Secondary outcomes after 24 monthsa
Abbreviations: PP denotes per-protocol; ITT denotes intention-to-treat; HDL-cholesterol 
denotes high densitiy lipoprotein cholesterol, and LDL-cholesterol low density lipopro-
tein cholesterol
a Plus-minus values are means ±SE from linear mixed models. 
b  Only participants who had (temporarily) deprescribed their preventive cardiovascular 
medication were analysed in the PP intervention group.
c  One participant who died of unknown cause during follow-up without having attempt-
ed to have her preventive cardiovascular medication deprescribed was left out in the 
analyses at 24 months in the ITT population of the intervention group.
d Compared to the usual care group at 24 months.
e To change value to mmol/l multiply by 38.61033861.
f   Using a generalised logistic mixed linear model adjusting for cluster randomisation did 
not result in a pooled estimate, therefore we calculated estimates for the 15 imputation 
sets and reported the lowest p value in this table.
g  For patients <55 years old only activities with a MET-score (Metabolic Equivalent score) 
≥4 kcal/kg/hour executed ≥60 minutes on one or more days were taken into account to 
assess physical activity level12; for patients ≥55 years old only activities with a MET-
score ≥3 kcal/kg/hour executed ≥30 minutes on one or more days were taken into 
account to assess physical activity level12.
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t=24 t=24 P valued t=24 P valued
Systolic blood pressure – mm Hg 136.0±0.8 142.4±0.9 <0.01 140.9±0.8 <0.01
Diastolic blood pressure – mm Hg 80.7±0.5 84.8±0.6 <0.01 84.2±0.5 <0.01
Total cholesterol/HDL-cholesterol ratio 3.83±0.04 3.89±0.05 0.22 3.90±0.05 0.35
Total cholesterol – mg/dl e 210.0±1.4 217.2±1.8 <0.01 214.1±1.6 0.05
HDL-cholesterol– mg/dl e 58.4±0.5 59.1±0.6 0.75 58.3±0.5 0.84
LDL-cholesterol– mg/dl e 128.2±1.3 135.1±1.7 <0.01 133.1±1.5 0.01
Smokers – no. (%)f 59 (10.3) 18 (5.6) >0.31 35 (7.1) >0.25
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Figure 1. Trial profile
Abbreviations: EMR, electronic medical records, GP, general practitioner; CVD, cardiovascular disease; 
FH, familial hypercholesterolemia.
a  The number of patients who declined to participate did not differ between intervention and usual care 
group adjusting for cluster randomisation (P=0.28).
b  At the measurement three months after the first visit 459 participants had complete data available 
for calculation of the 10-year CVD risk score; at the measurement 24 months after the first visit 403 
participants had complete data available for calculation of the 10-year CVD risk score.
c  At the measurement three months after the first visit 546 participants had complete data available 
for calculation of the 10-year CVD risk score; at the measurement 24 months after the first visit 499 
participants had complete data available for calculation of the 10-year CVD risk score.
d  Missing values of (systolic blood pressure and/or total cholesterol/HDL-cholesterol ratio and/or 
smoking status) of 88 participants in the intervention group and 76 in the usual care were imputed; 
one participant in the intervention group died of unknown cause without having attempted to have her 
medication deprescribed and was not included in the analysis
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Figure 5. Systolic blood pressure, LDL-cholesterol  level and predicted 10-year CVD 
risk over time in the usual care and intervention group
Abbreviations: CVD denotes cardiovascular disease; PP denotes per-protocol; ITT denotes inten-
tion-to-treat.
Measurements at t=0 were performed at the first visit. Error bars depict the 95% CI of the mean.
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SUPPLEMENTARY DATA
Additional file 1. Inclusion and exclusion criteria of the Evaluating Cessation of 
STatins and Antihypertensive Treatment In primary Care trial, as approved by the 
Medical Ethics Committee of the Leiden University Medical Center
Inclusion criteria
Patients in general practice are included in the study if they meet the following criteria:
- Age 40 to 70 years;
-  Prescription and use of antihypertensive medication and/or lipid-lowering drugs for 
hypertension and/or hypercholesterolemia during the last 12 months (using ATC codes: 
C02, C03, C07, C08, C09, C10).
Exclusion criteria
Patients with the following criteria are excluded:
-  Cardiovascular disease (ICPC codes: K74, K75, K76, K89, K90.03, K91, K92.01 and 
K99.01)1;
-  Use of platelet aggregation inhibitors (heparin excluded) (ATC code: B01AC);
-  Use of antihypertensive medication for another reason than prevention of CVD;
- Familial hypercholesterolemia/lipidemia (ICPC code: T93.04)a;
-  Patients with a current SBPb >180 mmHg, or a SBP >180 mmHg before the start of 
medication;
-  Patients with a current TC/HDL ratio >8, or a TC/HDL ratio >8  before the start of 
medication;
-  Patients with a 10-year CVD risk >16%c
-  10-year CVD risk of 10-16% based on the 2011 risk table, in combination with at least 
one additional major risk-increasing factor:
 -  Family history with ≥2 first degree family members with CVD <65 years or ≥1 
first degree family member with CVD <60 years;
 -  Physical activity: sedentary lifestyle;
 - Obesity: BMI >35 kg/m3;
 -  Kidney function: eGFR <30 ml/min/1.73m2;
 -  DM and poor metabolic control;
 -  DM and (micro)albuminuria;
 -  DM and microvascular complications;
 - RA with high disease activity.
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-  10-year CVD risk of 10-16%, based on the 2011 risk table, in combination with two or 
more additional minor risk-increasing factors: 
 - Family history: 1 first degree family member with CVD <65 years;
 -  Physical activity: <30 min/day ≤5 days per week (but not sedentary);
 -  Obesity: BMI >30-35 kg/m3 (or waist circumference >80 cm in women, >94 cm in 
men;
 -  Kidney function: eGFR <65 years 30-60 ml/min/1.73m2, eGFR ≥65 years 30-45 
ml/min/1.73m2.
-  10-year CVD risk of 10-16%, based on the 2011 risk table, in combination with one 
additional minor risk-increasing factor: 
 -  Family history: 1 first degree family member with CVD <65 years;
 -  Physical activity: <30 min/day ≤5 days per week (but not sedentary);
 -  Obesity: BMI >30-35 kg/m3 (or waist circumference >80 cm in women, >94 cm in 
men;
 -  Kidney function: eGFR <65 years 30-60 ml/min/1.73m2, eGFR ≥65 years 30-45 
ml/min/1.73m2;
AND
-  SBP >140 mmHg and/or LDL >2.5 mmol/L.
-  Patients <50 years with a repeatedly measured SBP >160 mmHg who do not reach 
their target SBP with help of lifestyle adjustments after 3 months.d
Abbreviations: SBP, systolic blood pressure; TC, total cholesterol; HDL, HDL-cholesterol; CVD, 
cardiovascular disease; BMI, body mass index; eGFR, estimated glomerular filtration rate; DM, diabetes 
mellitus; RA, rheumatoid arthritis; LDL, LDL-cholesterol.
a URL: http://www.kith.no/upload/2705/icpc-2-english.pdf
b  SBP was measured once at both arms, and twice at the arm with highest SBP at the first measurement 
after at least 5 minutes sitting rest; mean SBP of the two measurements at the same arm was noted 
as current SBP and SBP at baseline.
c  Patients with a 10-year CVD risk >16.99% (≥17%) were excluded.
d  This exclusion criterion appeared to be infeasible in practice.
Calculation of pre-treatment 10-year CVD risk
Pre-treatment CVD risk was based on current age, sex, and smoking behaviour 
(smoking yes/no), in combination with reported pre-treatment systolic blood pressure 
(SBP) and total cholesterol/HDL-cholesterol ratio levels in general practice EMRs. 
If these values were not available up to one year before the start of drug treatment, 
pre-treatment SBP was conservatively estimated at 180 mmHg; to estimate the pre-
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treatment total cholesterol ratio, 72 mg/dl (2.0 mmol/l) was added to the current total 
cholesterol level and 4 mg/dl (0.1 mmol/l) was subtracted from the current HDL level. 
In case patients were using only antihypertensive drugs, the current total cholesterol/
HDL-cholesterol ratio was used to estimate the pre-treatment CVD risk; in case patients 
were using only lipid-lowering drugs, current SBP was used to estimate pre-treatment 
CVD risk. The algorithm for the CVD risk calculation can be requested from the Dutch 
College of General Practitioners (Nederlands Huisartsen Genootschap, Utrecht, the 
Netherlands). Current SBP was measured with an automated sphygmomanometer 
(Omron HEM-907) once on both arms and twice on the arm with highest SBP at the first 
measurement, with an interval of five minutes after at least five minutes of seated rest. 
The mean SBP of the two measurements on the same arm was used as the current SBP 
to estimate the pre-treatment CVD risk. Local laboratories measured current levels of 
total cholesterol, HDL-cholesterol, and LDL- cholesterol.
We used an SBP of 120 mmHg for a mean SBP <120 mmHg to estimate CVD risk; an 
SBP of 180 mmHg, for a mean SBP >180 mmHg; a total cholesterol/HDL-cholesterol 
ratio of 4, when total cholesterol/HDL-cholesterol ratio <4; and a total cholesterol/HDL-
cholesterol ratio of 8, when total cholesterol/HDL-cholesterol ratio was >8.
In addition, for patients with intermediate pre-treatment CVD risk, to determine whether 
a patient met the inclusion criteria, current glomerular filtration rate (estimated using 
the Modification of Diet in Renal Disease Study equation measured by local laboratories) 
was used, together with current body mass index (BMI), physical activity level, and family 
history of CVD in accordance with the Dutch guideline.4
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CHAPTER 3
Additional file 2. Deprescribing guideline
The following examples of dose-lowering schemes (Table S1) were available for the 
general practitioners (GPs) to provide guidance when withdrawal of medication was 
attempted.
Table S1. Examples of dose-lowering schemes
Medication Example of dose-lowering scheme 
(in mg, per week)
Lipid-lowering drugs (in general) Stop at once
Hydrochlorothiazide 25 – 12.5 – 0
Chlorthalidone 25 – 12.5 – 0
Nifedipine 120 – 60 – 30 – 0
Amlodipine 10 – 5 – 0
Metoprolol 100 – 50 – 25 – 0
Enalapril 40 – 20 – 10 – 5 – 0
Lisinopril 30 – 20 – 10 – 5 – 0
Losartan 100 – 50 – 5
According to the research protocol, the GP or practice nurse monitored the patient 
when withdrawal of medication was attempted. In case antihypertensive drugs were 
deprescribed, blood pressure monitoring occured after four and 12 weeks and after 
six months; in case lipid-lowering drugs were deprescribed, lipid level monitoring was 
conducted after 12 weeks. After medication was stopped and monitoring had taken place 
according to the research protocol, patients were monitored according to the Dutch 
guideline for Cardiovascular Risk Management.
When monitoring patients according to the research protocol, in addition to blood 
pressure and lipid level measurement, the GP or practice nurse asked whether the 
patient experienced adverse effects. The GP or practice nurse always asked whether 
shortness of breath, oedema, or weight gain had occurred.  The pulse was assessed to 
determine pace and regularity. According to the research protocol, the practice nurse 
had to consult the GP in case the patient: 1) did not feel well; 2) experienced symptoms 
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of heart failure (shortness of breath, oedema); 3) gained >2 kg in body weight; 4) had 
a systolic blood pressure >180 mm Hg; 5) had a pulse rate >100/minute; 6) had an 
irregular pulse; 7) (possibly) experienced an adverse effect of withdrawal. The data safety 
monitoring board added a total cholesterol level  >308.9 mg/dl (8 mmol/l) and a LDL-
cholesterol level  >193.1 mg/dl (5 mmol/l) to this list.
84
of heart failure (shortness of breath, oedema); 3) gained >2 kg in body weight; 4) had 
a systolic blood pressure >180 mm Hg; 5) had a pulse rate >100/minute; 6) had an 
irregular pulse; 7) (possibly) experienced an adverse effect of withdrawal. The data safety 
monitoring board added a total cholesterol level  >308.9 mg/dl (8 mmol/l) and a LDL-
cholesterol level  >193.1 mg/dl (5 mmol/l) to this list.
        
85
CHAPTER 3
Additional file 3. Cost-effectiveness analysis
Table S2. Costs (in £) for the preparation of the intervention, per selected patienta
Activity Time investment 
(in minutes)
Costs per 10 
minutesb
Costs
Workshop GP 150 28 420
Workshop practice nurse 150 9 140
Patient group selection by GP 120 28 336
Group costs per GP practice 420 896
Group costs per selected patient 
(n=160)a
3 6
Individual preparation of 
invitation/consultation
10 28 28
Costs per selected patient 34
Abbreviations: GP denotes general practitioner.
a  Based on the number of patients invited to participate in the ECSTATIC trial, with an estimated GP 
practice size of 2168 (NZa 2016, URL: https://www.lhv.nl/uw-beroep/over-de-huisarts/kerncijfers-huis-
artsenzorg).
b Obtained from Dutch guidelines for economic evaluations, at the price level of 2015.21
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Year 1 0 34 -
Year 2 0 0 -
General practice consultations
Year 1 170 222 <0.01
Year 2 179 171 0.58
Preventive cardiovascular medication
Year 1 36 20 <0.01
Year 2 33 21 <0.01
Laboratoryb
Year 1 32 33 0.67
Year 2 31 29 0.34
Other healthcarec
Year 1 508 472 0.55
Year 2 617 606 0.93
Total primary care specific costsd
Year 1 239 309 <0.01
Year 2 243 220 0.19
Total primary care specific costs 
over two yearse 482 528 0.19
Total healthcare costsf
Year 1 742 787 0.49
Year 2 861 824 0.77
Total healthcare costs over two 
yearse 1607 1607 1.00
QALYs
Year 1 0.870 0.879 0.38
Year 2 0.874 0.879 0.58
Total QALYse 1.743 1.759 0.45
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Abbreviations: QALYs denotes quality-adjusted life years; ITT denotes intention-to-treat.
a  One patient who died of unknown cause during follow-up without having attempted to have her 
preventive cardiovascular medication deprescribed was left out in the analyses at 24 months.
b  Only cardiovascular management related
c Costs of specialist and physical therapist consultations, use of home care, and hospitalisations.
d  Sum of costs of implementation of the intervention, general practice consultations, preventive 
cardiovascular medication, and
  laboratory.
e  Sum of costs and QALYs in year 1 and year 2 do not exactly add up to the total costs over two years due 
to adjustment for cluster
  randomization in the analyses.
f Primary care specific costs plus other costs.
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Figure S1. EuroQol Utility at t=0, t=3, t=6, t=12, and t=24 in the usual care group and 
the intention to treat population of the intervention group.
Abbreviations: ITT denotes intention-to-treat.


























Figure S1. EuroQol Utility at t=0, t=3, t=6, t=12, and t=24 in the usual care group and 
the intention to treat population of the intervention group.
Abbreviations: ITT denotes intention-to-treat.
Measurements at t=0 were performed at the first visit.
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CHAPTER 3
Figure S2. Cost-effectiveness acceptability curve showing the probability that an 
attempt to deprescribe preventive cardiovascular medication is cost-effective 
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ABSTRACT
Background
The use of preventive cardiovascular medication by patients with low cardiovascular 
disease (CVD) risk is potentially inappropriate.
Objective
The aim of this study was to identify barriers to and enablers of deprescribing potentially 
inappropriate preventive cardiovascular medication experienced by patients and general 
practitioners (GPs).
Methods
A total of 10 GPs participating in the ECSTATIC trial (Evaluating Cessation of STatins and 
Antihypertensive Treatment In primary Care) audiotaped deprescribing consultations 
with low-CVD-risk patients. After initial conventional content analysis, 2 researchers 
separately coded all barriers to and enablers of deprescribing medication using 
framework analysis. We performed a within-case and cross-case analysis to explore 
barriers and enablers among both patients and GPs.
Results
Patients (n = 49) and GPs (n = 10) expressed barriers and enablers with regard to the 
appropriateness of the medication and the deprescribing process. A family history 
for CVD was identified as a barrier to deprescribing medication for both patients and 
GPs. Patients feared possible consequences of deprescribing and were influenced by 
the opinion of their GP. Additionally, a presumed disapproving opinion from specialists 
influenced the GPs’ willingness to deprescribe medication.
Conclusions
Patients appreciated discussing their doubts regarding deprescribing potentially 
inappropriate preventive cardiovascular medication. Furthermore, they acknowledged 
their GP’s expertise and took theiropinion toward deprescribing into consideration. 
The GPs’ decisions to deprescribe were influenced by the low CVD risk of the patients, 
additional risk factors, and the alleged specialist’s opinion toward deprescribing. We 
recommend deprescribing consultations to be patient centered, with GPs addressing 
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According to many international guidelines on the prevention of cardiovascular disease 
(CVD), patients with low CVD risk should be given lifestyle advice and do not require 
treatment with antihypertensive and/or lipid-lowering drugs.1-6 Nevertheless, it has been 
shown that drugs are frequently prescribed and used on a long-term basis by low-CVD-
risk patients. More or less depending on the reason for prescription, use of these drugs 
is considered potentially inappropriate because their potential risks (eg, side effects) 
outweigh their potential benefits.8-10 Deprescribing medication after long-term use is 
preferable for (subgroups of) patients with low CVD risk for whom deprescribing is found 
to be a safe and effective procedure.
Two recent systematic reviews based on studies concerning deprescribing medications 
identified several categories of barriers and enablers for patients and for prescribers 
to deprescribe potentially inappropriate medication.8, 11 Both reviews included studies 
of hypothetical deprescribing of various kinds of medication (eg, benzodiazepines, 
antidepressants, psychotropic medications).
We hypothesized that the barriers and enablers of deprescribing in general might differ 
from the factors playing a role in the decision concerning deprescribing preventive 
cardiovascular medication. Regarding implementation of a deprescribing policy, 
knowledge of these factors would be valuable. Therefore, the aim of our study was 
to identify the barriers and enablers encountered in real-life discussions between 
patients and their general practitioners (GPs) considering deprescribing preventive 
cardiovascular medication.
METHODS
The study population was selected from the ECSTATIC trial (started in 2012, end of 
follow-up December 2015). In the ECSTATIC trial (NTR3493), we evaluate whether it 
is cost-effective and safe to deprescribe antihypertensive and lipid-lowering drugs in 
primary care patients to whom medication is not recommended, according to the current 
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Box 1. ECSTATIC Trial
ECSTATIC Trial
The ECSTATIC trial evaluates whether it is cost-effective and safe to deprescribe 
antihypertensive and lipid-lowering drugs inprimary care patients to whom medication 
is not recommended according to the current Dutch guideline Cardiovascular Risk 
Management. Patients without cardiovascular disease (CVD) were included in 
the ECSTATIC-trial when having low CVD risk and using antihypertensive and/or 
lipidlowering drugs. GPs in the intervention practices received a training providing 
information about this guideline and its differences with respect to the former guideline. 
In preparation of the deprescribing consultations they were presented cases of fictional 
low-CVD-risk patients and they discussed these patients’ suitability to have their 
medication deprescribed. GPs participating in the trial sent a written invitation to their 
patients without CVD, using potentially inappropriate antihypertensive and/or lipid-
lowering drugs. After obtaining informed consent, the researchers determined eligibility 
on the basis of the patients’ pre-treatment 10-year risk of morbidity and mortality of 
CVD, using the SCORE risk function as well as their (possible) additional risk increasing 
factors (positive family history for CVD, obesity, decreased kidney function, and 
sedentary lifestyle).1 When, based on the combination of the risk score and additional 
risk increasing factors for CVD, medication was not recommended according to the 
current guideline Cardiovascular Risk Management, patients were considered eligible 
for inclusion and were advised to make an appointment for a deprescribing consultation 
with their GP.
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CHAPTER 4
In the intervention practices, patients knew in advance that, if found eligible (from here 
on referred to as low-risk patients), they would be offered a consultation with their 
GP discussing deprescribing and deciding whether to deprescribe or continue the 
medication.
Participants
Through purposeful sampling,12 we included 9 general practices that were in the 
process of organizing deprescribing consultations in the course of their participation 
in the ECSTATIC trial. The GPs of the included practices selected the patients based 
on opportunity (having an appointment for a deprescribing consultation) and on the 
patient’s informed consent to audiotape their consultation with their GP. The GPs did not 
receive additional training in communication skills, and the deprescribing consultations 
did not follow a predefined format. The patients signed a written informed consent 
before the consultation was audiotaped. The study was approved by the Medical Ethics 
Committee of the Leiden University Medical Center (P12.095/SH/gk).
General Description of the Deprescribing Consultations
All audiotaped consultations were transcribed verbatim. The transcripts were used to 
describe the characteristics of the consultation and the sequence of barriers to and 
enablers of deprescribing.
Analysis of Barriers and Enablers
To identify barriers to and enablers of deprescribing preventive cardiovascular 
medication for both patients and GPs, transcripts were analyzed using a conventional 
content analysis.13 This analysis revealed that emerging themes matched the theoretical 
framework of Reeve et al.8 This framework consists of 6 categories of barriers and 
enablers: (1) appropriateness, (2) fear, (3) process, (4) influences, (5) dislike, and (6) other 
(Table 1). To ensure that no themes were missed, we performed an additional round 
of coding using a framework approach based on Reeve et al,8 which allowed deductive 
and inductive coding. All coding was performed by 2 researchers (CHL and RMJJvdK), 
and differences in codes assigned were resolved by discussion. The codes identified 
inductively were added to Reeve’s framework (Table 1).8 We also described whether 
themes were intertwined when separate codes were assigned to the same citation.
Within-case and cross-case analyses were then conducted, as described by Miles and 
Huberman.14 We performed an indepth exploration of both patient and GP barriers 
and enablers for each consultation using the within-case analysis. This allowed us 
to properly interpret all mentioned barriers and enablers per consultation as we 
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investigated each consultation separately. We then used the cross-case analysis to 
evaluate whether barriers and enablers occurred in patterns across cases, intending 
to explore commonly mentioned barriers and enablers during the consultations. In 
addition, we specifically compared barriers and enablers mentioned in consultations 
in which the outcome was “deprescribing of medication” with consultations where 
the outcome was “continuation of medication”. The outcome of the consultation was 
deduced from the conclusion of the consultation itself by noting whether medication was 
continued or deprescribed. The barriers and enablers discussed in consultations were 
compared depending on the type(s) of medications the patient used (antihypertensive 
medication, lipid-lowering drugs, or both). If any inconsistencies in themes were found 
during the crosscase analysis, transcript information was consulted for verification.
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Table 2 shows the characteristics of the patients (mean age = 55.4 years) and the 
outcome of the consultation. We included 49 deprescribing consultations of 10 
different GPs from 9 general practices. In 42 of the 49 consultations, the outcome was 
deprescribing of medication. Median time for all consultations was 6½ minutes.
Table 2. Characteristics of the participating patients (n=49)
Patients
Male – no. (%) 14 (29)
Age in years – mean (SD) 55.4 (5.5)
Using antihypertensive medication – no. (%) 42 (86)
Using lipid-lowering drugs – no. (%) 12 (25)
Outcome of the consultation deprescribing of medication (%) 42 (86)
Outcome of the consultation continuation of medication (%) 7 (14)
Course of the Deprescribing Consultation
Table 3 shows the characteristics of the GPs and their deprescribing consultations. The 
GP often started the consultations by explaining the reason for consultation: the patient 
was included in the ECSTATIC trial and had a low risk.
Four GPs specifically mentioned that the decision whether or not to deprescribe the 
medication was a joint decision that needed to be made by both the patient and GP. 
Additionally, regardless of the outcome of the deprescribing consultation (deprescribing/
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GP-1 Male 35 3 11 4-25 10 (91)
GP-2 Female 60 28 6 5-29 4 (67)
GP-3 Male 52 9 3 1-2 1 (33)
GP-4 Male 58 28 10 3-7 10 (100)
GP-5 Male 60 30 5 1-4 5 (100)
GP-6 Male 56 24 5 5-8 5 (100)
GP-7 Female 53 25 1 10 0 (0)
GP-8 Male 58 19 3 5-10 3 (100)
GP-9 Female 60 32 2 4-12 1 (50)
GP-10 Female 48 14 3 8-14 3 (100)
GP, general practitioner.
Barriers and Enablers
Barriers were more frequently cited by patients than by GPs, and patients also 
mentioned more diverse barriers than GPs (Table 1). Irrespective of the outcome of the 
consultation, barriers to deprescribing were cited by both patients and GPs. Although 
the number of enablers mentioned by patients and GPs differed, in general, both cited 
the same enablers. The enablers cited by patients and GPs were similar regardless of 
the outcome of the consultation. However, GPs mentioned fewer and different barriers 
in consultations in which the outcome was to deprescribe medication. Furthermore, in 
a majority of consultations, the GP mentioned an enabler after a patient mentioned a 
barrier.
When the GP expressed doubts about deprescribing, the barriers mentioned were often 
personalized and directed toward the consulting patient. In contrast, the GPs more 
frequently brought a general, nonpersonalized barrier forward when they were positive 
toward deprescribing medication.
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‘The ophthalmologist can tell that that you have a high blood pressure based on the 
examination of your eyes . . . and that’s why we need to ask ourselves whether it would 
be wise to stop your medication.’ (GP-2 consulting a patient whose outcome was 
continuation)
‘And to some patients we say that their [CVD] risk is really too high, and that they 
have to continue their medication.’ (GP-10 consulting a patient whose outcome was 
deprescribing)
When comparing consultations of patients using antihypertensive medication, lipid-
lowering drugs, or both, we found no differences in the barriers and enablers mentioned 
by both patients and GPs.
Appropriateness
We found that 9 of 49 patients and 7 out of 10 GPs mentioned that medication was 
currently necessary or beneficial. This reason to continue intertwined with other themes 
in patients, such as (1) the GP’s advice to take preventive medication, (2) fear-related 
themes, and (3) mistrust or scepticism of the recommendation to deprescribe.
 ‘We were always told that there would be so much damage done to heart and blood 
vessels by high blood pressure.’ (52-year-old woman whose outcome was deprescribing)
In GPs, this theme was intertwined with the patient having an unhealthy lifestyle and/or 
having several risk factors for developing CVD:
‘As a doctor, I feel your smoking behaviour argues against withdrawal.’  
(GP-2 consulting a patient whose outcome was continuation)
When explaining the reason for the consultation or when the patient asked for advice, 
all GPs expressed that medication was not (medically) ecessary, implying a general 
positive attitude toward deprescribing — for example, when the patient had a low risk 
or when the revised recommendations concerning the use of preventive cardiovascular 
medication indicated that the medication was unnecessary for a certain patient.
 ‘So according to the current guidelines you would not need lipid-lowering drugs.’  
(GP-10 consulting a patient whose outcome was deprescribing)
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Patients expressed doubts regarding the necessity for medication use; they stated that 
they were “unsure about their (continuous) need” for it.
 ‘I used these [medications] for two years now, [or rather] one and a half years, maybe 
even longer. This makes me think, well, is it necessary? And . . . shouldn’t we stop it?’ 
(53-year-old man whose outcome was deprescribing)
Patients sometimes assumed that at the time their medication was initiated, stress 
had induced their hypertension. In that case, their rationale for having a well-controlled 
blood pressure at this moment in time was the absence of stressful events.
We found that 20 of 49 patients and 4 of 10 GPs expressed
a general positive attitude toward deprescribing, which makes it a dominant theme 
among patients:
 ‘That [deprescribing] would be fantastic.’ (61-year-old woman whose outcome was 
deprescribing)
Fear
Both patients and GPs cited the fear of the return of the previous condition for which the 
medication was started/prescribed:
‘I don’t know if we take one [of the medications] off, whether my blood pressure will rise 
again.’ (61-year-old woman whose outcome was continuation)
‘Also, how over the past few years we struggled to get that blood pressure under 
control, makes me say like, no, we’re not going to withdraw that medication now.’ (GP-7 
consulting a patient whose outcome was continuation)
Patients feared the return of hypertension or hypercholesterolemia and feared the 
dangers that might accompany these conditions (CVD/death). Two of the 3 GPs who 
forwarded fear of return of the previous condition advised to continue medication. Only 
patients expressed fear for the unknown consequences of deprescribing:
‘However, maybe I will have side effects [of deprescribing], such as dizziness or 
something?’ (64-year-old woman whose outcome was deprescribing)
Process
Both patients and GPs encountered problems with the timing or with the complexity of 
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the process of deprescribing. However, these problems were always solved: when timing 
was the issue, the deprescribing was postponed, and in the case of complexity, the GP 
wrote a dose-lowering scheme for the medications. Patients and GPs appreciated the 
availability of a follow-up scheme for the blood pressure and cholesterol levels after 
deprescribing and noted the possibility of restarting medication:
‘However, I can always return to have my blood pressure measured again and restart the 
pill?’ (59-year-old female whose outcome was deprescribing) ‘Yes, yes.’ (GP-5)
‘If your blood pressure rises above 180 [mm Hg], yes, then there is an indication again to 
restart medication.’ (GP-6 consulting a patient whose outcome was deprescribing)
Five of 10 GPs reassured patients that deprescribing would be safe by stressing that the 
medication would be deprescribed step-by-step.
Influences
In the analysis, several themes emerged as important factors in the decision-making 
process. The patient’s decision was strongly determined by the GP’s voiced opinion, 
which we deduced by noting whether the GP said it was justified to deprescribe the 
medication. The outcome of these consultations then was very likely to be deprescribing 
medication, and vice versa:
‘That doesn’t feel right with me, honestly speaking.’ (GP-2)
‘Then, we just don’t do it [name of GP].’ (61-year-old woman whose outcome was 
continuation)
This quote was derived from 1 of 2 consultations in which the GP’s arguments seem to 
change the patient’s initial thoughts about deprescribing. In this particular consultation, 
the patient expressed her desire to have her medication deprescribed. The GP had 
reservations because of the patients smoking behavior. The patient acknowledged the
hesitations of the GP and decided to persist using the medication. They continued 
discussing smoking cessation.
In the other consultation where the patient and GP had discordant views, the patient was 
afraid of getting agitated after stopping. The GP addressed her low risk that would justify 
deprescribing her medication, after which they decided to lower the dose. He indicated 
that medication was not necessary to lower her blood pressure. However, the GP did 
forward that the dose-lowering might prove the medication’s supposed necessity to keep 
her from getting agitated.
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When patients had earlier bad experiences with stopping their medication, they tended 
to decide to continue medication.
‘According to me, we stopped them once, but then it rose again . . . according to me  
. . . and then you prescribed it again, so . . .’ (52-year-old woman whose outcome was 
continuation)
Both patients and GPs cited a family history of CVD explicitly as a barrier to 
deprescribing.
‘I have a father who . . . got 5 bypasses. His youngest sister died of a stroke. So also in 
my family there are examples . . . of which I think, well . . .’ (58-year-old woman whose 
outcome was continuation)
‘So we have just gone through all your risk factors and we came to the conclusion that 
we won’t stop the medication. Predominantly based on your family history [being positive 
for CVD].’ (GP-3 consulting a patient whose outcome was continuation)
GPs considered the patient having an unhealthy lifestyle
and the specialist’s opinion that the patient needed medication
as serious barriers to deprescribing.
‘And then you went to see the specialist, isn’t it? . . . and he also advised to continue [the 
medication] isn’t it?’ (GP-7 consulting a patient whose outcome was continuation)
Dislike
Both patients and GPs expressed a general dislike of taking (or prescribing) medication.
‘The less [medication] the better.’ (51-year-old woman whose outcome was 
deprescribing)
‘Well, that means that someone who was used to taking medication, suddenly doesn’t 
need medication anymore, which is quite nice of course.’ (GP-6 consulting a patient 
whose outcome was deprescribing)
Other enablers for patients within the dislike theme were the following: (1) removing the 
stigma of “being a patient,” (2) psychological benefits of deprescribing, (3) lowering costs 
for society, and (4) easier access to a mortgage once off medication.
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A lack of fear of the consequences of deprescribing medication was cited by 7 of 10 GPs.
‘When your systolic blood pressure is above 180 [mm Hg], or when you get all kinds of 
complaints [of deprescribing], but, well, you didn’t have that much complaints back then 
[before medication was started], so that’s not to be expected.’ (GP-6 consulting a patient 
whose outcome was deprescribing)
GPs stated that they had positive expectations of deprescribing because no serious 
adverse events occurred in a previous study, or they assumed that patients might only 
experience light complaints after deprescribing.
DISCUSSION
Summary
Our study showed that patients were generally positive toward deprescribing preventive 
cardiovascular medication and that they relied on the information and expertise of their 
GP to determine whether deprescribing was justified. Patients also mentioned that they 
feared the consequences of deprescribing. However, knowing follow-up care was
available and that medication could be restarted facilitated the patients’ agreement to 
deprescribe.
The main reason for GPs to advise deprescribing was the low CVD risk of patients when 
recalculated following the current guideline. The GPs also considered the impact of 
additional risk factors such as a positive family history for CVD, unhealthy lifestyle, and 
earlier advice of the specialist to continue/start medication.
Strengths and Limitations
One of the strengths of this study is its unique nonhypothetical setting. We believe 
that this led to the emergence of themes reflecting those themes that in day-to-
day clinical practice play a role in the patient’s and GP’s decision to deprescribe/
continue. In contrast to other deprescribing studies that focused on older adults with 
polypharmacy, as a result of the prerequisite of having low CVD risk to be included in 
the ECSTATIC trial, our study investigated a relatively young population (mean age = 
55.4 years). This adds new information to the current knowledge of the deprescribing 
process. Furthermore, deprescribing of a specific kind of medication (ie, cardiovascular 
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plans to facilitate deprescription policies in general practice in patients with low CVD 
risk.
Two GPs (GP-1 and GP-4) together audiotaped 21 consultations of which the outcome 
was deprescription in 20 consultations. This suggests a strong positive attitude of these 
GPs toward deprescription, which possibly affected the statements of their patients. All 
GPs participating in the ECSTATIC trial were informed about their patient’s (low) CVD 
risk. We asked GPs to select patients themselves for our study, which may have led to 
an underestimation of patients with a presumed negative attitude toward deprescribing. 
Furthermore, the patients in our study agreed to and were, therefore, willing to have a 
deprescribing consultation. This selection bias may in turn have led to an incomplete 
overview of barriers to deprescribing. Despite these methodological limitations, in 
our opinion, the large sample of 49 patients from 10 GPs allowed the emergence of a 
generalizable framework of barriers and enablers.
Comparisons With Individual Studies in Patients
Our study showed many similarities between the mentioned barriers and enablers of 
patients and GPs. Anderson et al11 also concluded that there were similarities in the 
cited barriers and enablers in prescribers and patients when comparing their results 
(of barriers and enablers of prescribers) with the outcomes of the review by Reeve et 
al8 (of barriers and enablers of patients). However, in our study, we found even more 
similarities when comparing the barriers and enablers mentioned by GPs with the 
barriers and enablers that Reeve et al8 identified in patients. This discrepancy is probably 
caused by the fact that in our study, patients and GPs discussed real deprescribing of 
medication, and they were able to react to the barriers and enablers mentioned, whereas 
both reviews included studies regarding (hypothetical) medication deprescribing/
continuation. Additionally, we believe that having investigated nonhypothetical 
consultations, our findings are more close to day-to-day clinical practice.
Our study supports earlier findings that patients value the opinion of their physician 
when considering deprescribing.7, 15, 16 Our findings are also consistent with a study on 
the deprescribing of selective serotonin reuptake inhibitors; this study included patients 
who had actually tried or discussed deprescribing with their GP and highlighted the 
importance of being monitored and knowing that there was a possibility to restart their 
medication.17
The health care system in the Netherlands is funded by a combination of taxes and 
a state-controlled mandatory insurance for all people. Payments to physicians are 
combined per capita for service and are paid out-of pocket by patients themselves. A 
health care allowance is provided by the government for patients with lower incomes. 
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Patients aged 18 years and older have to pay for their own health care costs up to 350 
euro a year (2013). In our study, however, reducing individual costs was never mentioned 
as an enabler for deprescribing, in keeping with a study by Benson and Britten18 
concerning deprescribing antihypertensive drugs. This is possibly caused by the low 
prices of the most commonly prescribed generic antihypertensive and lipid-lowering 
drugs.
Comparisons With Individual Studies in Physicians
Most GPs take preventive measures, such as blood pressure monitoring in response to 
a positive family history of CVD, obesity, smoking, and other risk factors.19 Thus, it is not 
remarkable that in our study, GPs mentioned these patient characteristics as barriers to 
deprescribing.
Several themes emerging from the analysis that we added to the patient perspectives-
based framework of Reeve et al8 were actually described by Anderson et al.11 For 
example, themes such as the influence of the specialist and the positive attitude of 
physicians toward deprescribing were already present in the framework of Anderson et 
al.11 However, knowledge or skill deficits seemed to be less of a barrier to deprescribing 
in our study. This is probably a consequence of the fact that GPs were informed about 
suitability for deprescribing (ie, low CVD risk) by the researchers.
Anderson et al11 argued that physicians needed to discuss rather than assume the 
patients’ attitudes toward deprescribing. In this study, the GPs discussed the views of 
their patients adequately.
Possible Implications for Practice
In the context of implementation of a deprescribing policy of preventive cardiovascular 
medication in general practice, we believe, on the basis of our results, that a 
consultation aiming at deprescribing is not necessarily time-consuming and should be 
a patient-centered discussion. Based on their specific cardiovascular risk management 
expertise and individual knowledge of the patient involved, GPs should address all 
probable consequences of deprescribing, ensuring that patients make an informed 
decision. If necessary, they should stress that regular follow-up and the possibility of 
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Table 1.  Framework of Reeve et al8 including the added barriers and enablers
Category Theme Barrier (-)   
  or enabler (+)
Appropriateness Medication is currently necessary/ 
 beneficial for condition -
 Medication is necessary/beneficial  
 for condition in the short termd -
 Blood pressure well-controlled in the endb -
 Hope for future benefits -
 Many risk factors and therefore hope for 
 future benefits when taking medicationd - 
 Psychological benefits of taking the medication 
 (empowerment)b -
 Lack of suitable alternative/unwillingness to try
 alternativesc -
 Beliefs about lack of ability to continue/sustain 
  alternative treatments -
 Desire for increased dose of medicationc -
 Mistrust/scepticism of recommendation to cease -
 Acceptance of medical condition and therefore 
 need for medicationb -
 Lack of negativesb -
 Experiencing side effects +
 Fear for side effects +
 Medication is not necessary +
 Limited number of risk factors +
 Nonsmokerd +
 Good activity leveld +
 Blood pressure well-controlled +
 Lack of efficacy +
 Fear of addiction/dependencyb +
 Considering alternative treatment option +
 Advising alternative treatment optiond +
 Preference for lifestyle intervention over medicationd +
 Unsure about continued need +
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 Mistrust of prescriber who started the medicationc +
 General positive attitude toward ceasing +
 Benevolent toward goal of researchb +
 Mistrust of pharmaceutical industryd +
    
Fear Psychological issues related to cessation/ 
 non-specific fears -
 Fear of return of condition -
 Fear of withdrawal effectsb -
 Fear for CVD/deathb -
  
Process Lack of primary care physician support/timeb -
 Unknown how to cease/conflicting information -
 Lack of ongoing support neededc -
 Need for appropriate timing for cessation -
 Knowledge that there are possibilities to handle  
 negative effectsd +
 Knowledge that they could restart medication +
 Follow-up/primary care physician support available +
 Other support available (family or processes) +
 External factors relating to ability to cease removedd +
 External factors causing hypertension removedb +
 Action planningb +
 Withdrawing medication step-by-step +
  
Influences Previous bad experiences with stopping -
 Influence of primary care physician/family/friendsb -
 Influence specialist -
 Family history positive for condition -
 Family history negative for conditiond +
 Primary care physicianb +
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 Action planningb +
 Withdrawing medication step-by-step +
  
Influences Previous bad experiences with stopping -
 Influence of primary care physician/family/friendsb -
 Influence specialist -
 Family history positive for condition -
 Family history negative for conditiond +
 Primary care physicianb +
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Dislike Psychological benefits of ceasingb +   
 Inconvenience (including cost)c +
 Feeling of unfairness having to take medicationb +
 General dislike of taking medication +
 General dislike of prescribing medicationd +
 General dislike of taking tablets +
 Medications are unnaturalb +
 Stigma associated with taking medicationb +
 Beliefs about costs for societyb +
 Problem getting a mortgageb +
     
Other Pragmatic considerationsb -
 Habitb -
 Not wanting to have one’s mind occupied  
 with taperingc -
 Guilt related to depriving loved ones of something 
 that might workc -
 Inconvenience (including cost)b -
 Lack of fear of consequences of stopping +
 Concern about compatibility of drugsc +
Barriers and enablers written in italics were added to the existing framework of Reeve et al. 8; * barriers 
and enablers not mentioned by patients in this study; ** barriers and enablers not mentioned by GPs in 
this study; *** barriers and enablers both patients and GPs did not mention in this study.
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ABSTRACT
Background
Patients with low cardiovascular disease (CVD) risk potentially use preventive 
cardiovascular medication unnecessarily. Our aim was to identify various viewpoints 
and beliefs concerning the preventive CVD management of patients with low CVD risk 
using pre¬ventive cardiovascular medication. Furthermore, we investigated whether 
certain viewpoints were related to a preference for deprescription or the continuation of 
preventive cardiovascular medication.
Methods
In 2015, we purposively sampled patients from the intervention arm of the Evaluating 
Cessation of STatins and Antihypertensive Treatment In primary Care (ECSTATIC) trial 
in the Netherlands for this study. Participants made Q-sorts by ranking 43 statements 
concerning preventive CVD management from “totally disagree” to “totally agree”. These 
Q-sorts were analyzed using PQMethod 2.35 software. A varimax procedure presented 
the distinguishing viewpoints that were favored by our participants. We used group 
discussion quotations to underline our findings. For validation purposes, we asked 
participants how well each viewpoint fitted them.
Results
Of 291 invited patients, 33 participated. Thirty-one Q-sorts were analyzed. The following 
three viewpoints were found: 1) a controlling viewpoint, in which patients held the belief 
that monitoring blood pressure and cholesterol levels is important (n=13, of which 
seven had their medication deprescribed and six continued their medication); 2) an 
autonomous viewpoint, in which patients showed a dislike of medication (n=8, of which 
seven had their medication deprescribed and one had it continued); and 3) an afraid 
viewpoint, in which patients were fearful of developing CVD (n=8, of which two had 
their medication deprescribed and six had it continued). Seventy-four percent of the 
participants believed that the viewpoint to which they were assigned was a good fit.
Conclusion
Three well-discriminating viewpoints about preventive CVD management were 
determined. Knowing and recognizing these viewpoints is effective for general 
practitioners when discussing the deprescribing of preventive cardiovascular 
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According to the guidelines of many countries, patients with predicted low 
cardiovas¬cular disease (CVD) risk do not require medication to prevent CVD.1-6 
Nonetheless, preventive cardiovascular medication is often prescribed and used by 
patients with lower levels of predicted CVD risk than the actual guideline thresholds, 
because recommendations for drug initiation have been revised after treatment has 
been started.7, 8 Deprescribing these potentially inappropriate medications can reduce 
unnecessary adverse reactions in patients and undue medical costs. In an earlier study, 
we identified the barriers and enablers that patients and general practitioners (GPs) 
mention during consultations in which the deprescribing of preventive cardiovascular 
medication is discussed.9 Patients expressed doubts about the appropriateness of 
their medication and seemed to rely on the information and expertise of their GP in 
determining whether deprescribing was justified. This finding was also observed in 
other studies.10-12 Furthermore, a general dislike of medication and knowing that follow-
up care was available and medication could be restarted are known to be enablers of 
deprescribing.9, 13 Patients’ expectations of the long-term medications they use play a 
role in their willingness to have their preventive medication deprescribed. Dohnhammar 
et al14 reported that patients use medication to care for them¬selves above and beyond 
lifestyle changes alone and that they tend to overestimate the risk-lowering effects of 
preventive medication. Furthermore, patients and doctors balance risks and benefits of 
medication in a different way. For example, benefits in the short term are identified as 
more important to patients compared with doctors.14 Patients’ views on depre¬scribing 
their medication can thus be different than their physicians’ views, but patient viewpoints 
could influence the implementation of preventive CVD management. Therefore, our 
objective was to identify various viewpoints and beliefs in patients with low CVD risk 
using preventive cardiovascular medication concerning preventive CVD management. 
Hence, we performed a Q-methodological study in patients with low CVD risk who had 
discussed deprescribing their preventive cardiovascular medication with their GP.
METHODS
Q-methodology
To investigate the viewpoints of patients with low CVD risk concerning their preventive 
CVD management, a Q-methodological study was conducted. Q-methodology combines 
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of subjective perspec-tives into an objective outcome.15 Although Q-methodology does 
not claim to identify viewpoints that are consistent within individuals across time, it is 
expected that viewpoints should show some degree of consistency over time. Hence, 
for the possible future implementation of a deprescribing policy, Q-methodology 
seems to be an appropriate way to investigate whether certain viewpoints are related 
to a preference for deprescription or for the continuation of preventive cardiovascular 
medication.15 In contrast to quali¬tative analyses, Q-methodology focuses on groups 
instead of individuals, and therefore on the variety of viewpoints instead of on the 
viewpoint of the majority. It focuses on similarities and differences in a study population, 
resulting in various viewpoints or patterns of thought that specify a given population. 
The method consists of the following four steps, which we will further describe: 1) the 
determination of the concourse and generation of a Q-set, 2) the generation of a P-set 
(study population), 3) performing the Q-sorts, and 4) factor analysis and interpretation.
Q-set
The Q-set consisted of statements representing the concourse, the full range of 
contributions in the qualitative debate, on preventive CVD management. Statements 
were based on the literature,10, 11, 13 expert opinion and data from our previous study 
concerning the barriers and enablers that patients mention during deprescribing 
consultations with their GPs.9 Researchers (CHL, NLB, and RKEP) formulated 44 
statements to cover the concourse. After testing the Q-set with four patients to 
determine the clarity of the statements and their sufficiency in displaying different 
viewpoints, a final Q-set of 43 statements was established. These were randomly 
numbered and printed on cards.
P-set
The study population was purposively sampled from the Evaluating Cessation of STatins 
and Antihypertensive Treatment In primary Care (ECSTATIC) trial (NTR3493). In the 
ECSTATIC trial (a randomized controlled trial that started in 2012, with follow-up ending 
in November 2015), we evaluated whether it is cost-effective and safe to deprescribe 
antihypertensive and lipid-lowering drugs in primary care patients for whom medication 
is not recommended according to the current Dutch guideline on Cardiovascular 
Risk Management (Box 1). Participants from the intervention practices were offered 
a consultation with their GP to discuss whether to deprescribe their preventive 
cardiovascular medication.
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Box 1. ECSTATIC trial
The ECSTATIC trial evaluates whether it is cost-effective and safe to deprescribe 
antihypertensive and lipid-lowering drugs in primary care patients to whom medication 
is not recommended according to the current Dutch guideline on Cardiovascular Risk 
Management. Patients without CVD were included in the ECSTATIC trial when having 
low CVD risk and using antihypertensive and/or lipid-lowering drugs. GPs in the 
intervention practices received a training providing information about this guideline and 
its differences with respect to the former guideline. In preparation of the deprescribing 
consultations, there were presented cases of fictional low CVD risk patients and they 
discussed these patients’ suitability to have their medication deprescribed.
GPs participating in the trial sent a written invitation to their patients without CVD, 
using potentially inappropriate antihypertensive and/or lipid-lowering drugs. After 
obtaining the informed consent, the researchers determined eligibility on the basis of 
the patients’ pretreatment 10-year risk of morbidity and mortality of CVD, using the 
SCORE risk function as well as their (possible) additional risk increasing factors (positive 
family history for CVD, obesity, decreased kidney function, and sedentary lifestyle).1 
When, based on the combination of the risk score and additional risk increasing 
factors for CVD, medication was not recommended according to the current guideline 
Cardiovascular Risk Management, patients were considered eligible for inclusion and 
were advised to make an appointment for a deprescribing consultation with their GP.
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We sent written invitations to all patients from the intervention practices of the ECSTATIC 
trial (n=291) living in and around the cities of Leiden and Alphen aan den Rijn. Based on 
the preferred dates, we organized five sessions: three with patients who stopped their 
preventive cardiovascular medication 2 years ago and who still received no preventive 
cardiovascular medication (the deprescription group) and two with patients who had 
continued or restarted preventive cardiovascular medication or who had lowered their 
dose of their medication during the 2-year follow-up period (the continuation group).
 
Q-sorts
The sorting board that patients used to rank statements followed the Q-convention of a 
“forced normal distribution” (Figure S1).
Individual patients were given a pile of 43 statement cards and made piles containing 
statements with which they agreed, disagreed, or were neutral (no opinion or irrelevant). 
Next, each patient ordered the statements. On the extreme left, they placed the 
statements they disagreed with most. Next to those statements, they placed statements 
they disagreed with to a lesser extent, and so on. They did the same with the statements 
they agreed with most, except that these were placed on the right end of the sorting 
board. Finally, neutral statements were ordered and placed on the empty spots of the 
sorting board.
Factor analysis and interpretation
We analyzed the Q-sorts with PQMethod 2.35 software and used the varimax procedure 
to reveal the range of viewpoints that were favored by our study population.15 An 
algorithm was used to calculate how high the correlation coefficient must be and how 
much the correlation coefficient of the factor must differ from the correlation coefficient 
of the other factors to state that a person loads on to that specific factor. The patients 
loading on a specific factor are the patients with the most representative Q-sorts 
for this factor.16 Only the Q-sorts of patients loading on a specific factor were used 
for subsequent calculations. For each specific factor, an “ideal Q-sort” was created, 
showing how a hypothetical patient loading 100% on the factor would have ranked the 
statements. To interpret and name the factor, we used the Z-scores of the statements in 
these ideal Q-sorts, as well as the presented distinguishing and consensus statements 
of the factors. We reported statements distinguishing between any pair of factors with 
a P-value <0.01 (distinguishing statements) and statements not distinguishing between 
any pair of factors with a P-value >0.01 (consensus statements).
After patients ranked their statements on the sorting board and their informed consent 
was audiotaped, we asked them to reflect on their rank ordering. Their reflections and 
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CHAPTER 5
the following group discussions were audiotaped and used for the further interpretation 
of the factors. Due to a technical problem in one of the sessions, we had to leave one 
group discussion from the desprescription group out of our analysis.
We identified the distribution of patients from the deprescription and continuation 
group across the factors. A chi-square test was used to examine the significance of this 
distribution.
To validate the factors that resulted from the Q-methodology, we made factor 
descriptions highlighting the important distinguishing characteristics of the different 
factors. This validation questionnaire was sent to the patients. We asked them how well 
each factor description fitted them, using a five-point Likert scale ranging from “totally 
not” to “very well”. The study was approved by the Medical Ethics Committee of the 
Leiden University Medical Center.
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RESULTS
Of the 291 invited patients, 33 were willing to participate. There were no statistically 
significant differences between the respondents and nonrespondents with regard to 
age or gender. Two patients were excluded from the analysis of the Q-sorts (incomplete 
Q-sort and language barrier). The characteristics of the patients who performed the 
Q-sort (n=31) and of those who participated in the group discussions (n=28) are shown in 
Table 1.
Table 1. Characteristics of the patients that performed the Q-sort and of the patients 
that participated in the focus groups
 Q-sort Focus group patients (n=28)   
 patients  Netherlands Februari and 
 (n=31) March 2015=28)
 
Male – no. (%) 9 (29.0) 9 (32.1)
Age in years – mean (SD) 57.1 (6.8) 57.7 (6.8)
Using/used antihypertensive 
medication – no. (%) 18 (58.1) 16 (57.1)
Using/used lipid-lowering 
drugs – no. (%) 7 (22.6) 7 (25.0)
Using/used both 
medications – no. (%) 6 (19.4) 5 (17.9)
Deprescription group – no. (%) 17 (54.8) 13 (46.4)
Continuation group – no. (%) 14 (45.2) 15 (53.6)
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CHAPTER 5
Table 2 shows the consensus and distinguishing statements in the Q-set. All patients 
had the idea that they could do something to reduce their CVD risk, even if CVD 
ran in their families (statement 5). Patients placed importance on a GP with good 
communication skills who explained their treatment options clearly (statement 12). 
‘I feel that she shows interest in me as a patient and I always get a good advice, that is 
medically substantiated.’ (60-year-old female in the continuation group)
Another patient said:
‘When I go there [to the GP] I feel heard, and he takes time to explain things, and when 
he explains things to me, in the end, most of the time I don’t even need medication, so, 
that’s just really important to me.’ (66-year-old woman in the continuation group)
They did not feel medications were unnatural (statement 6), and all patients regarded 
hypertension management as one of the GPs’ job responsibilities (statement 7).
In addition, three distinguishable factors emerged from the Q-sorts (Table 2), explaining 
52% of the variance in our data. The patients from the description and con¬tinuation 
groups were unequally distributed across these factors (P=0.04).
Factor 1: controlling (n=13; seven from the deprescription group and six from the 
continuation group)
Patients loading on this factor placed great importance on the periodical monitoring of 
blood pressure and cholesterol levels by their GP, whether they were using medication 
or not (statement 19). During group discussions, these patients expressed dissatisfaction 
with their GP on this point:
‘For years, I’ve been getting these repeated prescriptions, but no one [in the general 
practice] has ever said to me: let’s measure your blood pressure […] well, I think that is 
regrettable.’ (56-year-old woman in the continuation group)
If CVD ran in their families, they were more inclined to start using medication (statement 
35):
‘I think that when it [blood pressure] is always really high and it is familial, you are more 
inclined to just continue tak¬ing that medication because in that case, it is different than 
just having [high blood pressure], well, yes.’ (66-year-old woman in the continuation 
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just having [high blood pressure], well, yes.’ (66-year-old woman in the continuation 
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group)
For patients loading on this factor, maintaining a healthy lifestyle was something 
obvious. 
‘Being aware of what you eat, a bit of exercising, just the normal things.’ (62-year-old 
woman in the deprescription group)
Hence, they felt that nobody should smoke (statement 34). In addition, they easily 
maintained a healthy lifestyle, and they never sought professional help to live (even) 
healthier (statements 23 and 36, respectively).
Factor 2: autonomous (n=8; seven from the deprescription group and one from the 
continuation group)
These patients would really appreciate living a long life without using medication, 
and they did not feel physically better when using medication (statements 33 and 21, 
respectively). Hence, they disagreed that using more and more medications comes along 
with growing old (statement 15). They disliked medication: 
‘Throw it [medication] in the dustbin, that crap.’ (50-year-old woman in the 
deprescription group)
Furthermore, they were interested in the way that the medication worked, and they 
knew exactly why they did or did not use medication to lower their blood pressure or 
cholesterol levels (statements 18 and 13, respectively).
‘I Googled like crazy, especially when it was suggested to start medication, why is that 
necessary, what is the matter, what are the effects [of the medication], I did it [Google] 
far less when stopping it [the medication] was discussed.’ (54-year-old man in the 
deprescription group)
Having a high blood pressure did not scare them, whereas having a low cardiovascular 
risk was a reason for them to deprescribe preventive cardiovascular medica¬tion, 
even if CVD ran in their families (statements 20 and 35, respectively). In contrast to the 
other factors, patients loading on this factor did not have that much confidence in the 
decisions their GP made for them (statement 32). These patients decided for themselves 
whether they would or would not use medication.
124
group)
For patients loading on this factor, maintaining a healthy lifestyle was something 
obvious. 
‘Being aware of what you eat, a bit of exercising, just the normal things.’ (62-year-old 
woman in the deprescription group)
Hence, they felt that nobody should smoke (statement 34). In addition, they easily 
maintained a healthy lifestyle, and they never sought professional help to live (even) 
healthier (statements 23 and 36, respectively).
Factor 2: autonomous (n=8; seven from the deprescription group and one from the 
continuation group)
These patients would really appreciate living a long life without using medication, 
and they did not feel physically better when using medication (statements 33 and 21, 
respectively). Hence, they disagreed that using more and more medications comes along 
with growing old (statement 15). They disliked medication: 
‘Throw it [medication] in the dustbin, that crap.’ (50-year-old woman in the 
deprescription group)
Furthermore, they were interested in the way that the medication worked, and they 
knew exactly why they did or did not use medication to lower their blood pressure or 
cholesterol levels (statements 18 and 13, respectively).
‘I Googled like crazy, especially when it was suggested to start medication, why is that 
necessary, what is the matter, what are the effects [of the medication], I did it [Google] 
far less when stopping it [the medication] was discussed.’ (54-year-old man in the 
deprescription group)
Having a high blood pressure did not scare them, whereas having a low cardiovascular 
risk was a reason for them to deprescribe preventive cardiovascular medica¬tion, 
even if CVD ran in their families (statements 20 and 35, respectively). In contrast to the 
other factors, patients loading on this factor did not have that much confidence in the 
decisions their GP made for them (statement 32). These patients decided for themselves 
whether they would or would not use medication.
        
125
CHAPTER 5
‘It was me [who made the decision to deprescribe]. The GP then checked whether it 
[deprescribing] was justified, and he said it was justified. Then I said, well, in that case 
I’ll stop [the medication].’ (64-year-old woman in the depre¬scription group)
 
Factor 3: afraid (n=8; two from the deprescription group and six from the continuation 
group)
Patients loading on this factor felt relieved when their blood pressure or cholesterol test 
result was in order and were afraid to develop a stroke or heart attack (statements 14 
and 26).
‘I’m scared I’ll get a heart attack or a stroke, although I use medication, I will always 
have that fear.’ (68-year-old woman in the continuation group)
In contrast to the other factors, these patients did not hesi¬tate to turn to professionals 
to help improve their lifestyle (statement 36). However, it was hard for them to change 
and maintain a healthy lifestyle (statement 23). 
‘There is nothing as hard as changing your lifestyle.’ (53-year-old man in the 
continuation group)
They were afraid of the negative effects of the long-term use of antihypertensive and 
lipid-lowering drugs (statement 10).
‘You take them [medications] because you think they will help you […] what would be the 
negative effect in the long term, concerning my cholesterol pills that is not that clear to 
me.’ (47-year-old man in the deprescription group)
Furthermore, they always read the information leaflet of their medications (statement 
25).
Validation questionnaire
The validation questionnaire was sent to 31 patients. A total of 29 patients responded. Of 
these, 27 loaded onto one of three factors (Table 3). In 74% (20/27) of the cases, patients 
self-selected the factor they loaded on, indicating that this factor fitted them “well” 
or very well. Seven patients reported that more than one factor description contained 
elements matching their ideas. 
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Table 3. Patients’ (n=31) reports on whether or not the three distinguishable factors 
that emerged from the Q-sorts fitteda them






Not loading on 
any factor (n=2)
Fitting factor 1 10 3 2 1
Fitting factor 2 3 6 2 1
Fitting factor 3 1 0 4 0
Fitting just one 
factor
9 5 4 0
Fitting two factors 1 2 2 1
Non-respondents 0 1 1 1
a‘well’ or ‘very well’.
126
Table 3. Patients’ (n=31) reports on whether or not the three distinguishable factors 
that emerged from the Q-sorts fitteda them






Not loading on 
any factor (n=2)
Fitting factor 1 10 3 2 1
Fitting factor 2 3 6 2 1
Fitting factor 3 1 0 4 0
Fitting just one 
factor
9 5 4 0
Fitting two factors 1 2 2 1
Non-respondents 0 1 1 1
a‘well’ or ‘very well’.




With our Q-methodology study, we aimed 1) to identify the viewpoints of patients with low 
CVD risk concerning preventive CVD management and 2) to investigate whether certain 
viewpoints were related to a preference for either the deprescription or continuation 
of preventive cardiovas¬cular medication. We found the following three viewpoints: 1) 
controlling, 2) autonomous, and 3) afraid viewpoints. Patients who had their preventive 
cardiovascular medica¬tion deprescribed were differentially distributed across these 
viewpoints relative to patients who continued their medi-cation. Most of the patients 
loading onto the autonomous viewpoint had their medication deprescribed, and most of 
the patients loading onto the afraid viewpoint had it continued. Several group discussion 
statements reinforced the findings of our Q-methodology, and in 74% of the cases, 
patients self-selected the factor they loaded on as fitting them well.
Strengths and limitations
Using Q-methodology and postsort group discussions led to profound understanding 
of the factor arrays. The inclusion of patients who had deprescribed their medication 
and patients who had continued their medication ensured that different viewpoints were 
represented in our data. The participation grade of the study was fairly low, probably 
because of the fixed dates we offered for our sessions, combined with our working 
class population. However, as discussed by Watts and Stenner,15 our sample size was 
considered sufficiently large for a Q-methodological study to reveal some of the main 
viewpoints that were favored by our specific study population. Moreover, our study 
population was similar to the nonrespondents in terms of age and gender. Because of 
their participation in the ECSTATIC trial, it is possible that our study population had more 
negative views toward preventive cardiovascular medication use than patients generally 
have. The outcomes might therefore not be generalizable in that respect. The goal of 
this Q-methodological study, however, was to identify different patterns of thought in 
our specific population. One of the strengths of this study is that the study population 
had previously discussed deprescribing with their GPs. We believe that this ensured 
that their views and opin¬ions were well thought-out, resulting in balanced outcomes. 
Furthermore, it enabled us to link the patients who had deprescribed or continued their 
medication with the factors we found, revealing a more defined image of the viewpoints 
of patients loading on these factors. This information may be helpful for implementation 
purposes. In addition, by asking all patients how well each factor fitted them, we were 
able to show that our factor description indeed represented the viewpoints of the 
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Comparison with existing literature
Results from our Q-methodology overlap with the outcomes of several other studies. 
For example, similar observations had been made previously regarding the importance 
patients place on monitoring blood pressure and cholesterol10, 13 (controlling and 
afraid), the role of stress as a cause of hypertension10 (controlling), the search for aides 
in chang¬ing one’s lifestyle to reduce the effects of modifiable factors that influence 
blood pressure and cholesterol,10 and the fear of developing CVD17 (afraid). It is known 
that a dislike of medication and a lack of confidence in its prescriber are enablers 
of deprescribing.13, 18 These characteristics were shared by the patients loading on 
the autonomous viewpoint, and these patients were indeed more likely to have their 
medi¬cation deprescribed. However, the fear of side effects is also known as an enabler 
of deprescribing,13 but patients loading onto the afraid viewpoint were more likely to 
continue their medication. This is likely because they feared CVD even more than the 
side effects, or because they were not able to change their lifestyle.14
Morecroft et al10 found that about half of the patients with hypertension believed that 
appropriate antihyperten¬sive treatment involved leaving medical decisions to their 
GPs. Interestingly, all patients in our study population appreciated being involved in 
the general decision-making process. Considering the comparable age groups of both 
study populations, this may represent changing medical attitudes or cultural differences 
between patients in the UK and the Netherlands.
Practice implications
Knowing which views and thoughts patients have concerning preventive CVD 
management may be helpful for GPs when discussing this topic with a patient in 
daily practice. Furthermore, when planning to implement a deprescription strategy 
for inappropriate preventive cardiovascular medication, it seems appropriate to start 
implementation in patients who have an autonomous viewpoint because deprescribing 
is most likely to be successful in this group of patients. We believe that this approach 
to start implementation will not be very time-consuming because most GPs can clearly 
identify the patients who fit this profile.
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The three well-discriminating viewpoints concerning preventive CVD management that 
emerged from our Q-methodological study (controlling, autonomous, and afraid) can be 
used for implementation and communication purposes in deprescribing. Table 4 shows 
some suggestions on how to detect patients with certain viewpoints and how to optimally 
communicate with them.
Table 4. Suggested approaches for general practitioners to discuss preventive 
cardiovascular management
Factor Main features of the patient Communication advice
Factor 1: Controlling Having a healthy lifestyle is 
something obvious
Discuss (treatment) options 
and explain why and how
Periodical monitoring of 
blood pressure/cholesterol is 
important
Focus the information 
on monitoring of blood 
pressure/cholesterol
No strong opinion regarding 
medication use
When the patient is 
indecisive, give your 
(expert) opinion
Factor 2: Autonomous Knows a lot about medication 
and healthy lifestyles 
Discuss (treatment) options 
and explain why and how
Little fear for cardiovascular 
disease
Focus the information 
on pro’s and cons of 
medication use
Negative towards medication 
use
Let the patient decide for 
themselves, eventually
Factor 3: Afraid Changing and maintaining a 
(healthy) lifestyle is hard 
Discuss (treatment) options 
and explain why and how
Fears cardiovascular disease Focus the information 
on a healthy lifestyle and 
suggest professional help
No strong opinion regarding 
medication use
When the patient is 
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Table 2. Consensus and distinguishing statements in the Q-set and the values of the 
ideal Q-sort per factor










1. A healthy lifestyle is important 
to keep my CVD risk as low as 
possible*
3 2 4
2. My individual CVD risk can change 
over time*
1 1 0
3. My own experiences and the ones 
from people around me were the 
most important in my decision 
whether or not to deprescribe the 
medication for my blood pressure/
cholesterol level*
0 -1 -1
4. Medications for blood pressure/
cholesterol level are very safe 
in comparison to other kinds of 
medications*
-1 -1 0
5. If CVD runs in your family, you can 
do very little to prevent developing 
CVD yourself**
-2 -2 -2
6. Medications are unnatural** 0 0 -1
7. I feel a bit ashamed when I come 
to my GP for my blood pressure; 
he does not have much time and 
should help patient who are really 
ill**
-2 -3 -4
8. I fear(ed) for side effects of blood 
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ill**
-2 -3 -4
8. I fear(ed) for side effects of blood 
pressure/cholesterol level lowering 
medication*
-1 0 -1
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9. I would rather use medication than 
change my lifestyle to reduce my 
CVD risk*
-4 -4 -3
10. I am afraid that long-term use of 
medication for my blood pressure/
cholesterol level will have negative 
effects on me*
0 0 1
11. It is important that I can 
communicate well with my GP*
2 3 2
12. It is important that my GP clearly 
explains why I need a certain 
treatment, what the options are and 
how the medication works**
4 3 3
Distinguishing statements
13. I understand well why I do or do 
not use medication for high blood 
pressure/cholesterol level
2 4*** 1
14. I feel relieved when my cholesterol 
level is ok when it is checked
1 1 4***
15. Using more and more medications 
just accompanies getting older
-2 -3 0***
16. I know which food is healthy 
and will help me lowering my 
cholesterol level
1 4*** 1
17. If I experience less stressful events 
my blood pressure will be lower as 
well
2 2 0***
18. I am interested in the mechanisms 
of different medications for high 
blood pressure
0 1 -1***
19. It is important that my GP keeps 
monitoring my blood pressure, 
whether I use medication or not
4*** 0*** 2***
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blood pressure
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monitoring my blood pressure, 
whether I use medication or not
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20. It is scary to walk around having a 
high blood pressure
3*** -2*** 2***
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21. I feel physically better when I use 
medication for my blood pressure 
or cholesterol level
0 -4*** 0
22. I do not make decisions concerning 
medication use alone, but together 
with my partner/family/friends
-2 0 -2***
23. It is hard to maintain a healthy 
lifestyle
-3*** 1 2
24. I would rather increase the dose 
of one medication than us a 
combination of two medications in 
a lower dose
0 -1 -2***
25. I always read the information leaflet 
before I start using medication
1 1 3***
26. I am afraid of developing a heart 
attack or stroke
-1 0 2***
27. Whether medication is reimbursed 
plays a role in my decision to use 
them or not
-3 -2*** -4
28. Doctors prescribe medication too 
easily
-2 0*** -1
29. Using medication for my high blood 
pressure gives me a feeling of 
control
0*** -1 -2
30. If I have a low risk of developing 
CVD I do not have to use medication 
to prevent it
1 2*** 0
31. It is just a small effort to take 
medication
2 0*** 1
32. I trust my GP in making the right 
decisions for me
1 -1*** 0
33. My wish is to become a 100-years 
old without using medication
0*** 3*** -1***
34. Nobody should smoke 3*** 1 1
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35. If CVD runs in my family I am more 
inclined to take medication
2 -1*** 1
36. I have searched for help in order to 
achieve a healthier lifestyle (e.g., 
help to stop smoking, dietary ad-
vice, advice of a sports instructor)
-3*** 0*** 3***
Remainder statements
37. Medications that lower blood 
pressure or cholesterol level are 
expensive
-1 -1 -2
38. If my partner or good friend/col-
league would advise me to con-
tinue my medication then I would 
definitely do that
-1 -2 -3
39. I would appreciate it more if my 
GP decides for me whether or not I 
should use medication than I would 
appreciate deciding that myself
-1 -2 -1
40. If my GP explains things to me, I 
am able to retell it when I am home
1 2 0
41. Use of medications should be 
prevented or restricted as much as 
possible
0 2 1
42. I would want to reduce my CVD risk 
with alternative medicine such as 
homeopathy or acupuncture
-1 1 0
43. If I can stop my medication for high 
blood pressure/cholesterol level, 
I will continue until the package 
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homeopathy or acupuncture
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43. If I can stop my medication for high 
blood pressure/cholesterol level, 
I will continue until the package 
is empty, otherwise it would be a 
waste
-4 -3 -3
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Notes: *Consensus statement that does not distinguish between any pair of factors with a p-value 
>0.01; **Consensus statement that does not distinguish between any pair of factors with a p-value 
>0.05; ***Distinguishing statement (the marker is placed at the Q-sort value of the factor for which the 
statement is a distinguishing between any pair of factors with a p-value <0.01).
Abbreviations: CVD, cardiovascular disease; GP, general practitioner.
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ABSTRACT
Background
Patients whose indication for the use of antihypertensive and/or lipid-lowering drugs 
changes, may want to stop their medication. We aimed to develop a decision rule 
for successfully stopping preventive cardiovascular medication, thus providing the 
physician with individualised information and enhancing decision making concerning 
deprescription.
Methods
We re-analyzed data from the intervention group of our own previously published 
Evaluating Cessation of STatins and Antihypertensive Treatment In primary Care 
(ECSTATIC) study, a controlled trial in primary care in which we assessed the (cost-)
effectiveness and safety of an attempt to deprescribe antihypertensive and/or lipid-
lowering drugs in a population with low cardiovascular disease risk. Potential 
determinants of successful deprescription were found in literature and expert opinion. 
We assessed demographic factors, physical examination measures, laboratory 
results, and information from questionnaires. Potential determinants showing a 
univariable association with a P<0.2 were tested in a multivariable prediction model 
with generalised estimating equations in SPSS version 23. We used cross-validation for 
internal validation of the model.
Results
Among those in the intervention group (N=492) 135 patients successfully stopped 
medication (27%). We found a systolic blood pressure (SBP) ≤140, using preventive 
cardiovascular medication ≤10 years, using either an antihypertensive or a lipid-
lowering drug, and using ≤1 class of antihypertensive drugs to predict successful 
stopping independently. Discrimination and calibration were reasonable, with an area 
under the curve of 0.70 (95% CI 0.65 to 0.75), reduced to 0.65 in cross-validation (95% 
CI 0.60 to 0.71). The decision rule derived from our model showed that the probability of 
successfully stopping medication was 45% if all four predictors were positive.
Conclusion
The highest probability of successful stopping (redundant) preventive cardiovascular 
medication is approximately 50% for patients who show all four factors when the 
decision is taken. If one of these factors is absent, probability is substantially lower. This 
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Hypertension and hypercholesterolemia are known risk factors for cardiovascular 
diseases (CVD).1 Over time, the recommendations for initiation of drug treatment 
for hypertension and hypercholesterolemia have been subject to change.2-7 Change 
of recommendations can lead to under- or overtreatment in specific populations. 
Overtreatment occurs for example in patients with predicted low CVD risk according to 
current guidelines, who are using antihypertensive or lipid-lowering drugs based on 
former recommendations.8 Our previously published Evaluating Cessation of STatins 
and Antihypertensive Treatment In primary Care (ECSTATIC) study showed that low 
risk patients without a strict indication for the use of antihypertensive or lipid-lowering 
drugs can stop their medication safely in the short term.9 Of all the study participants 
who were advised to consult their general practitioner (GP) to discuss deprescribing of 
their preventive cardiovascular medication however, only 27% (135/492) successfully 
persisted in not using the medication after two years of follow-up.9 Known predictors 
of normotension after withdrawal of antihypertensive drugs and of long-term stopping 
of antihypertensive drugs are low systolic blood pressure (SBP), monotherapy, using 
antihypertensive drugs for less than 5 years, low dosage of antihypertensive drugs, and 
young age.10-12 To the best of our knowledge, some studies reported predictors for short 
term discontinuation of lipid-lowering drugs, but no studies have looked into predictors 
of successful long-term withdrawal after stopping lipid-lowering drugs that might be 
helpful for physicians wanting to embark on a deprescribing trajectory with individual 
patients.13-15
Therefore, our aim was to develop a practical decision rule that can be easily used in 
daily general practice and can help patients and GPs in the decision making process 
by providing individualised information about the probability of successfully stopping 
preventive cardiovascular medication.
METHODS
We re-analyzed the data from the intervention group among participants of our own 
previously published ECSTATIC study. The ECSTATIC study is a cluster randomised 
non-inferiority controlled clinical trial in general practice in the Netherlands, with a 
two-year follow-up, conducted between 2012 and 2015.9 The results of the ECSTATIC 
study show that an attempt to deprescribe preventive cardiovascular medication in 
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risk management in general practice is safe in the short term.3,9 The participants of the 
ECSTATIC study were 40 to 70 years old, using antihypertensive and/or lipid-lowering 
drugs ≥1 year, without a history of cardiovascular events and with a recalculated low risk 
of future CVD, resulting in the absence of a strict indication for preventive cardiovascular 
drug treatment. The intervention group of the ECSTATIC study consisted of 492 
participants from 23 practice centres, who were all included in the present study.
At 24 months of follow-up, participants in the intervention group self-reported whether 
or not they were ‘currently not using medication’. Reporting ‘currently not using 
medication’ was defined as persistent successfully stopping preventive cardiovascular 
medication. As this was a self-reported outcome by the participants, it was blinded to 
information about potential predictors of successful stopping. Further methods used in 
the ECSTATIC study were extensively described elsewhere.9
Predictors
Potential determinants of successful depresciption, were found in literature, in the 
results of our qualitative study in the intervention group of the ECSTATIC study and in 
expert opinion.10-12,16 In developing our prediction model and the resultant decision rule, 
we used the following variables for each patient, extracted from the electronic medical 
records (EMR) of the general practices at inclusion: age, sex, duration of preventive 
cardiovascular medication use, use of both antihypertensive and lipid-lowering drugs, 
and number of antihypertensive drugs used. The results of laboratory tests that 
were also extracted from the EMR at inclusion were: low-density-lipoprotein (LDL) 
cholesterol, total cholesterol, and glomerular filtration rate. All variables considered as 
potential determinants of successful deprescription are summarized in Table 1.
Statistical analysis
We used the data of all participants in the intervention group of the ECSTATIC study 
(N=492) to develop the decision rule. We assumed that at least 10 occurrences per 
candidate predictor in the population, were necessary to prevent overestimation of the 
performance of the prediction model.17 We performed a complete case analysis, as the 
amount of missing data was very low (missingness for all variables was 0 % to 6.5%).
We explored nonlinear relationships of all the continuous variables, by fitting quadratic, 
logarithmic, hyperbolic, and exponential curves. Based on R2, a linear model provided 
the best fit in all cases. Interactions were unexpected and were not assessed, reducing 
the chance of overfitting of the prediction model.18  We used Generalised Estimating 
Equations (GEEs) in SPSS version 23 to develop a multivariable prediction model, based 
on all variables showing a univariable association with the outcome with a P<0.1 and 
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CHAPTER 6
with a P<0.2 succeedingly. One advantage of GEE models over mixed models is that the 
resulting decision rule can be applied to new independent single individuals, i.e. there is 
no cluster specific effect in the model.
We compared the discrimination of the prediction model built with all variables 
showing an association with a P<0.1 with that of the prediction model with all variables 
showing an association with a P<0.2. If variables showed strong co-linearity, they were 
separately assessed in different models with otherwise the same variables. Eventually, 
we continued with the model that performed best, based on the Area Under the Curve 
(AUC).
Because our aim was to develop a practical decision rule, the effect of categorisation 
of continuous variables on the AUC was assessed. If reduction in the AUC was believed 
to be small, we would continue with a dichotomised continuous variables in our final 
model. We further assessed our model building strategy, by applying a backward 
stepwise selection to our final model.
Our decision rule was derived from a further simplified final model. This simplified 
model was calibrated to assess how closely the predicted probability of successfully 
stopping of the simplified final model agreed with the observed probabilities as given 
by frequencies of affection status in bins of the risk score. We used cross-validation 
to assess the internal validity of the simplified final model. The simplified final model 
was tested in 23 folds (because the data consisted of 23 clusters/general practices) by 
leaving out each of the clusters once. In each of these folds, the model was first fitted 
based on data of 22 clusters and then used to calculate the predicted probabilities for 
the participants in the cluster that was left out. Each cluster was therefore predicted 
once as a hold-out sample, and these cross-validated predicted probabilities were 
used to calculate the cross-validated AUC in order to assess potential overfitting of the 
simplified final model. This procedure resulted in a decision rule with the same variables 
as the simplified final model, for supporting the decision to deprescribe in practice.
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RESULTS
In the intervention group (N=492) 135 participants (27%) persisted in successfully 
stopping their preventive cardiovascular medication after two years. Of those 135 
participants 115 participants had stopped antihypertensive drugs (85.2%) and 26 
participants had stopped lipid-lowering drugs (19.3%), so 6 stopped both. Most 
participants were female (N=374, 72%) and the mean age was 55 years (Table 1). Among 
the 18 predictors that were considered, five showed missing values ranging from 1.0% 
to 6.5% with 133 to 134 participants per predictor who succeeded to successfully stop 
medication.
A systolic blood pressure (SBP) ≤140 mmHg, lower education level (negatively), 
higher education level (positively), relatively short (1 to 5 years) as well as <10 years 
of preventive cardiovascular medication use, using only an antihypertensive or a lipid-
lowering drug (and not both), and using ≤1 class of antihypertensive drug, all were 
univariably associated (P<0.02) with successful deprescription (Table 2) and moved to 
the final model. Prediction of successful stopping with only dichotomous variables did 
not show a clinically relevant difference with prediction making use of both continuous 
(nonlinear) and dichotomous variables (AUC 0,71 versus 0,73 with a 95% CI 0.66 to 0.76, 
and a 95% CI 0.68 to 0.78, respectively). Sensitivity analysis using backward stepwise 
selection did not further improve our final model.
Based on the final model we produced a simplified final model with a AUC of 0.70 
(95% CI 0.65 to 0.75) (Table 2). Participants who had a SBP ≤140 mmHg, who used 
preventive cardiovascular medication ≤10 years, who used either an antihypertensive of 
a lipid-lowering drug, and who used ≤1 class of antihypertensive drug had the highest 
probability of successful stopping. Internal validation using cross-validation showed a 
decrease in the AUC from 0.70 to 0.65 (95% CI 0.60 to 0.71) of the simplified final model 
(Figure 1). A practically usable decision rule with the four remaining characteristics was 
derived from the simplified final model and predicted successful deprescription (Table 
3). Eight points or higher indicate a probability of successful stopping higher than the 
probability of 27% of successful stopping in general. Of 492 participants 91 (18%) had 
a total score ≤5 points, indicating a 0% to 10% probability of successful stopping. The 
highest probability of successful stopping according to the decision rule was 45%, which 
was present in 107 of 492 (22%) participants with a total score of 11 points.
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not show a clinically relevant difference with prediction making use of both continuous 
(nonlinear) and dichotomous variables (AUC 0,71 versus 0,73 with a 95% CI 0.66 to 0.76, 
and a 95% CI 0.68 to 0.78, respectively). Sensitivity analysis using backward stepwise 
selection did not further improve our final model.
Based on the final model we produced a simplified final model with a AUC of 0.70 
(95% CI 0.65 to 0.75) (Table 2). Participants who had a SBP ≤140 mmHg, who used 
preventive cardiovascular medication ≤10 years, who used either an antihypertensive of 
a lipid-lowering drug, and who used ≤1 class of antihypertensive drug had the highest 
probability of successful stopping. Internal validation using cross-validation showed a 
decrease in the AUC from 0.70 to 0.65 (95% CI 0.60 to 0.71) of the simplified final model 
(Figure 1). A practically usable decision rule with the four remaining characteristics was 
derived from the simplified final model and predicted successful deprescription (Table 
3). Eight points or higher indicate a probability of successful stopping higher than the 
probability of 27% of successful stopping in general. Of 492 participants 91 (18%) had 
a total score ≤5 points, indicating a 0% to 10% probability of successful stopping. The 
highest probability of successful stopping according to the decision rule was 45%, which 
was present in 107 of 492 (22%) participants with a total score of 11 points.
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Table 3. Probability of successful stopping per category of the decision rule of the 
simplified final model
Points Probability of  
successful stopping
Systolic blood pressure ≤ 140 mmHg 1
Using preventive cardiovascular 
medication ≤10 years
3
Using either an antihypertensive or a  
lipid-lowering drug
3
Using ≤ 1 class of antihypertensive drug 4
Total points ≤5 0% to 10%
Total points 6 to 7 20%
Total points 8 to 10 30% to 40%
Total points 11 45%
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Based on our study the four strongest predictors for successfully stopping medication in 
low-CVD-risk patients in general practice are: 1) having a SBP ≤140; 2) using preventive 
cardiovascular medication ≤10 years; 3) using either an antihypertensive or a lipid-
lowering drug; and 4) using ≤1 class of antihypertensive drugs. When all four predictors 
are positive the probability of successfully stopping medication is almost half.
Strengths and weaknesses of study
Data of our study were very complete and close to real life practice. Other strengths of 
this study included the relatively large total number of participants and the number of 
participants who successfully stopped their preventive cardiovascular medication.
Our predicted outcome was stopping for either antihypertensive or lipid-lowering drugs 
(or both). Combining these two events into a single one is motivated by the fact that 
clinically these two different drug regimens are often discussed together during a single 
consultation concerning prevention of CVD. GPs can now use the developed decision rule 
to assess the overall prospect of stopping during such a consultation. The number of 
participants who persisted successfully in stopping lipid-lowering drugs was relatively 
low, which would make our results less reliable if we would have analysed successful 
stopping of lipid-lowering drugs as a separate group. However, this small number of 
participants also suggests that the decision rule may be less appropriate for low-CVD-
risk patients only using lipid-lowering drugs.
Although participants were included based on the Dutch CVD risk score which is derived 
from the CVD risk score of the European guideline, the developed decision rule may 
not adequately predict successful stopping of preventive cardiovascular medication 
in patients with low CVD risk according to other CVD risk prediction calculations. Our 
decision rule should be further assessed in new populations and therefore should 
preferably only be used and documented in controlled situations first. However, AUC 
decreased from 0.70 to 0.65 after cross-validation, which suggests little or no overfitting 
and our model showed good calibration.13 Furthermore, three of four predictors 
we found are known predictors for successfully stopping antihypertensive drugs.2-4 
Therefore, we do believe that we built a simple, ready-to-use tool that can be helpful 
in the decision-making process concerning deprescribing of preventive cardiovascular 
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medication in low-CVD-risk patients in general practice.  
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Comparison with other studies and interpretation
Having a SBP ≤140, using preventive cardiovascular medication ≤10 years, and using 
≤1 class of antihypertensive drugs were already recognized as potential predictors for 
successfully stopping antihypertensive drugs in other projects.2-4 To the best of our 
knowledge, our study is the first to investigate also predictors of successful stopping 
lipid-lowering drugs (albeit for a small number of participants stopping lipid-lowering 
drugs). Predictors for discontinuation of lipid-lowering drugs have been reported, 
however, discontinuation is a process that in these studies is initiated by the patient, 
whereas we studied successful stopping after a deprescribing consultation in which 
patient and physician discuss whether it is appropriate to stop the medication. Despite 
this difference, there could be some overlap of predictors for discontinuation of lipid-
lowering drugs and of successful stopping of these drugs. In fact, we found that using 
either an antihypertensive or a lipid-lowering drug was a predictor of successful 
stopping preventive medication, and using no concurrent antihypertensive drugs was 
already known to be a predictor of discontinuation of statin treatment.5 Other known 
predictors of discontinuation of lipid-lowering drugs are for example: 1) experiencing 
side effects; 2) not being satisfied with their doctor’s explanation of treatment; 3) 
age <55 years; 4) female sex; and 5) lower socio-economic status.5-7 Although we did 
not measure experienced side effects, nor whether patients were satisfied with their 
doctor’s explanation, it is not plausible that these would be predictors of successful 
stopping in our study, because all patients in our study used their medication ≥1 
year. The chance that patients would have been included in our study if one of these 
predictors was positive is very low, because of the high probability that they would have 
already stopped the medication. We did not find that age ≤55 years and female sex 
were predictors for successfully stopping. Interestingly, lower socio-economic status 
as a predictor for discontinuation of lipid-lowering drugs on patients’ own initiative 
seems to be in contradiction with our results concerning successfully stopping after a 
deprescribing consultation, where we found that a low education level was negatively 
associated with the probability of successfully stopping. Apart from discontinuation and 
successfully stopping being something different, this is probably the result of inclusion 
of different patient populations as well (e.g., duration of medication use at baseline).
As a result of the ECSTATIC study, a structured deprescribing strategy in the overall 
low-CVD-risk population was not recommended because of its low gains in quality of 
life and costs, and because of its low effectiveness (only 27% of persistent quitters).9 
However, because of the better effectiveness in the low-CVD-risk patients in whom all 
four predictors of the decision rule are positive (45% persistent quitters), a structured 
deprescribing strategy in this population may well be cost-effective, and may be worth 
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Having a SBP ≤140, using preventive cardiovascular medication ≤10 years, using either 
an antihypertensive or a lipid-lowering drug, and using ≤1 class of antihypertensive 
drugs were all positively related with successfully stopping antihypertensive and lipid-
lowering drugs.
The decision rule we developed from this simplified final model can be used by 
physicians and may be helpful in supporting the decision-making process during 
deprescribing consultations in daily practice: if all four predictors are positive, the 
patient has about 50% chance to successfully stop preventive cardiovascular medication 
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an antihypertensive or a lipid-lowering drug, and using ≤1 class of antihypertensive 
drugs were all positively related with successfully stopping antihypertensive and lipid-
lowering drugs.
The decision rule we developed from this simplified final model can be used by 
physicians and may be helpful in supporting the decision-making process during 
deprescribing consultations in daily practice: if all four predictors are positive, the 
patient has about 50% chance to successfully stop preventive cardiovascular medication 
over a two-year period; if one or more predictors are negative the chance of success is 
less than 50%.
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Patients who attempted 
to stop their preventive 
cardiovascular medication 
0 (0) 319 (64.8%)
Patients who stopped 
preventive cardiovascular 
medication
0 (0) 135 (27.4%)
10-year CVD risk score for 
inclusion – %a
0 (0) 6.7 (±4.2)
Medication use at baseline
Using antihypertensive 
drugs – no. (%)
0 (0) 431 (87.6%) EMR, confirmed by self-report
Agents acting on the 
renin-angiotensin system 
– no. (%) 0 (0) 276 (56.1%) EMR, confirmed by self-report
Diuretics – no. (%) 0 (0) 216 (43.9%) EMR, confirmed by self-report
Beta blocking agents – 
no. (%)
0 (0) 125 (25.4%) EMR, confirmed by self-report
Calcium channel 
blockers – no. (%)
0 (0) 61 (12.4%) EMR, confirmed by self-report
Other antihypertensive 
drugs – no. (%)
0 (0) 2 (0.5%) EMR, confirmed by self-report
Using lipid-lowering drugs 
– no. (%)
0 (0) 105 (21.3%) EMR, confirmed by self-report
HMG CoA reductase 
inhibitors – no. (%)
0 (0) 101 (20.5%) EMR, confirmed by self-report
Other lipid-lowering 
drugs – no. (%)
0 (0) 11 (2.2%) EMR, confirmed by self-report
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Variables assessed for 
prediction model
Age – years 0 (0) 54.5 (±7.8) EMR, confirmed by self-report
Female – no. (%) 0 (0) 347 (70.5%) EMR, confirmed by self-report
Systolic blood pressure – 
mm Hg
0 (0) 140.9 (±20.8) Omron HEM-907
LDL-cholesterol – mmol/L 3 (1.0) 3.3 (±1.1) Local laboratory (EMR)
Total cholesterol – mmol/L 0 (0) 5.5 (±1.4) Local laboratory (EMR)
Glomerular filtration rate 
(MDRDb) – ml/min/1.73m2
16 (3.3) 77.6 (±29.5) Local laboratory (EMR)
Body mass index – kg/height 
in meters2
0 (0) 28.3 (±5.2) seca 762 and 213
Body weight – kg 0 (0) 81.9 (±19.2) seca 762
Smokers – no. (%) 0 (0) 38 (7.7%) Defined by self-reporting in a 
questionnaire





Duration of preventive 
cardiovascular medication 
use
0 (0) EMR, confirmed by self-report
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Fruit and vegetable 
consumption – grams per 
day
0 (0) 319 (±150) standard nutrition 
questionnaire of Dutch 
common health services23
Positive family history of 
CVD  – no. (%)
32 (6.5) 207 (42.1%) Defined by self-reporting in a 
questionnaire
Caucasian descent  – no. (%) 0 (0) 451 (91.7%) Defined by self-reporting in a 
questionnaire
Using either an 
antihypertensive or a lipid-
lowering drug – no. (%)
0 (0) 448 (91.1%) EMR, confirmed by self-report
Using ≤ 1 class of 
antihypertensive drug – no. 
(%)
0 (0) 290 (58.9%) EMR, confirmed by self-report
Abbreviations: CVD denotes cardiovascular disease; EMR denotes electronic medical record.
a  10-year CVD risk score estimated for inclusion with baseline values of age, sex, and smoking status, 
and pre-treatment systolic blood pressure and pre-treatment total cholesterol/HDL-cholesterol ratio as 
if participants did not use preventive cardiovascular medication.
b Modification of Diet in Renal Disease Study equation
c  For patients <55 years old only activities with a MET-score (Metabolic Equivalent score) ≥4 kcal/kg/hour 
executed ≥60 minutes on one or more days were taken into account to assess physical activity level22;  
for patients ≥55 years old only activities with a MET-score ≥3 kcal/kg/hour executed ≥30 minutes on one 
or more days were taken into account to assess physical activity level.22
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Table 2. Univariable associations with successful stopping preventive cardiovascular 
medication and derived final models for predicting successfully stopping preventive 
cardiovascular medication
Characteristic Beta Odds ratio 95% CI p value
Age ≤ 55 years 1.12 0.77 to 1.62 0.57
Systolic blood pressure ≤ 140 mmHg 1.41 0.97 to 2.06 0.07
LDL-cholesterol ≤ 2.5 mmol/L 1.15 0.71 to 1.86 0.57
Total cholesterol ≤ 6.5 mmol/L 1.42 0.68 to 2.99 0.35
MDRD ≤ 60 ml/min/1.73m2 1.06 0.45 to 2.47 0.90
Body mass index (kg/height in 
meters2) ≤ 27 points
1.19 0.84 to 1.69 0.33
Body weight ≤ 85 kg 0.98 0.62 to 1.55 0.93
Alcohol consumption ≤ 2 glasses per 
day
1.26 0.81 to 1.96 0.31
Physical activity level ≤ 150 minutes 
per day a
1.10 0.75 to 1.62 0.63
Fruit and vegetable consumption  
≤ 250 grams per day
0.96 0.58 to 1.59 0.88
Female sex 0.90 0.56 to 1.43 0.65
Smoker 0.69 0.35 to 1.34 0.27
Education level
Low 0.57 0.33 to 1.01 0.05
Middle 1.03 0.78 to 1.36 0.84
High 1.28 1.00 to 1.64 0.05
Duration of preventive cardiovascular 
medication use
1 to 5 years 2.04 1.42 to 2.93 <0.01
5 to 10 years 1.07 0.70 to 1.63 0.76
>10 years 0.37 0.22 to 0.61 <0.01
Positive family history of CVD 1.12 0.71 to 1.77 0.62
Caucasian descendence 1.62 0.65 to 4.00 0.30
Using either an antihypertensive or a 
lipid-lowering drug
2.56 1.23 to 5.32 0.01
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Using ≤ 1 antihypertensive drug 3.63 2.03 to 6.50 <0.01
Final modelb
Intercept -2.534
Systolic blood pressure ≤ 140 mmHg 0.351 1.42 0.93 to 2.17 0.10
Low education level -0.529 0.59 0.27 to 1.27 0.18
High education level 0.002 1.00 0.74 to 1.36 0.99
1 to 5 years of preventive 
cardiovascular medication use
0.272 1.31 0.87 to 1.99 0.20
Using preventive cardiovascular 
medication ≤10 years
0.712 2.04 1.44 to 3.63 0.02
Using either an antihypertensive or a 
lipid-lowering drug
0.801 2.23 1.16 to 4.29 0.02
Using ≤ 1 class of antihypertensive 
drug
1.164 3.20 1.71 to 5.98 <0.01
Simplified final modelc
Intercept -3.422
Systolic blood pressure ≤ 140 mmHg 0.332 1.39 0.92 to 2.12 0.12
Using preventive cardiovascular 
medication ≤10 years
0.849 2.34 1.36 to 4.01 <0.01
Using either an antihypertensive or a 
lipid-lowering drug
0.913 2.49 1.35 to 4.61 <0.01
Using ≤ 1 class of antihypertensive 
drug
1.185 3.27 1.79 to 5.97 <0.01
Abbreviations: CVD denotes cardiovascular disease.
a  For patients <55 years old only activities with a MET-score (Metabolic Equivalent score) ≥4 kcal/kg/hour 
executed ≥60 minutes on one or more days were taken into account to assess physical activity level22;  
for patients ≥55 years old only activities with a MET-score ≥3 kcal/kg/hour executed ≥30 minutes on one 
or more days were taken into account to assess physical activity level.22
b  The predicted probability of successful stopping preventive cardiovascular medication can be calcu-
lated as follows with the final model: 1/(exp(-(-2.534 + 0.351*SBP ≤140 mmHg - 0.529*Low education 
level + 0.002*High education level + 0.272*1 to 5 years of preventive cardiovascular medication use + 
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0.712*Using preventive cardiovascular medication ≤10 years + 0.801*Using either an antihypertensive or 
a lipid-lowering drug + 1.164* Using ≤ 1 class of antihypertensive drug))+1). 
c  The predicted probability of successful stopping preventive cardiovascular medication can be calculated 
as follows with the simplified final model: 1/(exp(-(-3.422 + 0.322*SBP ≤140 mmHg + 0.849*Using pre-
ventive cardiovascular medication ≤10 years + 0.913*Using either an antihypertensive or a lipid-lowering 
drug + 1.185*Using ≤ 1 class of antihypertensive drug))+1).
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GENERAL DISCUSSION
In this chapter the findings within this thesis will be discussed, mainly aiming at 
improving  preventive cardiovascular care in patients aged 40-70 years with a relatively 
low cardiovascular disease (CVD) risk. Based on these findings, we will appeal to 
policy makers revising the Cardiovascular Risk Management (CVRM) guideline, 
and we will present some tools to help general practitioners (GPs) in dealing with 
possible overtreatment with antihypertensive and/or lipid-lowering drugs (preventive 
cardiovascular medication) in low-CVD-risk patients. Specific findings will be illustrated 
using the cases presented in the introduction.
1. The strengths of a mixed methods approach to investigate deprescribing
Deprescription of medication is a process where quantitative evidence about 
deprescribing (if available) is discussed in the light of more qualitative views and 
opinions of the patient and the physician (and sometimes also of the pharmacist). 
Hence, studies investigating deprescribing are often pragmatic in origin.1-3 The goal of 
these pragmatic studies is to investigate the effect of deprescribing compared with an 
alternative strategy (e.g., usual care) within the ‘real world’, giving free rein to qualitative 
reasoning in the decision whether or not to deprescribe medication.4, 5 The discourse 
of the process of deprescribing, as well as the pragmatic designs used to investigate 
deprescribing, cause the combination of both quantitative and qualitative research, the 
so-called mixed methods approach, to be very valuable in investigating deprescribing. 
The addition of qualitative findings to quantitative results may help to reveal why an 
attempt to deprescribe is or is not carried out when a certain deprescribing strategy is 
implemented in clinical practice.
This thesis is an example of a mixed methods approach in deprescribing research. 
Chapter 3 of this thesis aimed at improving the evidence in favour or against 
deprescribing preventive cardiovascular medication in a quantitative way. The outcome 
was clear, but also led to some new questions that could not be answered with the 
collected quantitative data. With help of two studies, one study using qualitative data of 
audiotaped deprescribing consultations (Chapter 4) and one study ‘mixing’ qualitative 
and quantitative methods using Q-methodology and group discussions (Chapter 5), 
questions that arose concerning willingness to have medication deprescribed of both 
patient and GP could be answered. Subsequently, the quantitative study in Chapter 6 
resulted in a practical decision rule that can be used to improve the decision-making 
process of deprescribing. The following paragraphs in the general discussion show that 
these four studies together provide a broad perspective on deprescribing preventive 
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CHAPTER 7
cardiovascular medication, and that especially the (more) qualitative Chapters 4 and 5 
enrich the quantitative findings of Chapter 3 and Chapter 6.
2. No indication for initiating medication
We found that approximately 60% of the patients using antihypertensive and/or lipid-
lowering drugs to prevent a first cardiovascular event, strictly speaking have no 
indication for using this medication according to the current Dutch CVRM guideline 
(Chapter 2). One of the explanations for this observation may be that former guidelines 
based their treatment recommendation solely on a single risk factor (hypertension or 
hypercholesterolemia), and that the approach of calculating total cardiovascular risk, 
as used in the current guidelines, is more conservative in its recommendations to start 
medication.6-8 Another explanation for the possible overtreatment in low-CVD-risk 
patients is that GPs not only take absolute CVD risk into account, but also consider 
other factors that increase (relative) CVD risk in their opinion, when evaluating the 
need for preventive cardiovascular medication (Chapter 4). Or, maybe, GPs consider 
overtreatment in low-CVD-risk patients, but are hesitant to discuss deprescribing with 
the patient, because there is no evidence that deprescribing is safe.
2.1. Safety of deprescribing
The possible overtreatment in the low-CVD-risk population raised the question whether 
their preventive cardiovascular medication could be stopped safely in general practice.  
Our results show that deprescribing preventive cardiovascular medication in low-
CVD-risk patients is safe in the short term as long as adverse effects, as well as blood 
pressure and cholesterol levels are monitored by the GP after stopping (Chapter 3). 
The reported increase in SBP of 6 mmHg and an increase of LDL-cholesterol of 0.2 
mmol/L in the intervention group compared to the usual care group, are in keeping with 
reductions in SBP and LDL-cholesterol that medication can achieve.9, 10 This resulted 
in a difference in mean increase in CVD risk between intervention and usual care group 
of 0.1 percentage points (95% CI -0.3 to 0.6) after two years of follow-up, implying that 
deprescribing is safe in the short term (non-inferiority margin 2.5 percentage points). 
Time and budgetary restrictions kept us from using the difference in cardiovascular 
event rate as primary outcome, although this would have provided us with better 
data to assess the safety question. Cluster randomisation and pre-randomisation 
were necessary to avoid contamination of the usual care group, and for this reason 
we also used a complete-double consent design. These choices may have led to the 
discrepancies in the baseline values between the usual care and the intervention group. 
However, had we not undertaken these measures, the risk of contamination would 
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have been too high, leading to the intervention being (partly) carried out in the usual 
care group as well. Introduction of a type 2 error leading to the flawed conclusion that 
deprescribing is safe, would then have been a likely threat. We tried to minimise the 
bias introduced by the baseline differences, by adjusting for the baseline values in the 
analyses.
In patients who stopped antihypertensive drugs SBP increased on average 13 mmHg, 
and in patients who stopped lipid-lowering drugs LDL-cholesterol increased on average 
1.5 mmol/L (56 mg/dl). Most patients who stopped their medication will probably be 
recommended to restart the medication about 5-10 years later, because by that time 
they have a high-CVD-risk based on their age according to the guideline. It is not clear 
to what extent a rise of 13 mmHg in SBP and/or 1.5 mmol/L in LDL-cholesterol level 
(during about 5 to 10 years) increase the risk of developing CVD in the future in individual 
patients.
Unfortunately, because of the risk of contamination and poor reports of side-effects 
to the researchers as well as in the electronic medical records, it was impossible to 
collect a reliable overview of all side-effects of medication use and of deprescribing. 
However, serious adverse effects of deprescribing (e.g., heart failure) were not reported 
by the GPs, and (although underpowered) there was no difference in the number of 
cardiovascular events between the intervention and usual care group.
2.2. Effectiveness of deprescribing
Approximately 65% of the low-CVD-risk patients in the intervention group did an attempt 
to have their medication deprescribed, and a total of 27% persisted without medication 
after two years of follow-up (Chapter 3). Apparently, about 35% of the patients did not 
try to stop their preventive cardiovascular medication when a deprescribing consultation 
was offered to them. The findings of our qualitative study and our Q-methodology study 
suggest this may be explained by fear of the consequences of deprescribing, e.g. fear 
of hypertension, of hypercholesterolemia, and of cardiovascular events (Chapter 4 and 
5). Another explanation may be the GPs’ doubts about deprescribing in some cases, 
and the lack of negative effects of the medication patients experienced (Chapter 4). 
At baseline, all included patients were using their medication for one year or longer, 
and, had they experienced side-effects, they probably would have changed or stopped 
medication already before entering the study. More than half of the patients who did 
an attempt to deprescribe, restarted their medication within two years. The GPs of 34 
restarted patients (18% of all restarted patients) reported that hypertension, headache, 
nervousness/stress, and palpitations were the most common reasons for restarting 
medication.
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2.3. Cost-effectiveness of deprescribing
Although the intervention was 70% to 80% likely to be cost-effective for a willingness-
to-pay between €20,000 and €50,00011, we would not recommend implementation of 
a structured deprescribing strategy in a low-CVD-risk population in general practice 
(Chapter 3). The main reason for our recommendation is that costs and QALYs did not 
differ between intervention group and usual care group after two years of follow-up, and 
that the effectiveness of the intervention was low (27% persistent quitters).
The cost-analysis (Table S3, Additional file 3) suggests that the intervention was indeed 
carried out in the intervention practices. Costs for general practice consultations in the 
intervention group were higher in the first year, reflecting the protocolised deprescribing 
consultations and follow-up consultations after stopping the medication. In addition, 
costs for preventive cardiovascular medication for total follow-up were lower in the 
intervention group, suggesting withdrawal of medication. Although there is a reduction 
of approximately 40% in preventive cardiovascular medication costs, this reduction is 
small on an absolute scale (approximately 2%), because it predominantly concerns 
inexpensive, off-patent medication. Furthermore, the reduction in medication costs 
achieved by the intervention are evened out by the extra costs for general practice 
consultations.
In addition, the cost-analysis clearly shows that primary care specific (i.e. general 
practice) costs comprise about 30% of total healthcare costs in our study population. 
Because the general practice care costs, nationwide, are only a small part of total 
healthcare costs (approximately 6 %12), an intervention in general practice should 
at least have considerable effect on healthcare costs in general practice itself, but 
preferably also lead to a reduction of healthcare costs outside general practice. Our 
study shows that a structured deprescribing strategy of preventive cardiovascular 
medication in low-CVD-risk patients does not result in these effects. 
2.4. Factors influencing the outcome of the deprescribing consultation
When considering deprescribing of preventive cardiovascular medication, all low-
CVD-risk patients take more or less the same factors into account, however, individual 
patients weigh these factors differently (Chapter 4 and 5). The appropriateness of 
medication use, fear, process (especially knowledge that medication could be restarted 
and that follow-up care was available), influences, and dislike all played a role in the 
decision-making process of deprescribing preventive cardiovascular medication as 
was earlier described by Reeve et al.13 for deprescribing in general (Chapter 4). We 
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2.3. Cost-effectiveness of deprescribing
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CVD-risk population. These added barriers and enablers could be roughly divided into 
three topics: 1) presence of risk factors for CVD (barrier or enabler of deprescribing); 
2) positive attitude towards ceasing of medication (enabler); and 3) the influence of 
the (alleged opinion of) the specialist (barrier). In 42 of 49 (86%) of the audiotaped 
deprescribing consultations an attempt to deprescribe the medication was made versus 
65% in the total intervention group of the ECSTATIC study. Although we asked the GPs 
to audiotape every deprescribing consultation, GPs were probably more inclined to ask 
patients to participate in this qualitative study in case they thought it was likely that the 
outcome of the deprescribing consultation would be confirmative. This may be reflected 
by the general positive attitude towards ceasing expressed during the deprescribing 
consultation by both patients and GPs.
The viewpoints we found with our Q-methodology study showed, for example, that for 
some patients their dislike of medication use resulted in a positive attitude towards 
deprescribing with a tendency towards deprescription (autonomous viewpoint), whereas 
for other patients the fear of developing CVD predominated their view, resulting in a 
negative attitude towards deprescribing with a tendency towards continuation (afraid 
viewpoint) (Chapter 5).  Although 74% of the patients self-selected the viewpoint they 
loaded on according to our analysis, 7 of 29 (24%) patients made the remark that it was 
hard to choose which viewpoint fitted them best. They reported that elements of another 
(or all) viewpoint(s) also matched their views. The separation in the three viewpoints may 
thus be not that black and white. This shows how individual and complex the decision-
making process of deprescribing preventive cardiovascular medication in low-CVD-risk 
patients is.
2.5. Predictors of successful deprescribing
We found four strong predictors for successful deprescribing over a two-year 
period. If all four predictors were positive, the probability of successful stopping was 
approximately 50%. Although this probability was substantially higher than in a random 
low-CVD-risk patient (who had a 27% probability of successful stopping), this chance of 
successful stopping was still relatively low, presumably because of reasons described 
above.
We considered investigating characteristics of patients who developed more extreme 
values of hypertension (e.g., SBP>160 mmHg) or hypercholesterolemia (e.g., LDL-
cholesterol level >4 mmol/L), because this information would be helpful in the decision-
making process of deprescribing. However, we believed the sample size of the group 
of patients in the intervention group that persistently quitted their antihypertensive 
medication (n=115), or persistently quitted their lipid-lowering drugs (n=26), was too 
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small to reliably investigate this. Especially, because the number of events in these 
two groups was very limited, and only a few candidate predictors could be considered.14 
However, we were able to assess the average risk of developing hypertension (SBP≥140 
mmHg) and hypercholesterolemia (LDL-cholesterol level ≥2.5 mmol/L) for the total 
group of patients who did an attempt to have their medication deprescribed in the 
intervention group, which was approximately 20% to 60% and 5% to 15% higher 
compared to the usual care group, respectively (Chapter 3). 
3. IMPLICATIONS FOR MEDICAL PRACTICE
Following our findings, preventive cardiovascular medication in low-CVD-risk patients 
can be safely deprescribed in those patients willing to, under surveillance of the GP. 
However, judgement of overtreatment in low-CVD-risk patients is complex and consists 
of a mixture of ‘evidence about individual risk, prognosis, and treatment benefit-
harm calculations, combined with the personal values and preferences inherent in 
any decision-making’ as Moynihan et al. state so nicely.15 Given the complex nature 
of defining overtreatment in low-CVD-risk patients, the deprescribing consultation 
should be patient-centered and different aspects to judge overtreatment should be 
discussed, to be sure that the patient is able to make an optimally informed decision. A 
proposed format for the deprescribing consultation based on the findings of this thesis 




small to reliably investigate this. Especially, because the number of events in these 
two groups was very limited, and only a few candidate predictors could be considered.14 
However, we were able to assess the average risk of developing hypertension (SBP≥140 
mmHg) and hypercholesterolemia (LDL-cholesterol level ≥2.5 mmol/L) for the total 
group of patients who did an attempt to have their medication deprescribed in the 
intervention group, which was approximately 20% to 60% and 5% to 15% higher 
compared to the usual care group, respectively (Chapter 3). 
3. IMPLICATIONS FOR MEDICAL PRACTICE
Following our findings, preventive cardiovascular medication in low-CVD-risk patients 
can be safely deprescribed in those patients willing to, under surveillance of the GP. 
However, judgement of overtreatment in low-CVD-risk patients is complex and consists 
of a mixture of ‘evidence about individual risk, prognosis, and treatment benefit-
harm calculations, combined with the personal values and preferences inherent in 
any decision-making’ as Moynihan et al. state so nicely.15 Given the complex nature 
of defining overtreatment in low-CVD-risk patients, the deprescribing consultation 
should be patient-centered and different aspects to judge overtreatment should be 
discussed, to be sure that the patient is able to make an optimally informed decision. A 
proposed format for the deprescribing consultation based on the findings of this thesis 
is presented in Figure 1.
 
        
168
PROPOSED FORMAT OF 
DEPRESCRIBING CONSULTATION
STEP 1   The subject of deprescribing preventive cardiovascular 
medication is raised by the patient or the GP
STEP 2  Patient-centered consultation
 - CVD risk profile
 -  Explore views towards CVD risk profile, medication 
use, and lifestyle changes
 - Give information and advice when deemed necessary
STEP 3  The patient makes an informed decision about 
deprecribing
STEP 4   In case of an attempt to deprescribe follow-up 
consultations are planned
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Additional information based on this thesis that can be used in Step 1:
-  60% of the patients using preventive cardiovascular medication to prevent a first 
cardiovascular event strictly has no indication for this medication;
- A structured deprescribing strategy in this population is not recommended;
-  An attempt to deprescribe preventive cardiovascular medication in individual low CVD-
risk patients under surveillance of the GP is safe. 
Additional information based on this thesis that can be used in Step 2:
- GPs consider the impact of additional risk factors on the effects of deprescribing. 
- Individual patients balance the risks and benefits of deprescribing differently. 
-  Patients appreciate the availability of follow-up care and the possibility to restart 
medication. 
-  Patients rely on the information and expertise of their GP to determine whether 
deprescribing is justified. 
-  Compared to usual care, the risk of having a SBP ≥140 mmHg after two years of 
follow-up was approximately 20% to 60% higher, and the risk of having a LDL- 
holesterol ≥2.5 mmol/L was approximately 5% to 15% higher in patients who did an 
attempt to have their medication deprescribed
- Predictors of successful  stopping of the medication are:
 1) having a SBP ≤140;
 2) using preventive cardiovascular medication ≤10 years;
 3) using either an antihypertensive or a lipid-lowering drug (not both);
 4) using ≤1 class of antihypertensive drugs. 
   When all four predictors are positive the probability of successful
   stopping is approximately 50%.
Additional information based on this thesis that can be used in Step 4:
-  Mean SBP is 6 mmHg higher, and the total cholesterol and LDL-cholesterol levels 
are both on average 0.2 mmol/L higher in patients who do an attempt to have their 
medication deprescribed compared to usual care.
-  Reasons to restart medication were: hypertension, headache, nervousness/stress, and 
palpitations. 
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Figure 1. Proposed format for consultations in which a GP discusses deprescribing of 
preventive cardiovascular medication with a patient with a low 10-year cardiovascular 
disease risk, based on the findings of this thesis.
Abbreviations: GP denotes general practitioner; SBP denotes systolic blood pressure; LDL denotes low-
density lipoprotein.
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Topics to discuss during a deprescribing consultation are: the CVD risk profile, assessed 
in a broader sense than just assessing 10-year CVD risk score according to the 
guideline; exploration of the patient’s view about his or her risk of developing CVD and 
medication use; and the patient’s attitude towards lifestyle changes. In this way, the GP 
is able to give explanations when necessary, to redress misapprehensions, and to ensure 
that the patient feels capable to make an informed decision based on those aspects 
the patient values most. With help of the findings of this thesis, the GP can forward 
information about the possible negative effects of withdrawal and about the chance of 
successful deprescribing to the patient during a deprescribing consultation.
When it is decided to attempt deprescribing of the preventive cardiovascular medication, 
it is advised to plan follow-up consultations. During these follow-up consultations 
potential adverse effects of withdrawal should be discussed, and blood pressure and 
cholesterol levels should be measured in order to evaluate the necessity of restarting the 
medication. 
As an attempt to stop preventive cardiovascular medication is currently discouraged 
by the Dutch guideline for Cardiovascular Risk Management,8 we would advise the 
policy makers who are revising the guideline at this moment, to discuss the option 
to deprescribe preventive cardiovascular medication in low-CVD-risk patients in a 
paragraph of the guideline with help of this thesis’ findings.
3.1. Back to miss Bremer and mister Aalbers
How should the GP of miss Bremer and mister Aalbers deal with the possible 
overtreatment in these two patients coming to her for their routinely check-up? Cases 
like the ones of miss Bremer and mister Aalbers were presented to the GPs of the 
intervention practices during the ECSTATIC-workshop they received (Chapter 3). Given 
the discussion that followed the presentation of the cases, and based on the findings of 
our qualitative study, it is likely that the GP’s feeling about deprescribing will be more 
positive in miss Bremers’ case, than in mister Aalbers’ case. According to the findings 
of the ECSTATIC study an attempt to deprescribe medication in both these patients can 
be performed safely, although the results of this thesis also suggest that patients like 
mister Aalbers are probably underrepresented in the per protocol intervention group 
of the ECSTATIC study (Chapter 3). However, also for patients like mister Aalbers the 
chance of successful deprescribing can be assessed with help of the decision rule 
(Chapter 6).
First we will discuss miss Bremer’s case.
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Just after the revision of the CVRM guideline, miss Bremer visits her GP for her routine 
preventive check-up. She is 50 years old and uses an ACE-inhibitor (enalapril 5 mg once 
daily) for three years now. Her antihypertensive drugs were initiated during a period in 
which she had headache complaints and a relatively high systolic as well as diastolic 
blood pressure found repeatedly during consultations in the past (160/90 mmHg). She 
has never smoked, her TC/HDL ratio is 5, her current systolic blood pressure is 135 
mmHg, and she has no additional risk increasing factors (no elevated body mass index, 
normal kidney function, no family history of CVD, and a good physical activity level). 
She sees her GP during the yearly preventive check-up. Her headache has faded since, 
and the general practitioner questions herself whether miss Bremer could stop her 
antihypertensive drugs.
Things that will probably make the GP more positive towards an attempt to deprescribe 
in miss Bremers’ case are, for example, that deprescribing is safe because of her low-
CVD-risk, and that she has no additional risk factors for developing CVD. In addition, she 
has a relatively high chance (approximately 50%) to successfully stop her medication. 
Miss Bremer may have questions about the possible short- and long-term negative 
effects of deprescribing, that could be addressed by the GP. The short-term negative 
effects of deprescribing can be addressed as a result of the findings of this thesis. The 
knowledge that GPs gained about deprescribing preventive cardiovascular medication 
through this thesis, may drift their advice in case of miss Bremer more towards an 
attempt to have her medication deprescribed than before. 
Now, we move over to the case of mister Aalbers.
Just after the revision of the CVRM guideline, mister Aalbers visits his GP for his routine 
preventive check-up. He is 40 years old and uses antihypertensive and lipid-lowering 
drugs for two years now (hydrochlorothiazide 12.5 mg, enalapril 5 mg, and simvastatin 
40 mg, all once daily). At the time, the GP had advised him to start medication because 
of his risk factors for developing a cardiovascular disease. He is a smoker, has a TC/
HDL ratio of 5 (it was 6 at the time he started his medication), an LDL-cholesterol of 
2.4 mmol/L (it was 4.1 mmol/L at the time he started his medication), and his systolic 
blood pressure is 136 mmHg (it was 155 mmHg at the time he started his medication). 
Furthermore, he has a body mass index of 37 kg/m2, he has a sedentary lifestyle, and his 
kidney function is 55 ml/min/1.73m2. His brother was 48 when he had a heart attack and 
his mother suffered from a stroke at the age of 62. Mister Aalbers visits his GP and asks 
her if he could stop his medication because he does not see or feel any benefits of it and 
dislikes use of medication.
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Mister Aalbers brings up the subject of deprescribing himself, suggesting a positive 
attitude towards an attempt to deprescribe. The fact that he has many risk factors for 
developing CVD despite his low absolute CVD risk score, probably make the GP of mister 
Aalbers more reluctant towards deprescribing. The GP may feel she has to ‘convince’ the 
patient to continue the medication. Results of our qualitative study showed that the GP is 
capable to change the initial thoughts of the patient concerning deprescribing, resulting 
in the GP’s preferred outcome (deprescription or continuation) of the deprescribing 
consultations (Chapter 4). The GP could also emphasize that if it is decided to attempt 
deprescribing, the chance that he (mister Aalbers) is able to successfully stop his 
medication is very little, 10% at maximum, based on the decision rule presented in this 
thesis.
4. FUTURE RESEARCH
Future studies should focus on the long-term effects of an attempt to deprescribe 
preventive cardiovascular medication in patients without a strict indication for preventive 
cardiovascular medication use. It would be interesting to investigate in which individuals 
or group of patients deprescribing is safe in the long-term, and in which individual or 
group it is not. Hypothetically, long-term safety of deprescribing could be assessed 
by extending the follow-up of the participants of the ECSTATIC study to investigate a 
difference in hazard rate of cardiovascular events between usual care patients and 
intervention group patients.  However, an estimation showed that approximately 16000 
patients should be followed for 30 years to prove a 5% difference in disease free survival 
between usual care and intervention group patients. Obviously, with 1067 participants 
included in the ECSTATIC study, this is not feasible. 
An even more important field to focus on, is the field of CVD risk prediction and its 
usefulness in recommendations for drug treatment initiation. The SCORE equation, for 
example, on which the Dutch 10-year CVD risk score is based, overestimates risk on 
average by a factor five across all risk categories (low, medium, high), which may lead 
to overtreatment of patients.16, 17 In addition, the SCORE equation was compared to the 
American College of Cardiology/American Heart Association (ACC/AHA) guidelines in a 
European cohort, and was found to be inferior to the ACC/AHA guidelines in accurately 
assigning statin therapy to those who would benefit.17 Moreover, the use of population-
based prediction models for recommendation of drug treatment initiation in individuals 
without a history of CVD is questioned.18, 19 It is not even clear whether the use of CVD 
risk scores in general decreases the number of cardiovascular events.20
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risk scores in general decreases the number of cardiovascular events.20
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Hence, research should focus on finding the optimal way to predict development of a 
first cardiovascular event in individual patients, and search for the way to initiate drug 
treatment only in patients who really benefit from them. For CVD risk prediction on 
population-level, it is probably best to examine pre-existing models and recalibrate 
them in new target populations. In this way the effects of different prediction models 
can be compared and the best approach per population can be assessed.21, 22 However, 
the availability of a risk score not only assessing CVD risk, but also estimating the 
individual’s benefit of treatment, would even be better. The other way around, a similar 
risk score for patients already using preventive cardiovascular medication, to predict 
who would benefit from continuation of medication and who would be better off having 
the medication deprescribed, would improve the judgement of overtreatment and aid  
the decision-making process concerning deprescribing. Use of routinely registered data 
could aid the development of such personalised risk scores.18, 19 
5. CONCLUSION
Based on the findings of this thesis, we believe that an attempt to deprescribe preventive 
cardiovascular medication under surveillance of the GP in those low-CVD-risk patients 
willing to do so, is safe in the short term. The GP is advised to monitor adverse effects, 
blood pressure, and cholesterol levels after withdrawal, to evaluate whether drug 
treatment should be restarted (Chapter 3). The judgement of overtreatment in low-
CVD-risk patients is complex and should be an individualised, patient-centered process 
(Chapters 4 and 5). We advise the GP to let the patient’s views and preferences be 
leading the course of a deprescribing consultation, and to give information and advice 
(based on this thesis’ findings) when deemed necessary (Chapters 3, 4, 5, and 6).
With this thesis we aimed to improve cardiovascular preventive care in general practice 
for low-CVD-risk patients aged 40-70 years, in whom changing circumstances or 
changed guidelines resulted in losing the strict indication for (prolonged) preventive 
cardiovascular medication use. We trust that our findings provide both practical tools 
for GPs to improve the judgement of overtreatment in low-CVD-risk patients, as well as 
valuable information for policy makers appointed to revise the CVRM guideline.
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SUMMARY
Cardiovascular disease (CVD) contributes highly to mortality and is the leading cause of 
years of life lost globally. In many countries, recommendations to reduce the prevalence 
of CVD are integrated in guidelines. However, although the goal of these guidelines is 
the same, there is no consensus about the optimal preventive care. In search for further 
optimisation, medical knowledge progresses, resulting in regular revisions of guidelines 
in this area. The latest revision of the Dutch guideline was in 2012. It was unclear what 
this new guideline would imply for daily practice. This thesis’ research questions relate 
to the implications the revision of the guideline had in daily practice. To best address 
these research questions, a combination of quantitative and qualitative research, the so-
called mixed methods approach, is used in this thesis.
 
1. OVERVIEW OF THIS THESIS’ FINDINGS
 
1.1. Part 1
The findings in Chapter 2 show that the revision of the Dutch CVRM guideline had 
considerable impact on patient care. The revision has led to shifts in risk categories 
(high, medium, and low risk) in 20% of the patients using preventive cardiovascular 
medication (antihypertensive and/or lipid-lowering drugs). Furthermore, 12% of the 
patients shift in drug recommendation, notably: with unchanged initial risk factor values. 
In the Netherlands, following our estimates, approximately 60% of the patients using 
cardiovascular medication to prevent a first cardiovascular event, strictly speaking, have 
no indication for using this medication according to the current Dutch CVRM guideline. 
1.2. Part 2
The ECSTATIC study that is described in Chapter 3 shows that, compared to usual 
care, mean systolic blood pressure (SBP) in patients who did an attempt to have their 
medication deprescribed (the intervention) is 6 mmHg higher after two years of follow-
up. The total cholesterol and low-density lipoprotein (LDL) cholesterol levels are both on 
average 0.2 mmol/L higher compared to the usual care group. These differences in SBP 
and LDL-cholesterol level between intervention group and usual care group are already 
present after three months of follow-up.
Compared to the patients in the usual care group using antihypertensive drugs at 
baseline, SBP is on average 13 mmHg higher in the patients in the intervention group 
who had still stopped antihypertensive drugs after two years. The LDL-cholesterol level 
178
SUMMARY
Cardiovascular disease (CVD) contributes highly to mortality and is the leading cause of 
years of life lost globally. In many countries, recommendations to reduce the prevalence 
of CVD are integrated in guidelines. However, although the goal of these guidelines is 
the same, there is no consensus about the optimal preventive care. In search for further 
optimisation, medical knowledge progresses, resulting in regular revisions of guidelines 
in this area. The latest revision of the Dutch guideline was in 2012. It was unclear what 
this new guideline would imply for daily practice. This thesis’ research questions relate 
to the implications the revision of the guideline had in daily practice. To best address 
these research questions, a combination of quantitative and qualitative research, the so-
called mixed methods approach, is used in this thesis.
 
1. OVERVIEW OF THIS THESIS’ FINDINGS
 
1.1. Part 1
The findings in Chapter 2 show that the revision of the Dutch CVRM guideline had 
considerable impact on patient care. The revision has led to shifts in risk categories 
(high, medium, and low risk) in 20% of the patients using preventive cardiovascular 
medication (antihypertensive and/or lipid-lowering drugs). Furthermore, 12% of the 
patients shift in drug recommendation, notably: with unchanged initial risk factor values. 
In the Netherlands, following our estimates, approximately 60% of the patients using 
cardiovascular medication to prevent a first cardiovascular event, strictly speaking, have 
no indication for using this medication according to the current Dutch CVRM guideline. 
1.2. Part 2
The ECSTATIC study that is described in Chapter 3 shows that, compared to usual 
care, mean systolic blood pressure (SBP) in patients who did an attempt to have their 
medication deprescribed (the intervention) is 6 mmHg higher after two years of follow-
up. The total cholesterol and low-density lipoprotein (LDL) cholesterol levels are both on 
average 0.2 mmol/L higher compared to the usual care group. These differences in SBP 
and LDL-cholesterol level between intervention group and usual care group are already 
present after three months of follow-up.
Compared to the patients in the usual care group using antihypertensive drugs at 
baseline, SBP is on average 13 mmHg higher in the patients in the intervention group 
who had still stopped antihypertensive drugs after two years. The LDL-cholesterol level 
        
179
CHAPTER 8
of the patients who had stopped lipid-lowering drugs after two years of follow-up, was on 
average 1.5 mmol/L higher compared to the LDL-cholesterol level of the patients in the 
usual care group using lipid-lowering drugs at baseline. After an attempt to deprescribe 
preventive cardiovascular medication is made, the risk of having hypertension (SBP ≥140 
mmHg) after two years of follow-up is approximately 20% to 60% higher compared to 
the usual care group, and the risk of having hypercholesterolemia (LDL-cholesterol level 
≥2.5 mmol/L) is approximately 5% to 15% higher.
Predicted CVD risk increased by 2.0 versus in the intervention group and 1.9 percentage 
points in the usual care group; the difference of 0.1 (95% CI -0.3 to 0.6) fell within the 
pre-specified non-inferiority margin. Thus the ECSTATIC study reveals that an attempt 
to deprescribe preventive cardiovascular medication in general practice with predicted 
low-risk is safe in the short term (two years). 
The most frequently reported adverse effects of deprescribing and reasons to restart 
medication are: hypertension, headache, nervousness/stress, and palpitations. There is 
no indication of serious adverse effects of deprescribing in the short term.
Furthermore, the ECSTATIC study shows that after implementation of a structured 
deprescribing strategy in general practice, 65% of the low-risk patients attempt to have 
their medication deprescribed, and that 27% of the initial intervention group is still 
without medication after two years.
A structured deprescribing strategy in low-risk patients in general practice is 70% to 
80% likely to be cost-effective for a willingness-to-pay for one Quality Adjusted Life 
Year (QALY) between €20,000 and €50,000. However, implementation of a structured 
deprescribing strategy is not recommended, because it makes no difference in total 
healthcare costs, nor in quality of life of the patients. Furthermore, the effectiveness of 
the deprescribing strategy is fairly low (27% persistent quitters).
1.3. Part 3
Chapter 4 shows that low-risk patients, who discuss deprescribing of preventive 
cardiovascular medication with their GP during a deprescribing consultation fear the 
consequences of deprescribing. Therefore, they appreciate the availability of follow-up 
care and the possibility to restart medication. Chapter 4 and 5 show that patients are 
generally positive towards deprescribing. They rely on the information and expertise of 
their GP to help determine whether deprescribing is justified. Individual patients balance 
the risks and benefits of deprescribing differently and have different preferences with 
regard to an attempt to deprescribe. One of the reasons for GPs to advise deprescribing 
is the low-risk of the patients when recalculated following the current guideline. In 
addition, the GPs base their view concerning deprescribing on the presence of additional 
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risk factors such as a positive family history of CVD or an unhealthy lifestyle, and on the 
earlier advice of the specialist to continue/start medication. 
Chapter 6 shows that the four strongest baseline predictors for successfully stopping 
preventive cardiovascular medication in low-risk patients in general practice are: 1) 
having a SBP ≤140 mmHg; 2) using preventive cardiovascular medication ≤10 years; 
3) using either an antihypertensive or a lipid-lowering drug; and 4) using ≤1 class of 
antihypertensive drugs. When all four predictors are positive, the probability that a 
patient has still stopped the preventive cardiovascular medication after two years is 
approximately 50%.
2. CONCLUSION
In conclusion, this thesis shows that an attempt to deprescribe preventive cardiovascular 
medication in 40 to 70 year old low-risk patients under surveillance of the GP is safe in 
the short term. The deprescribing consultation should be patient-centered in order to 
optimally judge overtreatment.
Decision-making could be improved if more personalised risk scores were available, 
that assess an individual’s CVD risk and benefit of treatment. Opportunities for future 
development of these personalised risk scores lie in the use of routinely registered 
patient data.
Overall, this thesis’ findings provide both practical tools for GPs to judge overtreatment 
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SAMENVATTING
Wereldwijd zijn hart- en vaatziekten (HVZ) de belangrijkste oorzaak voor het verlies 
van levensjaren en is de sterfte aan HVZ hoog. Veelal worden aanbevelingen om het 
vóórkomen van HVZ te verminderen geïntegreerd in nationale richtlijnen. Ondanks 
het feit dat het doel van de richtlijnen uit de diverse landen hetzelfde is, is er geen 
consensus over de weg daar naar toe: wat is optimale preventieve zorg? Doordat de 
wetenschappelijke zoektocht hiernaar ononderbroken voortgaat, worden richtlijnen 
op het gebied preventie van HVZ met enige regelmaat herzien. De meeste recente 
herziening van de Nederlandse richtlijn vond plaats in 2012. Het is onduidelijk 
welke implicaties deze nieuwe richtlijn heeft gehad voor de dagelijkse praktijk. De 
onderzoeksvragen van dit proefschrift hebben betrekking op de impact van deze 
herziening van de richtlijn had op de dagelijkse praktijk. Om deze onderzoeksvragen 
zo goed mogelijk te beantwoorden is in dit proefschrift gebruik gemaakt van een 
combinatie van kwantitatief en kwalitatief onderzoek, de zogenaamde mixed methods 
approach.
1. OVERZICHT VAN DE BEVINDINGEN VAN DIT PROEFSCHRIFT
1.1. Deel 1
Hoofdstuk 2 van dit proefschrift laat zien dat de herziening van de richtlijn gevolgen 
heeft voor de patiëntenzorg. De herziening heeft geleid tot een verschuiving van 
risicogroep (hoog-, midden- of laag-risico) bij 20% van de patiënten die preventieve 
cardiovasculaire medicatie (antihypertensiva en/of lipiden-verlagende medicatie) 
gebruiken. Tegelijkertijd verandert het medicatieadvies in 12% van de gevallen, uitgaand 
van gelijkblijvende waarden van de risicofactoren. In Nederland heeft naar schatting 
ongeveer 60% van de patiënten die preventieve cardiovasculaire medicatie gebruikt, 
strikt genomen, géén indicatie voor het gebruik van deze medicatie volgens de huidige 
richtlijn.
1.2. Deel 2
De ECSTATIC studie, beschreven in Hoofdstuk 3, toont aan dat na twee jaar follow-up 
de systolische bloeddruk (SBD) bij patiënten die een poging doen om hun medicatie 
te staken (de interventie) gemiddeld 6 mmHg hoger is dan bij de patiënten die de 
gebruikelijke zorg ontvangen. Het totaal cholesterol en het low-density-lipoprotein (LDL) 
cholesterol zijn beide ongeveer 0,2 mmol/L hoger in vergelijking met de groep die 
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te staken (de interventie) gemiddeld 6 mmHg hoger is dan bij de patiënten die de 
gebruikelijke zorg ontvangen. Het totaal cholesterol en het low-density-lipoprotein (LDL) 
cholesterol zijn beide ongeveer 0,2 mmol/L hoger in vergelijking met de groep die 
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de gebruikelijke zorg ontvangt. Deze verschillen in SBD en LDL-cholesterol tussen de 
interventiegroep en de groep die de gebruikelijke zorg ontvangt zijn al aanwezig vanaf 
drie maanden follow-up.
In de groep patiënten die bij de start van het onderzoek een anithypertensivum 
gebruiken is de gemiddelde SBD van patiënten die na twee jaar follow-up nog steeds 
gestopt zijn met hun antihypertensivum 13 mmHg hoger dan die van patiënten die de 
gebruikelijke zorg krijgen. Het LDL-cholesterol van de groep patiënten die gestopt is 
met lipiden-verlagende medicatie is gemiddeld 1,5 mmol/L hoger in vergelijking met het 
LDL-cholesterol van de patiënten in de groep die de gebruikelijke zorg ontvangt. Indien 
een poging tot staken wordt gedaan is het risico op het hebben van hypertensie (SBD 
≥140 mmHg) na twee jaar follow-up ongeveer 20% tot 60% hoger dan in de groep die de 
gebruikelijke zorg ontvangt en is het risico op hypercholesterolemie (LDL-cholesterol 
≥2,5 mmol/L) ongeveer 5% tot 15% hoger.
Het voorspelde risico om binnen 10 jaar HVZ te ontwikkelen stijgt in twee jaar tijd met 
gemiddeld 2,0 procentpunt bij de patiënten die een poging doen de medicatie te staken, 
versus 1,9 procentpunt in de groep die de gebruikelijke zorg ontvangt; het verschil van 
0,1 procentpunt (95% CI -0,3 tot 0,6) valt binnen de (door ons vooraf gedefinieerde) non-
inferiority marge van 2,5 procentpunt. Daarmee toont de ECSTATIC studie aan dat een 
poging tot staken van preventieve cardiovasculaire medicatie bij patiënten met een laag 
risico op HVZ in de huisartspraktijk op de korte termijn (twee jaar) veilig is. 
De meest gerapporteerde negatieve effecten van het staken zijn tevens de meest 
voorkomende oorzaken voor het herstarten van de medicatie, te weten: hypertensie, 
hoofdpijn, nervositeit/stress en hartkloppingen. Er zijn geen aanwijzingen gevonden voor 
ernstige negatieve effecten van het staken op de korte termijn.
De ECSTATIC studie laat daarnaast zien dat na implementatie van een gestructureerde 
deprescribing (het staken van medicatie)-strategie in de huisartspraktijk, 65% van de 
laag-risico patiënten een poging tot staken van de medicatie doet en dat 27% van de 
totale interventiegroep na twee jaar nog steeds geen medicatie gebruikt.
De kans dat het implementeren van een gestructureerde deprescribing-strategie onder 
laag-risico patiënten in de huisartspraktijk kosten-effectief is, is 70% tot 80% voor een 
willingnes-to-pay voor één Quality Adjusted Life Year (QALY) tussen €20.000 en €50.000. 
Desondanks, zou een gestructureerde deprescribing-strategie niet geïmplementeerd 
moeten worden, omdat het geen verschil maakt voor de totale zorgkosten en het 
geen verschil maakt voor de kwaliteit van leven van de patiënten. Bovendien was de 
effectiviteit van de deprescribing-strategie tamelijk laag (27% definitieve stoppers).
185
CHAPTER 9
de gebruikelijke zorg ontvangt. Deze verschillen in SBD en LDL-cholesterol tussen de 
interventiegroep en de groep die de gebruikelijke zorg ontvangt zijn al aanwezig vanaf 
drie maanden follow-up.
In de groep patiënten die bij de start van het onderzoek een anithypertensivum 
gebruiken is de gemiddelde SBD van patiënten die na twee jaar follow-up nog steeds 
gestopt zijn met hun antihypertensivum 13 mmHg hoger dan die van patiënten die de 
gebruikelijke zorg krijgen. Het LDL-cholesterol van de groep patiënten die gestopt is 
met lipiden-verlagende medicatie is gemiddeld 1,5 mmol/L hoger in vergelijking met het 
LDL-cholesterol van de patiënten in de groep die de gebruikelijke zorg ontvangt. Indien 
een poging tot staken wordt gedaan is het risico op het hebben van hypertensie (SBD 
≥140 mmHg) na twee jaar follow-up ongeveer 20% tot 60% hoger dan in de groep die de 
gebruikelijke zorg ontvangt en is het risico op hypercholesterolemie (LDL-cholesterol 
≥2,5 mmol/L) ongeveer 5% tot 15% hoger.
Het voorspelde risico om binnen 10 jaar HVZ te ontwikkelen stijgt in twee jaar tijd met 
gemiddeld 2,0 procentpunt bij de patiënten die een poging doen de medicatie te staken, 
versus 1,9 procentpunt in de groep die de gebruikelijke zorg ontvangt; het verschil van 
0,1 procentpunt (95% CI -0,3 tot 0,6) valt binnen de (door ons vooraf gedefinieerde) non-
inferiority marge van 2,5 procentpunt. Daarmee toont de ECSTATIC studie aan dat een 
poging tot staken van preventieve cardiovasculaire medicatie bij patiënten met een laag 
risico op HVZ in de huisartspraktijk op de korte termijn (twee jaar) veilig is. 
De meest gerapporteerde negatieve effecten van het staken zijn tevens de meest 
voorkomende oorzaken voor het herstarten van de medicatie, te weten: hypertensie, 
hoofdpijn, nervositeit/stress en hartkloppingen. Er zijn geen aanwijzingen gevonden voor 
ernstige negatieve effecten van het staken op de korte termijn.
De ECSTATIC studie laat daarnaast zien dat na implementatie van een gestructureerde 
deprescribing (het staken van medicatie)-strategie in de huisartspraktijk, 65% van de 
laag-risico patiënten een poging tot staken van de medicatie doet en dat 27% van de 
totale interventiegroep na twee jaar nog steeds geen medicatie gebruikt.
De kans dat het implementeren van een gestructureerde deprescribing-strategie onder 
laag-risico patiënten in de huisartspraktijk kosten-effectief is, is 70% tot 80% voor een 
willingnes-to-pay voor één Quality Adjusted Life Year (QALY) tussen €20.000 en €50.000. 
Desondanks, zou een gestructureerde deprescribing-strategie niet geïmplementeerd 
moeten worden, omdat het geen verschil maakt voor de totale zorgkosten en het 
geen verschil maakt voor de kwaliteit van leven van de patiënten. Bovendien was de 
effectiviteit van de deprescribing-strategie tamelijk laag (27% definitieve stoppers).
        
186
1.3. Deel 3
Hoofdstuk 4 laat zien dat laag-risico patiënten die tijdens een stopconsult het 
staken van de medicatie bespreken met hun huisarts hun zorgen uitspreken over de 
mogelijke gevolgen van het staken. Ze vinden het afspreken van vervolgconsulten en de 
mogelijkheid tot het herstarten van de medicatie om die reden belangrijk. Hoofdstuk 4 
en 5 laten zien dat patiënten over het algemeen positieve houding hebben tegenover het 
staken van hun medicatie. Ze vertrouwen op de informatie en expertise van de huisarts 
om te bepalen of het verantwoord is om de medicatie te staken. Individuele patiënten 
wegen de voor- en nadelen van het staken op verschillende manieren tegen elkaar af 
en staan daarmee ook wisselend tegenover het staken van de medicatie. Eén van de 
redenen voor huisartsen om het staken van de medicatie te adviseren is het lage risico 
op HVZ, berekend volgens de meest recente richtlijn. Daarnaast bepalen huisartsen hun 
advies op basis van de aanwezigheid van additionele risicofactoren, zoals bijvoorbeeld 
een positieve familieanamnese voor HVZ of een ongezonde leefstijl. Ook het eerdere (of 
vermeende) advies van een specialist om de medicatie te continueren/starten speelt een 
rol in het advies dat huisartsen geven.
Hoofdstuk 6 laat de vier sterkste voorspellers voor het succesvol staken van preventieve 
cardiovasculaire medicatie bij laag-risico patiënten in de huisartspraktijk zien, te weten: 
1) huidige bloeddruk <140 mmHg; 2) ≤10 jaar gebruik van preventieve cardiovasculaire 
medicatie; 3) het gebruiken van óf een antihypertensivum óf een lipiden-verlagend 
medicijn (en niet beide); en 4) het gebruiken van ≤1 soort antihypertensivum. Indien al 
deze vier voorspellers aanwezig zijn dan is de kans dat een patiënt na twee jaar nog 
steeds gestopt is met preventieve cardiovasculaire medicatie ongeveer 50%.
2. CONCLUSIE
Dit proefschrift laat zien dat een poging tot staken van preventieve cardiovasculaire 
medicatie onder begeleiding van de huisarts bij patiënten van 40 tot 70 jaar met een laag 
risico op het krijgen van HVZ op de korte termijn veilig is. Het is belangrijk dat de patiënt 
centraal staat tijdens het stopconsult omdat dit ervoor zorgt dat het beoordelen van 
mogelijke overbehandeling door de huisarts zo optimaal mogelijk gebeurt.
Gepersonaliseerde risicoscores die het individuele HVZ-risico aangeven en inzicht 
geven in het nut van medicamenteuze behandeling kunnen dit beslisproces nog 
verbeteren. Patiëntgegevens die routinematig worden geregistreerd bieden een 
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Dit proefschrift verschaft praktische handvatten aan huisartsen voor het beoordelen van 
overbehandeling bij laag-risico patiënten. Daarnaast bevat het waardevolle informatie 
voor beleidsmakers die de richtlijn Cardiovasculair Risicomanagement herzien.
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Van mijn familie en schoonfamilie ervaar ik onvoorwaardelijke steun.
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inspireert mij nog altijd om gebruik te maken van de kansen die ik krijg en om mijn 
ambities na te streven.
Tot slot, Jasper, wat ben ik gelukkig met jou. Samen zijn we een topteam. Ik kan 
ontzettend met je lachen en je steunt me door dik en dun. We hebben twee prachtige 
kinderen, Job en Jule, waar we met volle teugen van genieten. Ik zou jullie alle drie voor 
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